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Abstract 
A major hurdle hindering the advancement of cell-based cancer vaccines is the 
inability to non-invasively track in vivo therapeutic cell migration. Within cancer 
immunotherapy, antigen presenting cell-based (APC) immunotherapies can be 
dendritic cell-based (DC) and elicit de novo anti-tumor immune responses or 
formulated as mixed APC-based immunotherapy generated from peripheral blood 
mononuclear cells (PBMC). Mixed APC-based therapies contain monocytes and B 
cells as APC and can enhance a pre-existing anti-tumor immune response such that 
objective anti-tumor responses are observed. In either APC-based formulation, the 
quantity of anti-tumor APC reaching a secondary lymphoid organ post injection is 
predictive of the magnitude of the ensuing anti-tumor immune response.  
This thesis investigates 19F cellular MRI in conjunction with a 19F-perfluorocarbon 
(19F-PFC) labeling agent as a non-invasive, quantifiable imaging modality that serves 
as a surrogate marker of APC-based cancer immunotherapy effectiveness. Pre-clinical 
studies involving murine bone marrow-derived DC (BMDC) and human monocyte-
derived DC (moDC) demonstrated 19F-PFC labeling of a high proportion (>95%) of 
DC without affecting viability, phenotype and function. In vivo migration of 19F-PFC-
labeled DC to the popliteal lymph node was detected and the subsequent induction of 
an anti-tumor CD8+ T cell response did not differ compared to control DC. Moreover, 
this thesis outlines a tumor-bearing mouse model of melanoma suitable for correlating 
19F-PFC-labeled BMDC migration to the lymph node with objective anti-tumor 
response. 
Similar to DC, 19F-PFC efficiently labeled human PBMC without altering viability, 
phenotype, function and in vivo migration. To progress towards a clinical trial to image 
autologous 19F-PFC-labeled PBMC in humans, a protocol to label human PBMC with 
19F-PFC under Good Manufacturing Practice-compliant (GMP) conditions was 
designed. Nearly 100% of PBMC incorporated 19F-PFC without affecting viability or 
cell lineage composition and were migration competent as demonstrated by in vivo 
migration to the popliteal lymph node in a mouse model. Furthermore, mock human 
 
ii 
 
injections in a ham shank using clinical MR parameters resulted in the first reported 
detection of 19F-PFC-labeled PBMC at a depth of 1.2 cm, demonstrating that clinical 
19F cellular MRI is a suitable non-invasive imaging technique to assess APC-based 
immunotherapy effectiveness. 
Keywords 
Dendritic cell (DC), antigen presenting cell (APC), peripheral blood mononuclear cell 
(PBMC), 19Fluorine, cellular MRI, cell tracking, cancer immunotherapy, APC-based 
cancer vaccine, Good Manufacturing Practice (GMP) 
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Chapter 1  
1 Thesis Introduction 
1.1 Emerging strategies to combat cancer: cancer 
immunotherapy 
Worldwide, 14.1 million new cancer cases were reported in 20121. For men, prostate cancer 
is the second most common malignancy, accounting for 14% of all male cancers, and is 
the cause of the second highest number of deaths related to cancer2. In the clinic, standard 
treatments such as the chemotherapeutic agents, docetaxel, mitoxantrone and estramustine, 
radiation therapy and surgical resection are first-line treatments that are commonly 
employed and have proven effective3, yet 30% of prostate cancer patients progress to 
hormone refractory metastatic prostate cancer, for which limited treatment options such as 
abiraterone and carbazitaxel are available4, 5, 6. This is in addition to 15% of prostate cancer 
patients that present with metastatic disease7. Therefore, there is an urgent need for the 
development of novel, effective therapies to combat prostate cancers that are not responsive 
to standard therapies8. 
In general, cancers develop one or more strategies to evade recognition by the immune 
system and thus, each have a different immunogenic potential9, 10. As cancer cells arise 
from host cells, the immune system is biased towards not recognizing a tumor as foreign 
and thus, not launching an appropriate and robust anti-tumor response in vivo11, 12. Tumor 
cells can also present mutated self-proteins or neo-antigens on their cell surface, up-
regulate surface expression of a specific protein or proteins as well as present germ line-
associated proteins that arise through epigenetic changes that would otherwise not normally 
be expressed on a differentiated cell12, 13, 14, 15, 16, 17. The immune system can recognize the 
subtle differences between tumor tissue and surrounding, healthy tissue and exploit 
differences to initiate an anti-cancer immune response. Manipulation of the immune system 
to improve its immune recognition and subsequent destruction of a tumor is a relatively 
new research area known as cancer immunotherapy3, 7, 18.  
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To evade the immune system, tumors often down-regulate surface expression of human 
leukocyte antigen (HLA), or major histocompatibility complex (MHC) in mice, so as to 
limit the amount of tumor-associated antigens (TAA) being presented to CD8+ and CD4+ 
T cells of the immune system and accordingly, dampen the tumor-specific immune 
response19, 20, 21, 22. Even if tumor antigen presentation in the context of surface HLA does 
occur to CD8+ T cells, tumors have developed the capacity to secrete immunosuppressive 
cytokines into the tumor microenvironment23. A robust immune response is not initiated in 
the absence of required signals as observed in an immunosuppressive environment where 
co-stimulatory molecules are not up-regulated24. Moreover, even if a proper immune 
response to a TAA is launched, there still is the possibility that the tumor microenvironment 
can suppress this immune response and in some cases, can even drive infiltrating 
lymphocytes towards exhaustion or anergy25, 26, 27.  
Depending on the combination of immune evasion properties a cancer possesses, each one 
may exhibit a different level of immunogenicity. Poorly immunogenic tumors, such as 
high-grade breast, gastric and pancreatic carcinoma28, 29, 30 are not ideal for investigating 
the effectiveness of cancer immunotherapy. However, cancers such as prostate cancer, 
melanoma, malignant glioma, non-small-cell lung carcinoma (NSCLC) and renal cell 
carcinoma are immunogenic and thus, serve as a suitable platform for improving upon 
existing cancer immunotherapies and for investigating novel immunotherapeutic 
approaches31, 32, 33, 34, 35, 36, 37, 38, 39. Prostate cancer also has well-defined TAA, such as 
prostate specific antigen (PSA), prostatic acid phosphatase (PAP) and prostate-specific 
membrane antigen (PSMA)40, 41, 42, 43, 44, all of which can be employed as a target for TAA-
specific immunotherapy. Furthermore, prostate cancer progresses slowly and the prostate 
gland itself is not necessary for maintaining life. Because of these attributes, 
immunotherapies have sufficient time to fully exert their anti-tumor function without 
concern over an immune response that is too strong and has the potential to destroy nearby 
healthy tissue in vital organs45 46, 47.   
A broad range of immunotherapeutic options have been investigated for use as novel anti-
tumor strategies, with the type, kinetics and immunogenicity of a tumor being taken into 
consideration. TAA-specific immunotherapies can arise from administration of ex vivo-
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cultured TAA-specific antigen presenting cell- (APC)-based vaccines, infusion of ex vivo-
expanded tumor-infiltrating lymphocytes (TIL) specific to a tumor or even genetically 
engineered chimeric antigen receptor (CAR) T cell designed to recognize a specific surface 
TAA48, 49, 50. Non-specific immunotherapies also exist, such as the systemic administration 
of cytokines51, 52. Combinatorial approaches have proven effective as well, such as using 
checkpoint inhibitors to prolong the activation state of TAA-specific T cell 
immunotherapies53 . Both non-specific, TAA-specific and combinations thereof will be 
discussed in detail in this thesis.      
1.2 Non-specific cancer immunotherapies 
Early research on cancer immunotherapy focused on systemically administering pro-
inflammatory cytokines, such as interleukin-2 (IL-2) or IL-1252, 54, 55, 56, 57, to create an in 
vivo environment that is capable of either controlling growth and metastasis or destroying 
an existing tumor. Without such up-regulation of the body’s immune response, the strong 
and sometimes overwhelmingly immunosuppressive effects that can be induced by a tumor 
could compromise the body’s immune system from fully recognizing, initiating and 
maintaining an immune response against a tumor27, 58, 59, 60. IL-2 administration serves to 
activate and expand CD8+ T cells into CD8+ cytotoxic T lymphocytes (CTL) that perform 
cell-mediated tumor destruction48, 61 while also indirectly initiating a tumor-specific 
humoral response via activation of CD4+ T helper (TH) cells that provide signals to B cells 
required for antibody production62. Pro-inflammatory cytokine treatment has shown 
beneficial results in the clinic, albeit at a level that is insufficient to promote objective 
tumor regression and render the patient tumor-free54, 63, 64. Furthermore, because such 
techniques are non-specific, there is great potential for over-activation of intended cell 
lineage targets. Such is the case with T cells and IL-2 treatment or non-specific activation 
of a pro-inflammatory microenvironment with IL-12 that results in broad activation of 
unintended immune cell lineages54, 65. Systemic administration of toll-like receptor (TLR) 
agonists have also been associated with toxicities in vivo66. Collectively, this leads to 
significant treatment-associated toxicity known as rapid lethal inflammatory syndrome as 
a result of immune system over-activation, contributing to patient morbidity and 
diminishing its effectiveness56, 57, 61, 67, 68, 69, 70, 71. To avoid broad and potentially 
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uncontrolled activation of the immune system, immunotherapies that elicit TAA-specific 
immune responses have garnered much research attention7, 72. This way, the body’s 
immune response can be directed specifically to the tumor and in theory, would limit off-
target effects and uncontrolled systemic immune responses that are potentially fatal in 
nature.  
1.3 TAA-specific cancer immunotherapies 
To avoid the detrimental effects of an immunosuppressive tumor environment, immune 
cells can be cultured ex vivo to expand existing tumor-specific T cell populations or 
rendered tumor-specific through TAA-loading of APC prior to administration back into the 
host to elicit new anti-tumor responses72, 73, 74, 75, 76, 77. With respect to TAA-specific 
immunotherapies, a wide variety of both naturally occurring cell lineages as well as 
engineered immune cells, can be cultured ex vivo as described below or specifically 
targeted in vivo. Regardless of which method is employed, the goal is to provide all the 
signals and conditions necessary to activate, expand and render the therapeutic cells of 
interest capable of launching a TAA-specific immune response78.   
T cells that have become properly activated in vivo in a TAA-specific manner are capable 
of tracking to a tumor to exert their function. In the case of CD8+ CTL, after migration, 
they have the capacity to specifically recognize tumor cells and initiate tumor cell lysis79, 
80, 81. Collectively, T cells, as well as B cells and NK cells, that track to and invade a tumor 
are referred to as TIL. Because only properly activated and functioning T cells are able to 
traffic to the tumor82, 83, TIL therapy takes advantage of the natural process of T cell 
activation occurring in vivo while improving their anti-tumor potential by ex vivo-
expanding these cells with multiple rounds of proliferation to a therapeutically-relevant 
number13, 14, 17, 84, 85, 86, 87. Previous research has shown that the presence of CTL infiltrating 
melanomas, an immunogenic cancer, correlated with improvements in patient survival. 
As mentioned above, activated TAA-specific T cells localize to a tumor and exert their 
function. However, in chronic conditions such as cancer, CTL are experiencing chronic 
stimulation as well as being surrounded by immunosuppressive cytokines25, 26. In this 
situation, T cell exhaustion can occur. This is characterized by a reduction in function, up-
5 
 
regulation of inhibitory receptors as well as negative regulation by cytokines in the tumor 
microenvironment88. Blocking antibodies such as ipilimumab and nivolumab, bind to 
cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1), 
respectively89, 90. This prevents ligands from binding to CTLA-4 and PD-1 and transmitting 
exhaustion signals to the CTL. Broadly speaking, these blocking antibodies are referred to 
as checkpoint inhibitors and extend the lifespan of CTL to permit a greater window of time 
to exert cell-mediated anti-tumor immune responses91, 92, 93, 94, 95, 96. Checkpoint inhibitors 
have been associated with toxicities as a result of prolonging the activation state of T cells 
that are not tumor-specific94, 97, 98, 99. However, uncontrolled T cell activation can be 
combated by ex vivo-targeting inhibitors to bind only TAA-specific CTL100, 101.    
More recently, techniques to engineer and expand immune cells that directly recognize a 
tumor and initiate its destruction have been developed. The most well-known of these cells 
are CAR T cells102, 103. The ability to engineer and ex vivo-expand tumor-specific T cells 
permits a large number of tumor-specific therapeutic cells to be generated without the need 
for repeated and time consuming apheresis procedures to obtain a large quantity of 
therapeutic cells104, 105. One drawback of this technique is that CAR T cells can only be 
targeted to surface-expressed TAA106, 107, limiting the repertoire of proteins for which to 
engineer a CAR T cell to recognize. Although TAA-specific in nature, toxicities have been 
observed in CAR-modified T cells targeting CD19, BCMA and CD22 immunotherapy in 
patients that have diffuse large B cell lymphoma, multiple myeloma and refractory acute 
lymphoblastic leukemia84, 108, 109, 110, 111. CAR T cell therapy toxicity is mediated through 
cytokine-release syndrome112, 113, 114 and can also lead to macrophage activation 
syndrome115, 116, 117, which has resulted in lethal toxicity 105.  Further research is required 
to properly harness the anti-tumor potential of CAR T cells without associated life-
threatening toxicities. 
Rather than ex vivo-culturing, expanding and/or engineering tumor-specific T cells, 
alternative cell-based cancer immunotherapies involve APC78. Dendritic cells (DC) are the 
primary professional APC that form the bridge between the innate and adaptive immune 
systems and can initiate novel TAA-specific immune responses118, 119. Monocytes, 
macrophages and B cells can also serve as APC and are capable of stimulating existing T 
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cell responses120, 121. APC-based immunotherapies exist either in the form of a mixed cell 
population, such as peripheral blood mononuclear cell- (PBMC)-based therapies or as an 
enriched cell-specific population, such as DC-based immunotherapy7, 122, 123. In the context 
of cancer immunotherapy, both formulations serve as the link between the innate and 
adaptive immune systems and function as an adjuvant118, 119. However, depending on the 
cell type used as the APC, the vaccine could either help boost a pre-existing immune 
response if non-professional APC are used, or initiate the cascade of events required to 
activate a naïve T cell and render it TAA-specific if a professional APC, like a DC, was 
used as an adjuvant124. In addition to TAA-specific adaptive immune responses, APC can 
activate Natural Killer (NK) and Natural Killer T (NKT) cells via release of IL-12 and cell 
surface-bound expression of IL-15125, 126, 127, 128, 129. This results in increased IFNg 
production by NK cells as well as activation of NK and NKT cells to exert their cytotoxic 
effects on tumor cells in a TAA-independent fashion130, 131, 132, 133. Lastly, APC have been 
shown to activate macrophages, both directly through IL-2 release and indirectly through 
APC-derived IL-12 stimulating NK cell production of IFNg that in turn, activates and 
enhances the cytolytic function of macrophages134, 135, 136, 137, 138.  
1.4 Professional APC 
DC exist in the periphery in an immature state, and due to their high endocytic capacity, 
are constantly sampling the environment and processing antigen such that it can be 
presented to the adaptive arm of the immune system139, 140. DC can be either myeloid-
derived DC (mDC) or CD123+ BDCA2+ or BDCA4+ plasmacytoid-derived DC (pDC)141, 
142. Although both types of DC have been used in cancer immunotherapy142, 143, 144, pDC 
are generally more important with respect to anti-viral immune responses due to their 
ability to secrete high levels of type I interferon upon virus recognition145, 146, 147. mDC 
consist of multiple subsets such as CD1a+ CD207+ Langerhan’s cells148, 149, CD14+ dermal 
DC150 and CD11c+, CD1c+, CD141+ mDC151. The DC-related data presented in this thesis 
focuses on CD11c+ monocyte-derived DC (moDC), which are the DC subset most often 
utilized in clinical trials152.  After taking up antigen, APC process protein antigens into 
peptides that bind MHC Class I and MHC Class II and this antigen:MHC complex is 
presented on the cell surface. This allows for T cell recognition of these antigens through 
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the T cell receptor (TCR) recognizing peptide in the context of MHC151, 153, 154.  MHC Class 
I presents endogenous peptides and initiates CD8+ T cell activation for T cells whose TCR 
specifically recognizes the antigenic peptide being displayed155, 156, 157, 158, 159, 160. In 
contrast, exogenous antigen is processed and presented as peptides in the context of MHC 
Class II, which leads to the activation of CD4+ TH cells and provides the necessary 
downstream signaling for B cells to produce an efficient humoral-mediated immune 
response62, 161. APC function further extends to their ability to initiate activation of CD8+ 
CTL that are responsible for direct cell-mediated killing162, 163. In this manner, APC not 
only bridge the innate and adaptive immune system but also activate both arms of the 
adaptive immune system, a feature of which much attention has been focused to develop 
novel APC-based immunotherapies in a cancer setting.  
Professional APC, such as DC, possess the unique ability to prime naïve T cells in 
secondary lymphoid organs and initiate a TAA-specific immune response27, 164. Prior to 
priming naïve T cells, DC are found in an immature state in the periphery processing and 
presenting antigens from their surrounding environment139. It is in this state where TAA 
uptake and processing for presentation to the adaptive arm of the immune system takes 
place119. If this TAA uptake coincides with pathogen- and damage-associated molecular 
patterns (PAMP/DAMP) signaling through the extensive cell surface and internal 
expression of pattern recognition receptors (PRR) associated with DC, they begin to 
mature163. Maturation includes up-regulation of cell surface molecules important for co-
stimulation, such as CD80, CD83 and CD86139, 165, 166 as well as surface expression of 
migration markers like CCR7167, which are required for DC to reach secondary lymphoid 
organs by following a gradient established by chemokine ligands such as CCL19 and 
CCL21168, 169, 170. CCR7 up-regulation occurs in conjunction with CCR1, CCR2 and CCR5 
down-regulation, which are known to promote retention of DC in peripheral tissues167, 171, 
172 and thus, DC migration to a lymph node, for example, takes place. 
 While migrating to secondary lymphoid tissues, DC continue to mature, lose their ability 
to take up and process antigen while optimizing antigen presentation and begin to express 
cell surface molecules critical to DC activation, such as CD409, 139. Ligation and signaling 
through CD40 by CD154 (CD40L) present on CD4+ T cells results in the production of IL-
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123, 173, 174, 175, 176 which skews the subsequent immune response in a TH1 direction177, 178, 
179. It should also be noted that ligation and signaling through CD40 is required for an 
effective, and not tolerogenic, TAA-specific immune response to take place180. Through 
maturation and activation, these DC are now capable of interacting with T cells in the 
paracortex area of the lymph node181, 182 such that a strong, anti-tumor immune response 
with appropriate co-stimulatory engagement can be initiated176, 183, 184. Within the lymph 
node, mature DC can stimulate naïve CD8+ and CD4+ T cells to become either CD8+ CTL 
or CD4+ TH cells and thus, have been widely used in cancer immunotherapy to elicit potent 
tumor-specific T cell activation3, 101, 185, 186. Furthermore, mature DC are capable of cross 
presentation, which is the processing and subsequent presentation of exogenous antigen in 
the context of MHC Class I.  This is the mechanism by which mature DC can present 
exogenous TAA to CD8+ T cells, which in turn become activated into CTL155, 156, 157, 158, 
159. Through cross presentation, the number of TAA for which a CTL immune response 
can be launched against is greatly increased. CD8+ CTL are normally associated with an 
adaptive immune response launched against viruses; however, with respect to cancer 
immunotherapy, cross presentation of TAA by mature DC can lead to activation of TAA-
specific CTL, which can directly recognize and destroy a tumor160, 187. Through cytokine 
release from a mature DC, they can dictate the type of tumor-specific immune response 
that ensues and activate a broad spectrum of immune cell lineages188, 189. For example, 
activated DC can secrete IL-2 and IL-12, which can further promote the differentiation of 
naïve T cells into TH1 cells185, 186, 190, 191, as well as the proliferation and increased CTL 
cytotoxicity, NK cells, and NKT cells125, 134, 192. IL-2 and IL-12 also serves to promote the 
release of IFNg by NK cells, which is a key cytokine mediator of anti-tumor immune 
responses, that leads to the activation of  macrophages which further aid in skewing a TH1 
CD4+ T cell response132, 135, 136, 193, 194.  DC can both directly and indirectly activate B cells 
to initiate a tumor-specific humoral immune response as well as activation of 
macrophages193, 195. This combination of both innate and adaptive immune cell activation, 
although complex, forms the basis of APC-based cancer immunotherapy.  
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1.5 Shortcomings of current DC-based cancer 
immunotherapeutic outcomes 
In the context of DC-based cancer immunotherapy, migration from a distal location to 
secondary lymphoid organ is critical for proper DC maturation and activation and hence, 
therapeutic success196, 197, 198. Previous studies have shown that the number of antigen-
loaded DC that reach a secondary lymphoid organ is directly proportional to the magnitude 
of the ensuing antigen-specific immune response. By increasing the number of DC that 
migrate to a lymph node, the probability of DC interacting with and activating T cells in 
the lymph node is improved199. Although this study used CD4+ TH cells as a readout of 
immune response, it can be extrapolated to CD8+ T cells as well, as activated CD4+ T cells 
and the cytokines they secrete dictate the duration and strength of CD8+ CTL-mediated 
immune responses185, 186. Moreover, injection of ex vivo-cultured DC at a distal site rather 
than directly into a secondary lymphoid organ is preferred as only the properly matured 
and activated DC have the capacity to efficiently migrate to a secondary lymphoid organ200. 
If immature DC, which are poor producers of pro-inflammatory cytokines, were to arrive 
at the lymph node presenting TAA without up-regulation of co-stimulatory molecules, 
proper T cell activation would not take place and thus, T cell anergy, deletion and/or 
tolerance would occur139, 201, 202. Intranodal injection of matured DC loaded with TAA has 
been performed; however, the integrity of the lymph node is lost with direct injection and 
this could negatively affect the interaction between DC and T cells198, 203. Also, even with 
image-guided injections, the lymph node is only directly injected successfully 
approximately 50% of the time64, 196, 204. Lastly, direct injections of DC into the lymph node 
bypasses and does not take advantage of the natural maturation and activation process that 
DC undergo while migrating to a lymph node33, 205, 206. This explains why more DC are 
found in the lymph node after intranodal injection compared to distal injection of DC, but 
the associated ensuing TAA-specific immune response is superior after intradermal distal 
injection64, 183, 198.  
As DC are found at a very low concentration in peripheral blood141, 157, human DC-based 
cancer immunotherapies can be generated through isolation of DC-precursor cells, such as 
monocytes207, 208, 209, and ex vivo-culturing these cells under strictly controlled conditions 
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to yield a high purity of moDC210. Thus, TAA-presenting moDC are generated without the 
influence of the tumor-induced immunosuppressive microenvironment75, 77. moDC can 
also be matured ex vivo through co-culture with a well-characterized cytokine cocktail 
containing tumor necrosis factor (TNF-a), IL-6, IL-1b and prostaglandin E2 (PGE2)207, 211, 
212, 213. This cocktail induces moDC maturation within 24 hours, such that upon 
administration into the host, they are capable of launching an efficient tumor-specific T 
cell response in vivo. In addition to maturation, IL-2 production by DC in secondary 
lymphoid organs binds CD25 of naïve T cells present at the immunological synapse and is 
absolutely required for proper T cell priming214.    
Currently, the efficacy of professional DC-based cancer vaccines is limited as only 3-5% 
of injected cells reach secondary lymphoid organs post injection183, 198, 199, 215, 216, 217. 
Therefore, their interaction with and stimulation of anti-tumor T cell-mediated immune 
responses is sub-optimal. Further research is needed to improve the proportion of DC that 
reach secondary lymphoid organs post injection53, 218, 219. Research pertaining to DC 
manufacturing can be optimized such that DC release appropriate pro-inflammatory 
cytokines and chemokines that result in enhancement of their immunogenic potential220, 
221. One approach to enhancing the immunogenicity of a DC-based immunotherapy is to 
formulate new cytokine cocktails or adding ligands that bind PRR, such as TLR agonists7, 
222, 223, 224, 225 to ex vivo DC cultures. Agonists for TLR3226, TLR4155, TLR7/8227 and 
TLR9228 have all been investigated for use in DC-based immunotherapies. The intent of 
this approach is to produce DC with improved migration capacity and to direct the 
maturation process to produce a pro-inflammatory (TH1-mediated) rather than tolerogenic 
response24, 229, 230 as well as promote the activation of innate immune cells24, 231. This serves 
as a means by which to increase the effectiveness of the TAA-specific response that DC 
initiate through TAA presentation and migration to secondary lymphoid organs232, 233.  
It is also important to note that DC-based cancer vaccines are expensive to manufacture in 
an ex vivo setting and are associated with extensive and often time-consuming protocols 
before they can be administered back into the host152, 165. Furthermore, for vaccine 
strategies in which monocytes are employed to generate moDC, negative selection of 
monocytes is required152, 234. This further increases the cost and time of DC-based cancer 
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immunotherapy and impedes introduction of novel DC-based immunotherapies into the 
clinic as not all reagents required for ex vivo cultures are manufactured under Good 
Manufacturing Practice (GMP)-compliant conditions, which is required if autologous DC 
are to be injected back into a patient235, 236.  Therefore, research has also focused on 
generating shorter cell culture protocols or on using non-professional APC-based cancer 
vaccine immunotherapy alternatives. The goal of these alternatives is to produce a vaccine 
that is capable of activating and potentiating anti-tumor responses in vivo to an 
immunologically-relevant strength with a decreased financial burden associated with ex 
vivo culture costs237. 
1.6 Non-professional APC 
Other APC, such as B cells, monocytes and macrophages, are prevalent in high numbers 
in vivo when compared to the most professional APC, DC238. Additionally, other 
leukocytes, such as NK cells, express MHC Class II on their surface but their overall 
numbers are small compared to B cells and monocytes131, 238, 239. Granulocyte populations 
can also serve as APC but they do not survive in culture long enough to be useful in ex 
vivo-prepared APC therapeutic approaches240. Furthermore, mixed APC-based 
immunotherapeutic approaches are derived from PBMC that are largely void of 
granulocytes following gradient centrifugation. Both professional and non-professional 
APC can serve as adjuvants in the context of cancer vaccines through appropriate 
presentation of tumor-specific epitopes to CD4+ and CD8+ T cells in conjunction with 
necessary co-stimulatory- and supportive cytokine-mediated signaling. However, non-
professional APC function to increase or expand on a pre-existing adaptive immunity to 
the peptide being presented, which in the context of cancer immunotherapy, is a TAA241, 
242, 243.  
Mixed or heterogeneous APC-based cancer immunotherapy strategies have proven 
effective in increasing overall survival in cancer patients7. However, research into 
improving these existing therapies such that the TAA-specific immune response can reach 
its full potential is required. Although heterogeneous APC-based cancer immunotherapies 
are not as costly as DC-based vaccines, they remain expensive compared to conventional 
therapies considering the modest increase in overall survival that they currently provide244, 
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245. The most well-known APC-based cancer immunotherapy strategy, Sipuleucel-T 
(ProvengeÒ), was the first ever approved for use in humans7. Sipuleucel-T significantly 
prolonged overall survival by 4.1 months in castrate-resistant prostate cancer patients in a 
double-blind, placebo-controlled multi-centre Phase III trial246. This immunotherapy is 
derived from autologous human PBMC, which consists of a heterogeneous leukocyte 
population. This population consists of a large percentage of APC such as monocytes and 
B cells as well as other cell types including T cells and NK cells247, 248 that have integral 
roles in establishing and maintaining long-term anti-cancer immunity.  
In this immunotherapy, prostate cancer patients receive three autologous leukapheresis 
infusions241, 249. PBMC from prostate cancer patients are cultured ex vivo with a fusion 
protein that consists of granulocyte-macrophage colony stimulating factor (GM-CSF) 
fused to PAP, which is expressed in 95% of prostate cancers42, 248, 250. GM-CSF serves to 
properly activate the APC within the PBMC while PAP is a prostate-specific immunogenic 
antigen required for increasing and potentiating an already-existing but dampened tumor-
specific immune response in vivo7, 249. Thus, the already primed anti-tumor immune 
response can be boosted to reach an immunologically relevant level that provides benefit 
to the host. The fusion protein was created such that all APC expressing the receptor for 
GM-CSF (CD116)251 that uptake and process this fusion product are rendered activated 
and present a prostate-specific TAA. This is especially important given that TAA-specific 
APC can lead to tolerance to a tumor antigen, or as described previously, can even be 
detrimental to the patient, if not co-expressing activation and co-stimulatory markers with 
TAA presentation201. Patients undergo three rounds of leukapheresis to obtain PBMC, 
which are then cultured ex vivo with the fusion protein mentioned above for three days and 
infused back into the patient intravenously at greater than or equal to 40x106 large cells 
expressing CD54241, 246. CD54 is the ligand for integrin complex lymphocyte function-
associated antigen (LFA-1, also known as CD11a252) and is expressed on a variety of 
immune cell subsets253, 254. Upon CD54 binding, LFA-1 on CD8+ T cells adopts a high 
affinity conformation that stabilizes the immunological synapse and results in a more 
robust subsequent immune response. In the absence of this increased immunological 
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synapse stability, the cytotoxic activity and IFNg secretion of activated CD8+ T cells is 
greatly diminished255, 256. 
1.7 Advantages of mixed APC-based cancer 
immunotherapies 
The process to generate this immunotherapy ranges from 48-72 hours, which is much 
shorter than a DC-based vaccine immunotherapy and does not employ the use of expensive 
enrichment procedures and costly pro-inflammatory cytokine cocktails required to 
properly mature DC246. Although only modest survival benefits have been observed with 
this type of cell-based prostate cancer vaccine immunotherapy, Sipuleucel-T set an 
important precedent in the field of cancer immunotherapy upon receiving Food and Drug 
Administration (FDA) approval78, 257. However, its mechanism of action is still not fully 
understood, and the approach requires improvement in order to be more efficacious246, 258. 
It is largely unknown where the PBMC that comprise Sipuleucel-T migrate to post injection 
and in which specific in vivo locations they expand pre-existing anti-tumor immune 
responses and exert their therapeutic effects. It has never been demonstrated that PAP-
specific T cells activated by Sipuleucel-T APC actually penetrate the tumor in increased 
numbers. It is assumed that they reach secondary lymphoid organs considering that 
antibodies to PAP and PAP-specific T cells have been detected in the peripheral blood of 
patients following treatment42, 120, 259, 260. Thus, tracking of the cells post injection, 
quantifying them in various anatomical locations and monitoring their persistence in vivo 
could serve as a non-invasive surrogate marker of predicting the ensuing tumor-specific 
immune response. Furthermore, as it is largely unknown where ex vivo-cultured APC 
migrate to post-injection and how long they persist at these locations, non-invasive tracking 
and quantification of APC could be advantageous. This would identify other in vivo 
locations in which these cells migrate to and what effect (positive or negative) this 
migration has on the host in the context of cancer immunotherapy8, 43, 83.  
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1.8 Non-invasive imaging modalities to predict cell-based 
cancer immunotherapeutic outcomes 
Although numerous types of non-invasive imaging modalities exist, care must be exercised 
when choosing the appropriate non-invasive imaging modality196, 261, 262, 263. Ultimately, 
data compiled from pre-clinical small animal studies and in vitro human studies should be 
used as the basis for clinically translating knowledge into human studies. Therefore, 
clinically relevant non-invasive imaging modalities can be used in combination with an 
established DC-based or APC-based cancer vaccine immunotherapy to predict the 
effectiveness of the ensuing immune response. This information can also be used to derive, 
as well as gain, insight into unanswered questions regarding the immunological importance 
of migration to other in vivo locations109, 264 such as sites of metastases. Moreover, this 
imaging modality should not affect the immunogenicity, viability and phenotype of the 
cell-based cancer vaccine.  
Therapeutic cell tracking has been conducted in vivo using a wide variety of imaging 
techniques, such as scintigraphy, single photon emission computed tomography (SPECT), 
and positron emission tomography (PET)196, 265, 266, 267, 268. The main limitation of these 
techniques is time, as they each employ radioactive tracers with short half-lives and are a 
source of radiation themselves269. When considering cell tracking in vivo in the context of 
cancer immunotherapy, therapeutic cells can reach secondary lymphoid organs within 
hours after injection and persist at a given location for many days77, 270, which is too long 
of a window to image with most radioactive tracers. Thus, scintigraphy, SPECT and PET 
imaging modalities are not amenable to longitudinal studies265, 266, 269, 271, 272. However, 
radionuclides with longer half-lives, such as Zirconium-89 (t1/2 = 3.3 days) in combination 
with stable transduction of cells with reporter transgenes that increase and maintain label 
uptake highlight the future potential use of PET imaging for longer term in vivo clinical 
cell tracking 267. Currently, radionuclide-based modalities do not provide an anatomical 
context to the observed signal, which is absolutely necessary when considering the 
immunological effect that a professional or non-professional APC has at a given in vivo 
location. These imaging techniques are often combined with computed tomography (CT) 
scans to provide two- or three-dimensional anatomical information; however, this 
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introduces further radiation exposure to the patient and is not practical when considering 
longitudinal imaging studies that includes multiple rounds of imaging of the same patient 
who may also have been subjected to significant radiation cancer therapy269, 273. 
Optical imaging techniques such as fluorescence and bioluminescence do not involve 
radiation exposure, are highly sensitive and have been used to detect DC in mice274. They 
are only well-suited for small animal imaging and pre-clinical studies. A FDA-approved 
fluorescence agent, indocyanine green (IC-Green) is suitable for use in humans; however, 
the limited depth that light can penetrate in vivo still poses an issue and thus, is not widely 
used for clinical studies141, 275. Current research into constitutive expression of reporter 
genes, such as cell surface receptors or transporters that facilitate increased label uptake, 
in targeted cells have broadened the applicability of these pre-clinical imaging techniques. 
Furthermore, labeling cells of interest using a reporter transgene expression system 
circumvents the limitations surrounding label dilution as a result of labeled cell 
proliferation267. However, repeated imaging using this technique may become 
compromised if an immune response to the reporter gene takes place in addition to or 
instead of an immune response to the TAA276, 277. Unlike the above imaging modalities, 
magnetic resonance imaging (MRI) permits exquisite soft tissue contrast, does not involve 
ionizing radiation and thus, is conducive to longitudinal imaging studies dealing with 
tracking and quantification of cell migration in vivo278.   
1.9 Cellular MRI as a suitable non-invasive imaging 
platform 
Traditionally, MRI is used to generate standard three-dimensional proton images that 
provide excellent contrast between soft tissues of varying composition278. Alternatively, 
MRI imaging can be exploited to track specified cell populations in vivo using a technique 
known as cellular MRI279. Therapeutic cells of interest can either be labeled with a contrast 
agent or cell labeling agent that permits their detection and is able to discriminate labeled 
cells from surrounding tissue that has not incorporated contrast or cell labeling agents (see 
Table 1-1)280, 281, 282. With respect to contrast agents, therapeutic cells can be labeled with 
such an agent prior to injection or targeted in vivo using a contrast agent directly injected 
into the body. In the latter case, the contrast agent can be taken up directly by 
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phagocytic/endocytic cells or targeted to a specific cell type through conjugation to a 
receptor ligand protein or to an antibody that specifically recognizes the cell population of 
interest, for example, the murine DC marker CD11c283, 284. A standard proton scan prior to 
infusion of therapeutics cells needs to take place, followed by the same scan post-infusion 
at an identified time point. Upon comparison of the two scans, labeled cells can be 
identified either by a loss or gain of contrast at a given location, depending on the contrast 
agent used285, 286. Contrast agents that produce a hyperintense signal, such as gadolinium- 
and manganese-based agents have been used in vivo287, 288, 289, 290. However, difficulties 
exist in loading certain therapeutic cell types with manganese, gadolinium and other 
lanthanide metals, the sensitivity of detection is low with these agents on the order of 105 
cells/voxel and under certain circumstances they may be associated with toxicity287, 288, 289, 
290, 291.  
An alternative class of cell labeling agents are iron oxide-based contrast agents, such as 
superparamagnetic iron oxides (SPIO) Feridex and Resovist, micron-sized Bangs particles 
and ultra-small SPIO (USPIO) nanoparticles such as Feraheme or Sinerem292. Iron oxide 
nano- or micron-sized particles generate a hypointense signal293. Feridex and Resovist were 
previously approved for human use until they were removed from the market in 2008 
primarily due to lack of clinical use. Currently, Resovist is now only available for purchase 
in Japan294, 295, 296. Although the sensitivity of detection of iron oxide particles using clinical 
1.5-3 Tesla (T) MRI scanners that generate hypointensities is on the order of tens to 
hundreds of cells per voxel in vivo, a hypointense signal is difficult to quantify and is semi-
quantitative at best297, 298. Furthermore, hypointense signals observed in vivo can also result 
from the inherent physical and chemical properties of soft tissue and bone and result in the 
generation of chemical shift artifacts.  Therefore, iron-labeled cells cannot be detected with 
100% certainty and in combination with this contrast agent being removed from the market 
and not yielding unambiguous detection of injected cells, researchers began to explore 
alternative means of cell detection using MRI299, 300, 301. 
1.10 19Fluorine (19F-based) cellular MRI 
The high endocytic ability of APC and more specifically, DC, can be exploited to label 
these therapeutic cells with a large amount of labeling agent that in turn, leads to an 
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increased sensitivity of detection using cellular MRI302. A 19fluorine perfluorocarbon- 
(PFC)-based cell labeling agent (CS-1000, Celsense, Inc.) is manufactured from a 
hydrocarbon in which all hydrogen atoms are replaced with 19fluorine atoms to create a 
19F-PFC and formulated into an emulsion to increase the capacity of cells to uptake larger 
amounts of the label299. Labeling of these cells occurs via macropinocytosis and results in 
label being incorporated into multi-lamellar macropinosomes in the cytoplasm303. A GMP-
compliant formulation that obtained FDA conditional approval as a new investigational 
drug for use in a DC cancer immunotherapy vaccine clinical trial for the treatment of 
colorectal cancer77 exists, which is an important aspect for those interested in translational 
research. It should also be noted that this same type of agent has been previously used as a 
replacement oxygen carrier in humans without any observed adverse reactions304, 305 as 
well as used in contrast-enhanced ultrasound306. By using this cell labeling agent in 
conjunction with 19F cellular MRI, labeled therapeutic cells can be directly detected in vivo 
because of 19F incorporation, with anatomical context to this observed signal being 
provided upon overlaying a 19F scan with a conventional proton (1H) MRI scan. This is 
made possible by using a dual-tuned radiofrequency coil capable of detecting both 19F and 
1H atoms77. This labeling agent has garnered much attention due to its ability to label a 
high percentage of APC and has been shown to label primary human DC on the order of 
1013 19F atoms/cell291. Additional cell types such as T cells, both manufactured and 
primary, macrophages and mesenchymal stem cells (MSC) have been labeled with this 
agent270, 283, 299, 307, 308. Also, the positive signal produced from labeled cells in vivo can be 
quantified. For quantification to be ascertained, the in vivo signal intensity must be 
compared to a reference tube of known concentration of 19F atoms, followed by conducting 
nuclear magnetic resonance (NMR) spectroscopy to determine the average loading of 19F 
atoms into cells and thus, permits the quantification of the number of 19F-labeled cells at a 
given location in vivo77, 307, 309. Although the sensitivity of detection is lower than iron-
based contrast agents and is on the order of 103-104 cells per voxel, 19F-labeled cells can 
be unambiguously detected due to the negligible endogenous 19F signal observed anywhere 
in the body, including immunologically-relevant locations, such as secondary lymphoid 
organs261, 291, 310. Although fluorinated anesthetics can concentrate in vivo in regions 
containing high amounts of lipids, such as the fat pad surrounding lymph nodes, it is 
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possible to eliminate this contaminating fluorine signal from true signal produced by 19F-
PFC-labeled cells311. Moreover, the stable isotope of fluorine is exploited for this imaging 
technique, allowing for longitudinal cell tracking of terminally differentiated cells for up 
to one week, or even longer provided the labeled cell remains viable77, 270, 307, 308. In the 
case of terminally differentiated cells such as DC there will be little to no dilution of signal 
due to cell proliferation203. It is unknown if loss of 19F signal occurs due to release of 
exosomes, but it should be noted that DC do actively produce exosomes312. This cell 
labeling agent is very stable as no known eukaryotic enzyme capable of degrading or 
modifying it exists, it is not cytotoxic at therapeutic levels and is stable at low pH311, 
eliminating the worry that acidification of endosomes containing this labeling agent would 
reduce signal detection.  Finally, the amount of 19F incorporated in a therapeutic cell 
injection is so low that researchers are not concerned from a patient safety perspective77. 
The total 19F incorporation amount is multiple orders of magnitude less than the fluorine 
content contained within toothpaste and other oral care products such as mouthwash 
(personal calculation). Altogether, this agent permits accurate quantification of therapeutic 
cells in a defined in vivo location.   
Extensive immunological characterization of the cell labeling agent and how it affects the 
inherent function of immune cells that it is incorporated into was conducted in this thesis. 
Rather than simply focusing on labeling a cell with a cell labeling agent and detecting it, 
an immunological approach was investigated, such that upon translation to future clinical 
trials, one can be assured that a cell label is simply being used to label a cell without any 
negative impact on the normal immunological function of that given cell type. 
By using a novel 19F MRI-based imaging technique to track and quantify in vivo migration 
of therapeutic cells in both human and murine models of cancer immunotherapy, as well 
as using this technique to non-invasively predict immunotherapeutic outcome, the 
unanswered questions of where therapeutic cells migrate to post-injection and what the 
immunological consequence of such migration is can begin to be answered. Lastly, this 
platform can be broadly used to study and improve the effectiveness of cell-based therapies 
in alternative contexts such as tracking the fate of transplanted stem cells and investigating 
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the migration and persistence of immune cells in the context of autoimmune diseases270, 
313.   
Regardless of whether a cancer immunotherapeutic approach consists of introduction of 
tumor-specific peptides in vivo to be taken up and processed by resident APC, infusion of 
checkpoint inhibitors, CAR T cell intravenous infusion or an ex vivo-cultured and activated 
APC vaccine presenting TAA, knowledge of the location and persistence of therapeutic 
cells in vivo still largely remains unknown17, 314. The lack of knowledge of location and 
quantification of therapeutic cell or cell products once administered in the host is impeding 
the development of novel strategies to increase the effectiveness of previously established 
therapies as well as serve as a surrogate marker for comparing the effectiveness of newly 
emerging vaccine or cell-based immunotherapy formulations. Furthermore, knowledge of 
off-target migration of therapeutic cells can help to modify new therapies such that 
associated toxicity issues (eg. CAR T cell off-target effects in non-tumor cell-bearing 
tissues105, 114, 315) can be prevented prior to introduction into humans and thus, improve the 
safety profiles of immunotherapies without decreasing their effectiveness in vivo. This 
thesis serves to establish 19F cellular MRI as a non-invasive imaging modality to track and 
quantify APC-based cancer vaccine immunotherapies upon re-injection into the host as 
well as compare and contrast the immunological effectiveness and ease of translation of 
homogeneous professional APC-based vaccines such as DC-based vaccines and mixed 
heterogeneous APC-vaccines derived from PBMC.  
Both human and mouse-derived DC are investigated to determine if they can be labeled 
with a 19F-PFC compound without affecting their viability, phenotype, function and in vivo 
migration. Assessing tumor-specific T cell proliferation launched by a DC-based vaccine 
as well as the effect this 19F-PFC has on a tumor-specific immune response is explored. 
Finally, pre-clinical translation of APC-based immunotherapies is conducted using a 
heterogeneous mixed-APC based vaccine approach. Taken together, the extensive 
knowledge learned in pre-clinical small animal models regarding APC-based 
immunotherapy, as well as the proof of principle investigation into labeling human primary 
cells with this 19F-PFC-based cell labeling agent under GMP conditions was used to 
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assemble a clinical trial application to Health Canada to image autologous 19F-PFC-labeled 
cells in humans. 
Table 1-1. Properties of MRI-based contrast and cell labeling agents used in vivo. 
Class of Agent Examples Type of Agent Sensitivity of Detection 
(cells) 
 
Iron Oxide 
Nanoparticles 
 
Lumiremâ 
Feridex I.V.â 
Resovistâ 
Ferahemeâ 
Sinerem281, 284 
 
Negative 
(hypointense) 
contrast agent316 
 
 
10-100/voxel317, 318  
 
Gadolinium 
Chelates 
 
ProHance291 
Positive 
(hyperintense) 
contrast agent291  
 
105/voxel291  
 
Manganese 
Oxide/Carbonate 
 
MnCO3, MnO2 
Positive 
(hyperintense) 
contrast agent290 
 
105/voxel291 
 
19Fluorine 
Perfluorocarbon 
(19F-PFC) 
 
CS-1000282 
 
 
Direct 19F 
detection 
 
 
 
103-104/voxel291 
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2.2 Introduction and Rationale 
As dendritic cells are professional APC, they can activate naïve T cells to launch a potent 
TAA-specific immune response27, 164. To function as an adjuvant in the context of APC-
based cancer immunotherapy, DC must present TAA in combination with appropriate co-
stimulation and activation molecules and cytokine support to launch an effective non-
tolerogenic TAA-specific immune response78. Thus far, the overall efficacy of DC serving 
as an adjuvant within a cancer immunotherapy has been sub-optimal yet free of toxicity 
concerns207, 319.    
One possible explanation for the overall ineffectiveness of DC-based immunotherapies is 
the lack of standardization in pre-clinical models that persist when translated into human 
clinical trials74. As circulating DC account for less than 1% of total PBMC157, culturing 
DC from precursor cell populations is widely used to generate a sufficient number of DC207, 
208, 209. Also, variations in delivering TAA to DC and their route of administration have 
been described64, 74, 153, 204, 320. As a result of the often harsh immunosuppressive 
environment induced by a tumor in vivo, ex vivo culturing of DC is preferred such that 
culture conditions can be strictly controlled to yield properly matured and activated DC 
prior to administration back into the host74, 76, 321. Ex vivo culturing conditions have also 
been modified in an effort to increase the immunogenicity of TAA-specific DC218, 220, 221. 
Therefore, due to the lack of standardization when investigating DC in the context of cancer 
immunotherapy, comparing the effectiveness of novel anti-cancer strategies as well as 
improving upon the immunogenicity of an established vaccine formulation becomes 
difficult.  
Irrespective of the methods employed to yield therapeutic DC, injected DC must traffic 
from a distal location to a secondary lymphoid organ to properly exert their function196, 197, 
198. Previous research indicates that only approximately 5% of injected DC reach a 
secondary lymphoid organ, such as a lymph node, post injection198, 200, 217. This limited 
migration is another main contributing factor to sub-optimal effectiveness of DC-based 
cancer vaccines218, 219 as the quantification of DC migration to the lymph node is directly 
proportional to the outcome of the ensuing immune response199. Currently, the absence of 
a non-invasive longitudinal imaging technique to track therapeutic cells after injection 
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hinders the development of more effective immunotherapies109, 264, as knowledge 
pertaining to in vivo anatomical locations and persistence of therapeutic cells in these 
locations cannot be ascertained through non-invasive means.  
19F cellular MRI can serve as a suitable non-invasive imaging platform to detect and 
quantify migration of DC in vivo 291, 302, 310, which in turn can be used as a surrogate marker 
to compare and improve upon the effectiveness of different immunotherapeutic DC vaccine 
formulations. To test this non-invasive imaging platform, an investigation to determine if 
murine bone marrow-derived DC (BMDC) can be labeled with a 19F-PFC cell labeling 
agent without alterations to viability, phenotype and function was conducted. BMDC were 
chosen as the immune cell type for initial studies of 19F-PFC labeling as BMDC bone 
marrow precursors are very similar to blood monocytes, are highly endocytic and upon 
maturation and activation, become migration-competent to reach lymph nodes and initiate 
an antigen-specific immune response279, 322. Also, BMDC are terminally differentiated and 
therefore, 19F-PFC signal dilution as a result of cell proliferation is not a concern203.  
Using a wide range of culture conditions that included increasing the concentration of 19F-
PFC in culture, optimal ex vivo culture conditions for labeling BMDC with 19F-PFC 
without significantly altering viability and phenotype were determined. As previous 19F 
cellular MRI studies have simply reported that 19F-labeled therapeutic cells were migration 
competent in vivo77, 302 without comparison to the migration competency of unlabeled cells 
from the same source, it cannot be said that 19F cell labeling agents do not hinder in vivo 
migration. Therefore, we designed in vivo migration experiments that permit migration 
comparisons between control unlabeled and 19F-PFC-labeled BMDC.  All previous studies 
employing mouse models to examine the feasibility of using 19F-PFC to track cells in vivo 
employed high field MRI scanners in the range of 7 T to 11.7 T, far from the normal 
magnetic field strength available in the majority of clinical scanners299. Therefore, it was 
important to assess whether 19F-PFC-labeleled BMDC can be labeled with sufficient 
amounts of 19F-PFC and reach the lymph node in detectable quantities via 19F cellular MRI 
using a 3 T clinical scanner. The sensitivity of detection was further tested to determine if 
differences in migration can be ascertained between different in vivo conditions, such as 
25 
 
pre-treatment of the popliteal lymph node area with an inflammatory cytokine prior to 
BMDC administration. 
Experiments to measure the antigen-specific immune response induced by BMDC 
immunization were conducted to determine if 19F-PFC labeling of BMDC affected their 
capacity to present a model tumor antigen to and induce proliferation of cognate CD8+ T 
cells when compared to unlabeled BMDC. The model tumor antigen used was ovalbumin, 
which has a well-defined immunogenic peptide, SIINFEKL (OVA257-264), that is surface-
presented in the context of MHC Class I and is restricted to the murine b haplotype, H-2Kb 
261. A commercially-available tetramer that detects SIINFEKL-peptide in the context of a 
CD8+ T cell TCR was used to measure antigen-specific immune responses. Lastly, 
ovalbumin has been used as a model tumor antigen in B16-F10 melanoma261, 323.  
The B16-F10 melanoma cell line, originally developed by Fidler324 was generated by 10 
successive adoptive transfers of lung metastases following intravenous injection of B16 
cells in C57Bl/6 mice323, 325. This cell line326, which usually metastasizes to the lung, is 
highly aggressive and proliferative, resulting in the death of most tumor-bearing mice if 
left untreated at or before 40 days post subcutaneous or intradermal inoculation327, 328. 
BMDC from tumor-bearing mice, in the absence of immunotherapy, are unable to stimulate 
a sufficient TAA-specific T cell response due to the harsh immunosuppressive environment 
induced by this cell line329, 330, 331, 332. Therefore, BMDC-based and T cell-based 
immunotherapeutic strategies have been investigated to combat this cancer261, 333. 
However, it has yet to be determined if this immunotherapy can be used as a platform to 
investigate if 19F cellular MRI can successfully detect and quantify the migration of TAA-
specific BMDC in vivo and serve as a surrogate marker of vaccine effectiveness in a tumor-
bearing mouse model. 
For human moDC studies, different maturation cytokine cocktail and TLR ligand 
combinations used to induce maturation of ex vivo-cultured 19F-PFC-labeled moDC were 
conducted and compared to unlabeled control moDC from same donor. The viability and 
phenotype as assessed by antigen presentation and co-stimulation (HLA-DR, CD80, 
CD86)139, activation (CD83, CD40, CD54)9 and migration (CCR7)167 cell surface markers 
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was measured for both 19F-PFC-labeled and control unlabeled moDC in each culture 
condition. Cytokine secretion profiles were measured for each culture condition and 
included both pro-inflammatory (IL-12p70 and IFNg) and anti-inflammatory (IL-10) 
cytokines173. Cytokine secretion by ex vivo-maturated moDC is important as it dictates the 
type and strength of ensuing immune response, which in the case of cancer immunotherapy, 
a TH1-mediated immune response is preferred136, 190, 193. These studies seek to efficiently 
label human moDC with 19F-PFC to permit in vivo detection using 19F cellular MRI 
without altering viability, phenotype and function. The data for this part of the study is 
presented in Appendix I.  
This chapter outlines the pre-clinical studies conducted using an established therapeutic 
BMDC model to investigate whether 19F cellular MRI is a suitable, non-invasive, 
longitudinal imaging technique sensitive enough to permit correlating the strength of an 
ensuing immune response with 19F-PFC-labeled BMDC migration to a secondary 
lymphoid organ in a tumor-bearing mouse model.   
2.3 Materials 
2.3.1 Animals 
C57Bl/6 male mice (8-10 weeks old) were purchased from Charles River Laboratories 
(Wilmington, USA) and B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J male mice (8-10 weeks) 
were originally purchased from Jackson Laboratories (Bar Harbor, USA) but were later 
provided as a gift by Dr. Steven Kerfoot (Department of Microbiology and Immunology, 
University of Western Ontario). All experiments were pre-approved by the Animal Use 
Subcommittee at the University of Western Ontario and conducted in accordance with an 
approved protocol from University of Western Ontario’s Council on Animal Care (Protocol 
#2015-046). All experiments complied with policies published by the Canadian Council 
on Animal Care. Mice were anaesthetized with 2% isoflurane in oxygen.   
2.3.2 Reagents 
RPMI was purchased from ThermoFisher Scientific (Burlington, Canada) and completed 
with 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, minimal 
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essential media non-essential amino acids (MEM NEAA), sodium pyruvate (10 mM), 
HEPES and 2-mercaptoethanol (55 µM) (all from ThermoFisher Scientific). Cytokines 
used in culture media, GM-CSF, IL-4, IL-6, IL-1b, and TNFa were obtained from 
PeproTech (Montreal, Canada), and murine CpG ODN 1826 was purchased from 
InvivoGen (San Diego, USA) and PGE2 was purchased from Sigma (Oakville, Canada).  
To generate BMDC, Hank’s balanced salt solution (HBSS), phosphate buffered saline 
(PBS) and Trypan blue was sourced from ThermoFisher Scientific, while bovine serum 
albumin (BSA) and normal goat serum (NGS) were purchased from Calbiotech (Spring 
Valley, USA) and Jackson Immunoresearch (West Grove, USA), respectively. Sigma 
supplied Histodenz™ non-ionic density gradient medium and SIINFEKL peptide (the 
immunogenic protein of chicken ovalbumin, amino acid residues 257-265). Rabbit 
complement was obtained from Cedarlane (Burlington, Canada), purified anti-mouse I-Ab 
(clone 25-9-17) was ordered from Biolegend (San Diego, USA) and purified rat anti-mouse 
B220 (RA3-6B2) was purchased from BD Bioscience (Mississauga, Canada).  
For flow cytometry, FITC Annexin V/7-aminoactinomycin D (7-AAD), CD19-PE (6D5), 
CD11b-Alexa Fluor 700 (M1/70), CD3e-FITC (145-2C11), CD86-BV421 (GL-1), CCR7-
PE (4B12), H-2Kb-PerCP/Cy5.5 (AF6-88.5), H-2Kb SIINFEKL-PE/Cy7 (25-D1.16), and 
CD11c-APC (N418) were all obtained from Biolegend. CellTrace™ carboxyfluorescein 
succinimidyl ester (CFSE) cell proliferation kit, CD8a monoclonal antibody (KT15) and 
goat anti-rat IgG (H&L) secondary antibody conjugated to APC were obtained from 
ThermoFisher Scientific, while Class I iTAg MHC Tetramer H-2Kb/PE SIINFEKL was 
purchased from MBL International Corporation (Woburn, USA).  
Ammonium-chloride-potassium (ACK) lysis buffer was purchased from Stemcell 
Technologies, Vancouver, Canada). Lastly, 19F-PFC cell labeling agents (CS-1000 ATM 
and CS-ATM DM Red, with the latter being the red fluorescent version of CS-1000 ATM) 
were purchased from Celsense, Inc. (Pittsburgh, USA).  
For experiments related to the transduction and transfection of the B16-F10 mouse 
melanoma cell line (B16-F10 (ATCC® CRL-6475™) obtained from Dr. Grant 
McFadden334 that stably expresses ovalbumin and luciferase, Geneticin™ (G418 sulfate), 
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ampicillin, PureLink™ HiPure plasmid filter midiprep kit, Opti-MEM™, Lipofectamine® 
2000, 0.25% trypsin-EDTA, pre-cast NuPAGE® 10% Bis-Tris gel, iBlot® 2 nitrocellulose 
(NC) regular stacks, iBlot® 2 system, ovalbumin polyclonal antibody conjugated to 
horseradish peroxidase (HRP), 10X loading buffer, and SuperSignal™ West Pico PLUS 
chemiluminescent substrate were all purchased from ThermoFisher Scientific (Burlington, 
Canada). Plasmid DNA (pcDNA3-TfR-OVA) was shipped as a bacterial stab in agar from 
Addgene (Cambridge, USA), purified ovalbumin protein was obtained from Sigma Aldrich 
(Oakville, Canada), and a BLUeye pre-stained protein ladder was purchased from 
FroggaBio, Inc. (Toronto, Canada). Perkin Elmer (Guelph, Canada) supplied the lentiviral 
particle used in transduction, RediFect™ Red-FLuc-green fluorescent protein (RediFect™ 
Red FLuc-GFP), RediJect D-Luciferin Ultra, hybrid optical/X-ray scanner IVIS Lumina 
XRMS in vivo imaging system and LivingImage Software. Lastly, an Odyssey® Fc 
Imaging System from LI-COR (Lincoln, USA) was used to image western blots.   
2.3.3 BMDC generation and 19F-PFC labeling 
BMDC were prepared based on the method of Inaba et al and Dekaban et al298, 335. Briefly, 
C57Bl/6 mice were euthanized using isoflurane and both femurs and tibias were collected. 
Surrounding soft tissue was cleared from bones which were subsequently disinfected with 
70% ethanol for 1 min at room temperature. Following the transfer of disinfected bones to 
sterile HBSS+0.1% BSA, epiphyses were cut at both ends and a 10 mL syringe with 
HBSS+0.1% BSA and 27G1/2 needle was used to flush bone marrow through a 70 µm 
filter to create a single cell suspension. Red blood cells were removed from cell suspension 
via a 5 minute room temperature incubation with ACK lysis buffer. After washing with 
cold HBSS+0.1% BSA and centrifugation, remaining cells were counted and resuspended 
in 2 mL complete RPMI. Anti-B220 and anti-I-Ab antibodies were added at 1 µL per 107 
cells and incubated on ice for 30 minutes. After washing in HBSS+0.1% BSA, the bone 
marrow cell suspension was incubated with 4 mL rabbit complement at 37°C to lyse B and 
T cell precursors. After extensive washing, the remaining cells were resuspended in 
complete RPMI at 3x105 cells/mL and GM-CSF and IL-4 were added at final 
concentrations of 4 ng/mL and 10 ng/mL, respectively. The cell suspension was then 
cultured for 4 days at 37°C/5% CO2 (20 mL cell suspension per T75cm2 flask).  
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On day 4 of culture, BMDC were isolated using 13.5% Histodenz™ gradient centrifugation 
(25 min, 500xg, 20°C, no brakes). Approximately half of the enriched BMDC were 
resuspended in complete RPMI (5x105 cells/mL) containing GM-CSF and IL-4 as 
mentioned above (control unlabeled BMDC), while the remaining BMDC were 
resuspended in the same media, followed by the addition of 19F-PFC cell labeling agent at 
either 2.5, 5.0, and 7.5 mg/mL. For all subsequent studies following the initial labeling 
with 19F-PFC, the concentration of 19F-PFC used was 5 mg/mL. All BMDC were then 
cultured overnight in 6 well plates at 37°C/5% CO2.  
A cytokine cocktail consisting of IL-1b (10 ng/mL), IL-6 (25 ng/mL), TNFa (25 ng/mL), 
PGE2 (10-6 M) and CpG ODN 1826 (0.2 µM) was added to all wells on day 5 of culture to 
induce maturation of BMDC for the final 24h of culture. On day 6 of culture, each BMDC 
condition was collected separately and an aliquot of mature BMDC was removed from 
each condition for viability and phenotyping analysis. Remaining BMDC were then 
formulated into injection doses and NMR spectroscopy cell pellets for in vivo 19F cellular 
MRI studies. For some experiments, further processing of BMDC took place immediately 
prior to injection and is explained in detail below.  
2.3.4 BMDC phenotyping and viability assessment 
An aliquot of cells from day 0 (before and after complement depletion), day 4 and from all 
culture conditions on day 6 was collected for phenotypic analysis. Cell aliquots were 
blocked in 5% NGS (v/v) in HBSS+0.1% BSA for 30 minutes on ice and then stained for 
CCR7-PE for 20 minutes at room temperature. Cells were then moved to ice and stained 
for an additional 25 minutes with CD11c-APC and CD86-BV421. Cells were washed and 
resuspended in HBSS+0.1% BSA, fixed with 4% paraformaldehyde (PFA), and stored at 
4°C until acquisition on an LSRII analytical flow cytometer (BD Biosciences).  
Trypan blue exclusion was used to determine viability each time an aliquot was removed 
for phenotyping. A more stringent viability assessment was also performed using FITC-
Annexin V and 7-AAD staining. After phenotype staining was complete, BMDC were 
stained with FITC-Annexin V at room temperature for 20 minutes followed by the addition 
of 7-AAD immediately prior to acquisition on an LSRII analytical flow cytometer (BD 
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Biosciences). Any sample containing 7-AAD was not fixed with 4% PFA and was acquired 
immediately. 
2.3.5 Adoptive cell transfer 
Day 6 mature BMDC labeled with or without 19F-PFC cell labeling agent were washed 
extensively with PBS and formulated into 2.5x106 cell injection doses in 40 µL of PBS. 
Footpad injections conducted on isoflurane-anesthetized mice with 2.5x106 19F-PFC-
labeled BMDC into one hind footpad and 2.5x106 control unlabeled BMDC into the 
contralateral hind footpad.  In a second group of mice, adoptive cell transfer was performed 
the same as above; however, 1x106 BMDC were injected instead of 2.5x106 BMDC.  
To compare migration between 19F-PFC-labeled and unlabeled BMDC, 2.5x106 and 1x106 
BMDC injections were performed as stated above, but with one modification. Immediately 
prior to injection, 19F-PFC-labeled BMDC and control unlabeled BMDC were additionally 
labeled with the intracellular fluorescent labeling agent CellTrace™ CFSE to allow for 
histological comparison of migration to popliteal lymph nodes post injection between 19F-
PFC-labeled and unlabeled BMDC. Collected BMDC were resuspended in warm PBS + 
0.5% FBS at 1x106 BMDC/mL and combined with 1 µM CFSE for 10 minutes at 37°C. 
The reaction was quenched with cold complete media for 5 minutes on ice and formulated 
into 19F-PFC+ CFSE+ BMDC and CFSE+ BMDC injection doses. CFSE incorporation for 
both BMDC conditions was verified using flow cytometry by comparing to an aliquot of 
cells from the same culture condition before CFSE staining took place.  
In addition to the aforementioned experiment that used an external fluorescent label into 
the cytosol (CFSE), a similar experiment was conducted that relied on a constitutively 
expressed fluorophore such that migration between 19F-PFC-labeled BMDC and control 
BMDC could be compared without having to incorporate or consider the effect of an 
external label on the adoptively transferred cells. B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J 
mouse bone marrow was cultured as previously described above to yield day 6 mature 
BMDC that all express a variant of red fluorescent protein (DsRed, 558 nm excitation, 583 
nm emission). Then, 2x106 DsRed+ BMDC were injected into the hind footpad of 4 mice, 
with 2x106 DsRed+ 19F-PFC+ BMDC injected into the contralateral hind footpad. Thus, 
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after 48 hours of migration, popliteal lymph nodes were removed following euthanasia, 
and a histological comparison of the migration capacity of 19F-PFC-labeled BMDC and 
control unlabeled BMDC can be compared and quantified using DsRed fluorescence as a 
readout.  Flow cytometry was used to verify DsRed-expression of 19F-PFC+ DsRed+ and 
DsRed+ control BMDC immediately prior to injection. 
To determine if pre-conditioning of the popliteal lymph node with murine IL-1b increased 
BMDC migration, 3x106 19F-PFC+ BMDC were injected into the footpads of 7 C57Bl/6 
mice. Injections were prepared exactly as stated above. However, 3h prior to footpad 
injections, 4 C57Bl/6 mice were anesthetized with isoflurane and received injections of 
300 ng of murine IL-1b into both popliteal lymph node regions, while the 3 remaining 
C57Bl/6 mice did not receive a cytokine pre-injection. 
The last adoptive cell transfer that took place was performed to assess model tumor 
antigen-specific immune responses. Two hours prior to hind footpad injection, all day 6 
19F-PFC-labeled BMDC and half of unlabeled day 6 BMDC were co-cultured with 0.2 
µg/mL of cell suspension of the immunogenic chicken ovalbumin peptide, SIINFEKL. 
Injections of 2.5x106 cells were formulated as described above for 3 injection conditions: 
unlabeled BMDC not presenting SIINFEKL peptide, unlabeled BMDC presenting 
SIINFEKL peptide, and 19F-PFC-labeled BMDC presenting SIINFEKL peptide. Injections 
for each condition were performed into both the right and left hind footpad of anesthetized 
C57Bl/6 mice (n=5 per group).  
2.3.6 MRI of BMDC migration 
For studies that required 19F cellular MRI imaging, C57Bl/6 mice were imaged 48 hours 
following footpad injection. Mouse imaging was performed with either a 9.4 T Varian 
small-animal MRI scanner (Santa Clara, CA, USA) or a 3 T clinical MRI scanner (General 
Electric, ON, CA). Three dimensional-balanced steady state free precession (bSSFP) 
sequences were used for both proton and 19F MR imaging at 9.4 T and 3 T. Animals were 
imaged alongside reference tubes containing a known 19F concentration (3.33x1016 19F/μL 
or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with 2% isoflurane, with 
breathing rate and temperature monitored throughout the scan. MR images were acquired 
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at 9.4 T using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), tuned 
to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively.  For proton imaging 
the scan parameters were: repetition time (TR) = 5.0 ms, echo time (TE) = 2.5 ms, receiver 
bandwidth (rBW) = ±39 kHz, flip angle (FA) = 30°, phase cycles (PC) = 4, averages = 3, 
resolution = 200x200x200 μm3. For 19F imaging the parameters were: TR = 4.0 ms, TE = 
1.9 ms, rBW = ±12.5 kHz, FA = 70°, PC = 4, averages = 200, resolution = 1x1x1 mm3. To 
avoid 19F present in isoflurane confounding the 19F-PFC signal, imaging was performed by 
centering on the 19F-PFC Cell Sense-specific frequency as we previously described270.  The 
total protocol time for both proton and 19F imaging was under 90 minutes for both 9.4 T 
and 3 T. MR images were acquired at 3 T using a 4.3x4.3 cm dual-tuned surface coil 
(Clinical MR Solutions, WI, USA). For proton imaging the scan parameters were TR = 
12.8 ms, TE = 6.4 ms, rBW =  ±31.25 kHz, FA = 20°, PC = 6, NEX = 1 and 200x200x200 
µm3 resolution. For 19F imaging the parameters were, TR = 5.8 ms, TE = 6.4 ms, rBW =  
±10 kHz, FA = 20°, NEX = 200 and 1x1x1 mm3 resolution.   
2.3.7 19F-PFC loading efficiency and signal quantification 
The mean intracellular 19F content of BMDC was determined by NMR spectroscopy using 
a 400 MHz Varian vertical spectrometer.  First, a known number of 19F-PFC-labeled cells 
was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a 
solution containing 100 µL of 5% Triton X-100.  After lysing, the cells were transferred to 
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with 
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA 
provides a reference peak for quantifying the number of 19F spins/cell, since NMR signal 
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters 
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm. 
The number of BMDC detected within MR images was determined with Voxel TrackerTM 
software (Celsense Inc, Pittsburgh, PA)270, 308.  Prior to analysis, a signal correction was 
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest 
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal 
contained within a hand-drawn region of interest (ROI) was compared to the average signal 
produced by the reference tube containing a known 19F concentration. This information 
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was used alongside the 19F spins/cell, measured by NMR, to quantify the apparent number 
of cells located at the ROI.   
2.3.8 Post-MRI histology 
Immediately following MR imaging of C57Bl/6 mice that received hind footpad injections 
of 2.5x106 or 1x106 19F-PFC+ CFSE+ BMDC or CFSE+ control BMDC, both the left and 
right popliteal lymph nodes from each animal were removed and fixed in 4% PFA at room 
temperature. Cryoprotection of lymph nodes using sucrose gradients of 10, 20 and 30% 
was conducted at 4°C. The popliteal lymph nodes were then cryosectioned into 16 µm 
sections, digitally imaged and the CFSE+ fluorescence of 19F-PFC+ CFSE+ BMDC and 
CFSE+ control BMDC were quantified using Image Pro Plus 5.1 software and compared 
between BMDC culture conditions and between high (2.5x106) and low (1x106) BMDC 
injections. The same methodology for fluorescence microscopy quantification was 
conducted 48 hours after footpad injection of 2x106 DsRed+ 19F-PFC-labeled BMDC and 
2x106 DsRed+ BMDC, only with endogenous DsRed fluorescence being quantified rather 
than externally added CFSE fluorescence.  
2.3.9 Quantification of ovalbumin-specific in vivo immune response 
To create a model tumor antigen-specific immune response, day 6 matured 19F-PFC-
labeled BMDC and control BMDC were loaded with the MHC Class I (H-2Kb) 
immunogenic peptide of ovalbumin, SIINFEKL, prior to footpad injections (SIINFEKL 
loading mentioned in detail previously above). Control BMDC not presenting SIINFEKL 
served as the negative control. An aliquot of BMDC from all three injection conditions was 
phenotyped as stated previously with the following antibodies: CD11c-APC, CCR7-PE 
and CD86-BV421 as well as stained with H-2Kb-PerCP/Cy5.5 and H-2Kb:SIINFEKL-
PE/Cy7 for 25 minutes on ice to confirm peptide presentation in the context of H-2Kb.   
Following BMDC footpad injections, C57Bl/6 mice were left for 7 days to allow for a 
CD8+ T cell-specific immune response to be launched against the SIINFEKL peptide. At 
this point, both popliteal lymph nodes were removed from each mouse in each injection 
condition and were passed through a 70 µm strainer to obtain a single cell suspension. Flow 
cytometry staining for CD3e-FITC, CD8a monoclonal antibody and goat anti-rat IgG 
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APC-conjugated secondary antibody to identify all CD3+ CD8+ T cells in the lymph node 
cell suspension was then performed for each mouse for 25 minutes on ice. Within this 
population, a Class I iTAg MHC Tetramer H-2Kb/PE SIINFEKL was used to stain cells 
for 20 minutes at room temperature to identify CD8+ T cells that have specific 
immunoreactivity to SIINFEKL peptide in the context of H-2Kb as a result of SIINFEKL-
presenting BMDC injection. After staining for CD3e, CD8a and tetramer, cells were 
washed and resuspended in HBSS+0.1% BSA, followed by immediate acquisition on an 
LSRII analytical flow cytometer (BD Biosciences). 
2.3.10 Generation of ovalbumin- and luciferase-expressing B16-F10 
melanoma cell line 
A murine B16-F10 melanoma cell line was grown in RPMI media supplemented with 10% 
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, HEPES and 
2-mercaptoethanol (55 µM). A lentiviral transduction (RediFect™ Red-FLuc-GFP) was 
performed in the laboratory of Dr. Paula Foster such that this cell line stably expressed 
Luciola italica luciferase and GFP. A FACSAria III flow cytometric cell sorter (BD) was 
used to sort and collect the highest 2% of GFP-expressing cells. B16-F10 GFP+ Luc+ cells 
were then propagated in culture. Next, a bacterial stab in agar containing a plasmid that 
expresses ampicillin and G418 sulfate resistance as well as codes for ovalbumin, pcDNA3-
TfR-OVA, was quadrant streaked on lysogeny broth (LB) agar containing ampicillin (100 
µg/mL) and cultured overnight at 37°C. The next day, a single colony was picked from the 
LB agar plate and cultured overnight in 200 mL of LB broth containing ampicillin (100 
µg/mL). A PureLink™ HiPure plasmid filter midiprep kit and manufacturer’s instructions 
permitted the collection of plasmid DNA. Plasmid DNA (3 µg) and Opti-MEM™ (142.5 
µL) were combined and Lipofectamine® 2000 (15 µL) and Opti-MEM™ (142.5 µL) were 
combined in a separate Eppendorf tube. Both solutions were then mixed and left to sit at 
room temperature for 5 minutes. This 300 µL solution was then added to a well of a 6 well 
plate (VWR) which contained adherent B16-F10 Luc+ cells grown at approximately 60% 
confluency. A further 500 µL of Opti-MEM™ was added and a transfection then took place 
for 48 hours at 37°C/5% CO2.  
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After 48 hours, the transfected cells were collected using 0.25% trypsin-EDTA and 
resuspended in 50 mL complete RPMI containing Geneticin™ G418 sulfate (3 mg/mL)336 
as the selection pressure for ovalbumin expression. After 48-72 hours, 3 individual cell 
clusters were picked from the plate with a sterile P200 pipette tip and cultured in a T25cm2 
flask (VWR). B16-F10 Luc+ ovalbumin+ cells were then frozen for long-term storage while 
a cell pellet from each cell cluster was prepared to verify ovalbumin production via a 
Western blot analysis. 
A Western blot was conducted on lysates of these cell lines and included appropriate 
controls. Briefly, 160 µg of protein from each lysate was loaded into a lane, followed by 
160 µg of protein from an untransfected B16-F10 Luc+ cell line as a negative control and 
50 ng of purified ovalbumin as the positive control. All samples were combined with 10X 
loading buffer and boiled for 5 minutes prior to loading in their appropriate lanes, with 
BLUeye pre-stained protein ladder being added to the outside lanes. A pre-cast NuPAGE® 
10% Bis-Tris gel was run for 135 minutes at 150 V, followed by a transfer to a NC 
membrane (iBlot® 2 NC regular stacks) using the iBlot® 2 system. A 5% milk solution 
(w/v) in TBST was added for 1 hour at room temperature as a block step, followed by an 
overnight incubation at 4°C with a 1:2500 dilution in TBST of a polyclonal HRP-
conjugated antibody (ThermoFisher Scientific) to detect ovalbumin. Two 30 minute 
washes in TBST were performed and ~2 minutes after addition of a SuperSignal™ West 
Pico PLUS chemiluminescent substrate, the blot was read on an Odyssey® Fc Imaging 
System (LI-COR). 
Alongside the Western blot analysis, B16-F10 Luc+ ovalbumin+ cells were then stained 
with an antibody to detect surface expression of H-2Kb to verify that this melanoma cell 
line has not down-regulated its surface expression of H-2Kb. To determine if this B16-F10 
cell line was transduced appropriately, 1x105 cells were added to an Eppendorf tube and 
suspended in 150 µL of RediJect D-luciferin Ultra (30 mg/mL). An Eppendorf tube 
containing only D-luciferin substrate served as the negative control. After a 6 minute room 
temperature incubation, the cells were centrifuged, supernatant was discarded and the cell 
pellet was overlaid with 1% agarose. Both a GFP image and bioluminescent image were 
acquired on a hybrid optical/X-ray scanner IVIS Lumina XRMS in vivo Imaging System 
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and LivingImage Software.  Lastly, to confirm luciferase expression in a more biologically-
relevant context, a subcutaneous injection of 2x105 transfected and transduced B16-F10 
cells in the back of a C57Bl/6 mouse was performed. Once the tumor was established, 150 
µL of RediJect D-Luciferin Ultra (30 mg/mL) was administered intraperitoneally and after 
6 minutes, a bioluminescent image was acquired as described above.  
2.3.11 Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC 
migration to the lymph node with the ensuing antigen-specific 
immune response to a model tumor antigen ovalbumin (OVA) 
in a mouse model of melanoma 
To assess the correlation between 19F-PFC-labeled BMDC migration and ensuing tumor 
antigen-specific immune response in a mouse model of melanoma, tumors were established 
on the back of C57Bl/6 mice as described previously. Two days later, both 19F-PFC-labeled 
BMDC and unlabeled BMDC were co-incubated with SIINFEKL peptide and surface 
presentation of SIINFEKL in the context of H-2Kb was verified using flow cytometry as 
previously stated. Unlabeled BMDC not presenting SIINFEKL served as the negative 
control. A 3x106 cell injection for each population was performed into each hind footpad 
(n=2 per cell culture condition completed, n=10 in total upon completion). Tumor-bearing 
mice that received 19F-PFC-labeled BMDC injections underwent 3 T MRI scans with a 
4.3x4.3 cm dual-tuned 1H/19F surface coil (Clinical MR Solutions, Wisconsin, USA). The 
parameters were as follows: for 1H imaging, 0.2 mm3 spatial resolution, field of view 
(FOV) = 60 x 30 mm, matrix = 300 x 150, slice thickness = 0.2 mm, FA = 20°, rBW = +/-
31.25 kHz, TR/TE = 12.8/6.4 ms, NEX = 1 and 6 PC with a scan time of 23 
minutes. 19F imaging parameters were: 1 mm3 spatial resolution, FOV = 60 x 30 mm, 
matrix = 60 x 30, slice thickness = 1 mm, FA = 72°, BW = +/-10 kHz, TR/TE = 5.8/2.9 ms 
and NEX = 200, resulting in a scan time of 28 minutes. For mice that received unlabeled 
BMDC injections, 1H imaging parameters were: 0.2 mm3 spatial resolution, FOV = 60 x 
30 mm, matrix = 300 x 150, slice thickness = 0.2 mm, FA = 20°, BW = +/-31.25 kHz, 
TR/TE = 12.8/6.4 ms, NEX = 1 and PC = 4, with a scan time of 13 minutes. Finally, tumor-
bearing mice underwent bioluminescent imaging every second day until the pre-
determined experimental endpoint was reached (primary tumor ³ 600 mm3). Tumor 
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volumes were calculated using the formula: volume = (width2 x length)/2, with width and 
length being perpendicular tumor diameter measurements.  
2.3.12 Statistical analysis 
All data was presented as the mean with the standard error of the mean. A paired t-test 
(Graph Pad Prism, Version 7, La Jolla, USA), one-way ANOVA or two-way ANOVA 
were used and was defined when statistics were reported. Multiple comparisons were 
conducted for one- and two-way ANOVAs. Differences between means were considered 
significant if p ≤ 0.05. When written, the number of independent experiments is denoted 
by (N) while the number of replicates per independent experiment is defined by (n).  
2.4 Results 
2.4.1 The current established BMDC protocol generates high 
purity of CD11c+ BMDC and permits efficient loading of 19F-
PFC without affecting viability or phenotype 
On day 4 of the 6 day established protocol for generating BMDC from bone marrow 
precursors, immature BMDC are enriched from culture using Histodenz™ gradient 
centrifugation, which yields immature dendritic cells that are CD19-CD3-CD11b+CD11c+ 
with >80% purity (Fig. 2-1A-D). On day 6 of culture, mature CD11c+ BMDC constitute 
>80% of total cells (Fig. 2-2A). This established protocol was used to determine the highest 
concentration of 19F-PFC that can be added to BMDC culture on day 4 without affecting 
viability or phenotype. Concentrations ranging from 2.5 mg/mL to 7.5 mg/mL were added 
in culture and the resulting phenotype and viability was assessed. The viability of control 
BMDC in which no 19F-PFC was added was also included in this experiment. Irrespective 
of the concentration of 19F-PFC in culture, the phenotype of BMDC did not differ with 
respect to CD11c, CCR7 and CD86 cell surface percentage expression (Fig. 2-2A-C/E). 
Next, the viability of BMDC for each 19F-PFC concentration (and appropriate control) was 
investigated using trypan blue exclusion and more rigorously with FITC-Annexin V/7-
AAD staining (Fig. 2-2D). Viability was unaffected when increasing the concentration of 
19F-PFC from 2.5 mg/mL to 5 mg/mL (Fig. 2-2F) while also resulting in a 1.7-fold increase 
in the amount of 19F-PFC incorporated on average per cell as ascertained using nuclear 
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magnetic spectroscopy (NMR) (Fig. 2-2G).  This is in contrast to the decrease in viability 
observed with the 7.5 mg/mL 19F-PFC cell culture condition. Although a significant 
increase in 19F-PFC incorporation was observed at the highest labeling concentration, the 
decrease in viability associated with this label concentration was deemed not acceptable 
for future studies (Fig. 2-2F/G).  Therefore, all other experiments that required BMDC to 
be labeled with 19F-PFC were conducted at a cell labeling concentration of 5 mg/mL.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Representative flow cytometric gating 
strategy to confirm enrichment of CD11c+ BMDC.  
Figure 2-1. Representative flow cytometric gating strategy to confirm enrichment of 
CD11c+ BMDC. Prior to labeling of BMDC with 19F-PFC, CD11c+ BMDC were enriched 
from bone marrow cell culture using a Histodenz™ centrifugation gradient. Following this 
enrichment and debris rem val (A), singlet (B) cells were selected for to reveal the lack of 
CD19+ B cells and CD3+ T cells present following complement depletion of these cell 
lineages of day 0 of culture (C). CD3- and CD19- cells were then gated on CD11b and 
CD11c to reveal that post enrichment, consistently greater than 80% of cells remaining are 
CD11b+CD11c+ BMDC (D).   
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Figure 2-2. Increasing concentrations of 19F-PFC does not affect 
the phenotype of BMDC but does affect viability at high 
concentrations.  
Figure 2-2. Increasing concentrations of 19F-PFC does not affect the phenotype of BMDC 
but does affect viability at high concentrations. Flow cytometry and appropriate FMO 
controls were employed to phenotype CD11c+ BMDC (A) to confirm CCR7 (B) and CD86 
expression (C). The viability of CD11c+CCR7+CD86+ BMDC was assessed using Annexin 
V/7-AAD discrimination (D). CD11c+ BMDC phenotype remained unchanged by the 
addition of increasing concentrations of 19F-PFC in culture (E). At 2.5 mg/mL and 5.0 
mg/mL of 19F-PFC, BMDC viability was largely unaffected by 19F-PFC addition; however, 
a 19F-PFC concentration of 7.5 mg/mL was associated with increased cell death using 
Annexin V/7-AAD staining and confirmed with trypan blue exclusion (F, colours chosen 
to match with quadrant in panel D). NMR spectroscopy revealed that increasing the 
concentration of 19F-PFC to 5.0 mg/mL and 7.5 mg/mL resulted in a 1.7- and 1.9-fold 
increase in 19F-PFC incorporation compared to 19F-PFC labeling at 2.5 mg/mL (G). Data 
shown as means ± SEM, ((F) two-way ANOVA, * p<0.05, (G) one-way ANOVA, * 
p<0.05).  
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2.4.2 19F-PFC-labeled BMDC are migration competent as 
assessed via 19F cellular MRI quantification of in vivo 
migration to secondary lymphoid organs 
Previous phenotyping of day 6 19F-PFC-labeled CD11c+ BMDC demonstrated that they 
express the CCR7 chemokine receptor that mediates DC migration to lymph nodes and 
express the cell surface marker CD86. The next logical step was to determine the in vivo 
capacity of 19F-PFC-labeled BMDC to migrate from the hind footpad injection site to 
draining lymph nodes as assessed by 19F cellular MRI 48 hours after injection. Migration 
of 19F-PFC-labeled BMDC was detected and quantified in the iliac lymph node (1.1x105 
cells, Fig. 2-3 top panel), inguinal lymph node (2x105 cells, Fig. 2-3 middle panel) and 
popliteal lymph node (2.15x105 cells, Fig. 2-3 bottom panel). This quantification of BMDC 
migration indicated that 19F-PFC-labeled BMDC are migration competent in vivo.  
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Figure 2-3. 19F-PFC-labeled BMDC can be detected and 
quantified in draining lymph nodes 48 hours post 
footpad injection.  
Figure 2-3. 19F-PFC-labeled BMDC can be detected and quantified in draining lymph 
nodes 48 hours post footpad injections. Following hind footpad injection of 2.5x106 19F-
PFC-labeled BMDC, BMDC can be detected and quantified in the iliac (top panel, 1.1x105 
cells), inguinal (middle panel, 2x105 cells) and popliteal (bottom panel, 2.15x105 cells) 
lymph nodes two days later using 19F cellular MRI. R (top panel) is a reference tube of 
known concentration of 19F atoms required for quantification of in vivo signal. 
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2.4.3 19F MRI lymph node signal is the result of originally injected 
cells and using fluorescence microscopy, 19F-PFC-labeled 
BMDC and control BMDC have the same migration capacity 
in vivo 
With 19F-PFC-labeled BMDC in vivo migration being quantified, it was important to 
establish that the migration of 19F-PFC-labeled BMDC compared to control unlabeled 
BMDC was not substantially different. To compare in vivo migration of 19F-PFC-labeled 
BMDC to control unlabeled BMDC, BMDC from both conditions were first phenotyped 
to confirm similar maturation and migration status. Greater than 95% of control unlabeled 
CD11c+ BMDC and CD11c+ 19F-PFC BMDC stained for CCR7 (Fig. 2-4A/B, middle 
panel) and although lower than what is normally observed (>90%), the CD86+ percentage 
for both cell populations is comparable (Fig. 2-4A/B, right panel). To track in vivo 
migration, both the control unlabeled and 19F-PFC-labeled BMDC were also labeled with 
the fluorescent membrane intercalating dye, CFSE, immediately prior to injection. The 
incorporation of CFSE into control BMDC (Fig. 2-4C) and 19F-PFC-labeled BMDC (Fig. 
2-4D) was 100% and also labeled both cell populations with similar intensity. Thus, CFSE-
labeling of both cell populations was equal.   
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Figure 2-4. 19F-PFC-labeled and unlabeled BMDC have a 
similar phenotype and label  similarly with CFSE prior to 
adoptive cell transfer.  
Figure 2-4. 19F-PFC-labeled and unlabeled BMDC have a similar phenotype and label 
similarly with CFSE prior to adoptive cell transfer. Control unlabeled BMDC (A) and 19F-
PFC-labeled BMDC (B) express a similar phenotype as assessed through CD11c, CCR7 
and CD86 expression. CD11c dot plots were gated on viable cells. All other dot plots are 
gated on viable CD11c+ cells. 19F-PFC does not affect the expression of CD11c, CCR7, or 
CD86 when compared to unlabeled BMDC. In addition, no differences were found in 
CFSE labeling between control BMDC (C) and 19F-PFC-labeled BMDC (D), with CFSE-
labeled BMDC from each condition presented as black histogram compared to CFSE-
unlabeled BMDC (blue histograms). Flow plots are representative of two independent 
experiments. 
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In vivo migration studies were then performed in which CFSE+ 19F-PFC-labeled BMDC 
were injected into one footpad and an equal number of CFSE+ 19F-PFC-unlabeled BMDC 
were adoptively transferred into the contralateral footpad. This was performed for both a 
low (1x106) and high (2.5x106) injection condition (N=2, n=2 per condition). After 48 
hours, the popliteal lymph nodes were then removed to quantify fluorescence by digital 
morphometry as a readout of cell migration. Representative images of CFSE+ 19F-PFC-
labeled BMDC for both low and high injection conditions are shown in Figure 2-5A and 
2-5C, respectively. The same is illustrated for low and high injection doses of CFSE+ 
control BMDC in Figure 2-5B and Figure 2-5D. These images reveal the presence of 
originally injected CFSE+ BMDC in the central areas of the lymph node, which is where 
BMDC need to migrate in order to interact with T cells and initiate an immune response. 
Quantification of this migration demonstrates that 19F-PFC does not impede the in vivo 
migration capacity of 19F-PFC-labeled BMDC compared to control unlabeled BMDC for 
both low (Fig. 2-5E) and high (Fig. 2-5F) injection doses. It should also be noted that 
migration appears to occur in a dose-dependent manner, as the quantification of 
fluorescence signal increases with increasing the number of injected BMDC.  
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Figure 2-5. 19F-PFC does not impede BMDC in vivo migration.  
Figure 2-5. 19F-PFC does not impede BMDC in vivo migration. Mice were given 
subcutaneous hind footpad injections of 19F-PFC-labeled BMDC (n = 7, 1.0x106 cells; n = 
7, 2.5x106 cells; combined data from 2 independent experiments). Equal numbers of 
control BMDC were injected into contralateral hind footpads of the same mice. Prior to 
injection, both populations were labeled with CFSE to provide fluorescent detection. Two 
days after injection, popliteal lymph nodes were removed, cryosectioned and analyzed by 
digital morphometry to determine the area of CFSE+ fluorescence per area of interest. 
Images were taken at 100X magnification (scale bar = 300 μm) and the experimenter was 
blinded before digital morphometry was performed. Representative images for both 19F-
PFC-labeled BMDC (A & C) and control unlabeled BMDC (B & D) populations at both 
injection concentrations are shown. Quantification of migration for both the low injection 
concentration (E) and high injection concentration (F) was conducted and compared 
between 19F-PFC-labeled and control unlabeled BMDC populations. Data shown as means 
± SEM (t-test, p > 0.05). 
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While conducting the previous experiment, a question arose as to whether 19F-PFC and 
CFSE could interact with each other inside the cell and affect migration. A similar 
experiment was conducted as in Figure 2-5; however, CFSE was not used as an intracellular 
fluorophore. Instead, transgenic mice that express a variant of red fluorescent protein, 
DsRed337, in all cell lineages were used to generate red fluorescent BMDC without the need 
to introduce an external fluorescent label. DsRed+ 19F-PFC-labeled BMDC (2x106 cells, 
Fig. 2-6A) were injected into one footpad and DsRed+ control BMDC of equal number 
were injected into the contralateral footpad of non-fluorescent mice of the same C57Bl/6 
background (Fig. 2-6B). Quantification of migration to the popliteal lymph node 48 hours 
later was determined by digital morphometry (Fig. 2-6C) and confirmed that 19F-PFC-
labeled BMDC and control BMDC migrated equally to draining lymph nodes and home to 
central lymph node regions as well. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6. 19F-PFC does not 
impede the in vivo migration of 
DsRed+ BMDC.   
Figure 2-6. 19F-PFC does not impede the in 
vivo migration of DsRed+ BMDC. Mice were 
given subcutaneous hind footpad injections of 
19F-PFC-labeled DsRed+ BMDC (n = 4, 2.0 x 
106 cells). Control DsRed+ BMDC were 
injected at equal number into contralateral 
hind footpads. Two days post-injection, the 
popliteal lymph nodes were removed, 
cryosectioned and analyzed using digital 
morphometry to determine the area of DsRed 
fluorescence per area of interest. Images were 
taken at 100X magnification (scale bar = 300 
μm) and the experimenter was blinded prior to 
conducting digital morphometry. 
Representative images for both 19F-PFC-
labeled DsRed+ BMDC (A) and control 
DsRed+ BMDC (B) are shown. No significant 
difference in migration quantification was 
observed (C). Data shown as means ± SEM (t-
test, p > 0.05). 
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2.4.4 Pre-treatment of draining popliteal lymph node with murine 
IL-1b does not appear to increase migration of 19F-PFC-
labeled BMDC in vivo 
It has been shown that the number of DC that migrate to a lymph node post injection is 
directly proportional to the ensuing immune response launched in vivo. Thus, it was of 
interest to determine whether one can increase DC migration by pre-treating the popliteal 
lymph node area with murine IL-1b (mIL-1b, 300 ng) as a means to increase the efficacy 
of a DC-based immunotherapy. In this experiment, three hours after injecting the popliteal 
lymph node area with mIL-1b, 3 C57Bl/6 mice received footpad injections of 3x106 19F-
PFC-labeled BMDC. Another group of 4 C57Bl/6 mice received the same injection but did 
not receive a pre-injection of murine IL-1b into the popliteal lymph node area. Both sets 
of mice were left for two days and then imaged using 19F cellular MRI to detect migrated 
cells. 19F-PFC-labeled BMDC produced signal in the footpad (Fig. 2-7A, red arrow) and 
popliteal lymph node (Fig. 2-7A, green arrow). An overlay of a 1H MRI with a 
pseudocoloured 19F MRI (hot-iron colour scale shown in Fig. 2-7A), in conjunction with a 
reference signal of known concentration of 19F atoms (denoted “R” in Fig. 2-7A) permits 
the quantification of signal observed in the popliteal lymph node to be calculated as a 
number of migrated cells. For mice that did not receive murine IL-1b pre-injection, 19F-
PFC-labeled BMDC were detected in the popliteal lymph node on 4 of 6 occasions ranging 
from 4 300 ± 600 cells to 17 000 ± 2 000 cells (Fig. 2-7B; excluding two lymph nodes that 
did not have quantifiable signal). For mice that did receive murine IL-1b pre-injection, 
migration was quantified in 5 of 8 popliteal lymph nodes and ranged from 4 000 ± 800 to 
20 000 ± 3 000 cells (Fig. 2-7B). After averaging the number of migrated cells for each 
condition in which migration was able to be quantified, there was no significant increase 
in cell migration associated with the pre-injection of the popliteal lymph node areas with 
murine IL-1b (Fig. 2-7C).  
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Figure 2-7. The migration of 19F-PFC-labeled BMDC to the 
draining popliteal lymph node can be detected using 19F MRI.  
 
 
 
 
 
 
 
 
Figure 2-7. The migration of 19F-PFC-labeled BMDC to the draining popliteal lymph 
node can be detected using 19F MRI. Three mice (M1 – M3, panel B), did not receive a 
pre-injection of mIL-1β three hours prior to BMDC footpad injection while four mice (M4 
– M7, panel B) did receive a pre-injection of mIL-1β (300 ng) into both left and right 
popliteal lymph node regions. 19F-PFC-labeled mature BMDC were injected 
subcutaneously into the hind footpads (3 x 106 cells/footpad). Forty-eight hours after 
BMDC injection, 19F and 1H MRI scans were performed to reveal 19F-PFC-labeled BMDC 
migration. The 19F and 1H MR overlay composite image for mouse M2 is shown in (A). 
The 1H images are rendered in grey-scale and 19F images rendered in ‘hot-iron’ 
pseudocolour. The 19F reference tube (R) is denoted by a white circle, with the red arrow 
denoting the injection site and the green arrow indicating the popliteal lymph node. 
Composite MR images of both left and right popliteal lymph node regions 48 hours after 
BMDC footpad injection for all mice imaged in this study are shown in (B). The numbers 
at the bottom of each panel represent the number of BMDC that migrated to a target lymph 
node as assessed by 19F MRI. MR images in which BMDC migration was below the 
threshold of detection are denoted with a star (*). (C): Average number of MRI detectable 
BMDC that migrated to a target lymph node between untreated (n= 4) and mIL-1β treated 
(n = 5) populations as assessed by cellular MRI. To calculate the average number of 
migrated BMDC for both untreated and mIL-1β treated groups, the total number of 
migrated DC (as assessed by cellular MRI) within each group was totaled, then divided 
by the total number of lymph nodes within each group that had a detectable signal (n = 4 
and n = 5 for untreated and mIL-1β treated groups, respectively). Lymph nodes in which 
the number of migrated BMDC was below the threshold of detection were not included 
in the calculation of these averages. Data in (C) shown as means ± SEM (t-test, p > 0.05). 
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2.4.5 The ability of BMDC MHC Class I to be loaded with a model 
tumor peptide antigen and initiate an antigen-specific 
immune response in vivo is unaffected by 19F-PFC labeling 
Upon determination that 19F-PFC-labeled BMDC are capable of migrating to and being 
detected in the popliteal lymph node, assessing the functionality of 19F-PFC-labeled 
BMDC to present antigen and initiate an antigen-specific response was compared to control 
unlabeled BMDC.  As conducted previously, the phenotype of both control BMDC and 
19F-PFC-labeled BMDC on day 6 of culture was first assessed using CD11c, CCR7 and 
CD86 expression. CD11c+ BMDC in both conditions were found to be nearly identical in 
their high expression of CCR7 and CD86, which was calculated to be greater than 96% in 
all cases (Fig. 2-8A-C and Fig. 2-8a-c). Surface expression of H-2Kb in general was also 
determined to be nearly 100% for both control BMDC (Fig. 2-8D) and 19F-PFC-labeled 
BMDC (Fig. 2-8d). Next, the percentage of BMDC from each condition that are able to 
present the immunogenic peptide (SIINFEKL) of ovalbumin in the context of MHC Class 
I (H-2Kb of C57Bl/6 mice) following co-incubation with this peptide was determined using 
flow cytometry and an antibody specific for SIINFEKL peptide bound to H-2Kb. 19F-PFC 
does not alter surface peptide presentation of a model tumor antigen, SIINFEKL, in the 
context of H-2Kb on BMDC as 99.9% of both control BMDC (Fig. 2-8E) and 19F-PFC-
labeled BMDC (Fig. 2-8e) presented this peptide. Taken together, this data suggests that 
the current six-day BMDC protocol can be employed to efficiently present SIINFEKL:H-
2Kb complex peptide for both control unlabeled and 19F-PFC-labeled BMDC.  
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Figure 2-8. 19F-PFC does 
not affect BMDC 
phenotype or its ability 
to present SIINFEKL 
peptide.   
Figure 2-8. 19F-PFC does not affect 
BMDC phenotype or its ability to 
present SIINFEKL peptide. 
Unlabeled control (A) and 19F-
PFC-labeled (a) CD11c+ BMDC 
were enriched from culture and 
phenotyped for expression of 
CCR7 on (B) unlabeled control 
BMDC and (b) 19F-PFC-labeled 
BMDC, and expression of CD86 on 
(C) unlabeled control BMDC and 
(c) 19F-PFC-labeled BMDC. 
Nearly 100% of CD11c+ CCR7+ 
CD86+ BMDC from both unlabeled 
control (D) and 19F-PFC-labeled 
(d) conditions express MHC Class 
I (H-2Kb). Following a 2 hour 
incubation with SIINFEKL 
peptide, an antibody detected 
surface expression of SIINFEKL in 
the context of H-2Kb for unlabeled 
control (E) and 19F-PFC-labeled (e) 
BMDC. All gating is based on 
appropriate FMO controls.  
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To assess a CD8+ T cell antigen-specific response in vivo, 2.5x106 BMDC not presenting 
SIINFEKL peptide were injected into the hind footpads of 5 mice and served as the 
negative control (Fig. 2-9A). SIINFEKL-presenting unlabeled BMDC (2.5x106 cells) were 
injected into the hind footpads of 7 different mice (Fig. 2-9B), while the same number of 
SIINFEKL-presenting 19F-PFC-labeled BMDC were injected into the hind footpads of a 
third cohort of mice (Fig. 2-9C, n=7 mice). All mice were then left for 7 days for a 
SIINFEKL-specific CD8+ T cell immune response to be initiated in the draining popliteal 
lymph nodes. Following euthanasia, both popliteal lymph nodes were removed and pooled 
together for each individual mouse. Tetramer staining to identify CD8+ T cells whose T 
cell receptor recognizes SIINFEKL peptide in the context of H-2Kb was performed. Once 
single cell suspensions of pooled lymph nodes were generated for each mouse, singlet 
CD3+CD8+ T cells were selected for using flow cytometry, followed by further gating to 
identify tetramer+ cells in each other the three aforementioned injection conditions, BMDC 
not presenting SIINFEKL (Fig. 2-9D), SIINFEKL-presenting BMDC (Fig. 2-9E) and 19F-
PFC-labeled SIINFEKL-presenting BMDC (Fig. 2-9F). No significant difference was 
noted in the percentage of tetramer+ CD8+ T cells between control unlabeled BMDC 
injections and 19F-PFC-labeled BMDC injections that were presenting SIINFEKL peptide 
(Fig. 2-9G). It is important to note that the percentage of tetramer+ CD8+ T cells for each 
of the two injection conditions that included SIINFEKL peptide presentation were 
significantly higher than the non-specific staining observed in the negative control BMDC 
injection condition (Fig. 2-9G, white circles). Therefore, the SIINFEKL-specific immune 
response launched as a result of SIINFEKL-presenting BMDC labeled with or without 19F-
PFC was equivalent.  
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Figure 2-9. 19F-PFC labeling of BMDC does not affect the 
antigen-specific CD8+ T cell response induced following 
vaccination.  
Figure 2-9. 19F-PFC labeling of BMDC does not affect the antigen-specific CD8+ T cell 
response induced following vaccination. BMDC not loaded with SIINFEKL (A), control 
unlabeled BMDC loaded with SIINFEKL (B) and 19F-PFC-labeled BMDC presenting 
SIINFEKL (C) were stained with an antibody to detect SIINFEKL:H-2Kb complex 
expression followin  a 2 hour incubation with SIINFEKL in culture. Footpad injections 
of 2.5x106 BMDC from ea h of the 3 aforem nti ed injection conditions were 
performed on C57Bl/6 mice and mice were left for 7 days to permit a CD8+ T cell immune 
response to develop against SIINFEKL peptide. After 7 days, popliteal lymph nodes were 
removed, pooled for each mouse and digested into single cell suspensions. To identify 
SIINFEKL-specific CD3+CD8+ T cells, flow cytometry was performed on lymph node 
cell suspensions for mice that received vaccinations consisting of unlabeled BMDC not 
presenting SIINFEKL (D), unlabeled BMDC presenting SIINFEKL (E) and 19F-PFC-
labeled BMDC presenting SIINFEKL (F). Regardless of whether SIINFEKL-presenting 
BMDC were unlabeled or labeled with 19F-PFC (G, grey squares and black triangles, 
respectively), the magnitude of the ensuing SIINFEKL-specific CD8+ T cell response did 
not differ and was significantly greater than the non-specific flow cytometric staining 
levels measured with BMDC vaccination in the absence of SIINFEKL peptide (G, white 
circles). Data is representative of 4 independent experiments. Data in (G) is shown as 
means ± SEM (one-way ANOVA, * p > 0.05). 
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2.4.6 The murine B16-F10 melanoma cell line can be engineered 
to stably express the model tumor antigen, ovalbumin, GFP 
and luciferase 
An experiment to stably transfect a B16-F10 melanoma cell line to express ovalbumin 
protein, which contains the immunogenic model tumor epitope, SIINFEKL, was 
performed. Plasmid DNA encoding for ovalbumin was transfected into B16-F10 
melanoma cell line and transfected cells were selected for G418 resistance. A western blot 
analysis to detect full length ovalbumin was performed on 3 individual transfected B16-
F10 cell lines, with purified ovalbumin serving as the positive control and untransfected 
B16-F10 cell lysate serving as the negative control. Ovalbumin was detected strongly in 
one of the three transfected cell lines (Fig. 2-10A, black arrow) at its predicted molecular 
weight of approximately 45 kDa. The same band was observed in the positive control and 
absent in the untransfected B16-F10 cell lysate negative control (Fig. 2-10A, white arrow). 
Using flow cytometry, 99.4% of B16-F10 cells surface express H-2Kb (Fig. 2-10B, black 
histogram) compared to unstained cells of the same origin (Fig. 2-10B, blue histogram). 
This transfected cell line was transduced with a lentiviral particle encoding luciferase and 
GFP. One hundred thousand transfected and transduced B16-F10 cells in an Eppendorf 
tube were resuspended in D-luciferin. After overlaying with 1% agarose, GFP (Fig. 2-10C, 
top tube) and bioluminescence (Fig. 2-10C, bottom tube) expression confirmed successful 
lentiviral transduction.  To verify constitutive expression of GFP and luciferase in a more 
biologically relevant context, a tumor developed on the back of a C57Bl/6 mouse following 
subcutaneous injection of 2x105 B16-F10 ovalbumin+ luciferase+ cells. D-luciferin 
substrate was intraperitoneally injected into the mouse and bioluminescent imaging was 
used to image the tumor (Fig. 2-10C).     
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Figure 2-10. The B16-F10 melanoma cell line was transfected to 
stably express chicken ovalbumin as well as stably transduced with 
a lentiviral particle coding for luciferase and GFP.  
Figure 2-10. The B16-F10 melanoma cell line was transfected to stably express chicken 
ovalbumin as well as stably transduced with a lentiviral particle coding for luciferase and 
GFP. Cell lysates from 3 individual cell populations were generated following transfection 
with plasmid DNA coding for ovalbumin as selected for with G418 resis ance. Western blot 
analysis using a polyclonal HRP-conjugated antibody rev als a strong b nd from cell lysate 
TfR3 (A, black arrow) that is lso d tected in the positive control (OVA) and not detected in 
the untransfected negative control cell lysate (U/T) (A, white arrow). This band corresponds 
with the molecular weight of ovalbumin (~45 kDa) and thus, the TfR3 B16-F10 cell 
population was used for all subsequent experiments. Flow cytometry confirmed that 99.4% 
of B16-F10 cells surface express H-2Kb (B, black histogram) compared to unstained B16-
F10 cells (B, blue histogram). An Eppendorf tube containing a 105 transfected and transduced 
B16-F10 cell pellet was overlaid with 1% agarose. Imaging on a IVIS Lumina XRMS in vivo 
imaging system detected GFP (C, top tube) and luciferase (C, bottom tube) expression. A 
GFP+ ovalbumin+ luciferase+ B16-F10 tumor developed from subcutaneous injection of 
2x105 cells into the back of a C57Bl/6 mouse. Following intraperitoneal administration of D-
luciferin, bioluminescence imaging identified the tumor (C, BLI radiance scale depicted on 
the right (p/sec/cm2/sr)). 
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2.4.7 Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC 
migration to the lymph node with the ensuing immune 
response to a model tumor antigen, ovalbumin (OVA), in a 
mouse model of melanoma 
The end goal of the research presented in this chapter is to correlate 19F-PFC-labeled 
SIINFEKL-presenting BMDC migration to the draining popliteal lymph node with the 
magnitude of the ensuing SIINFEKL-specific immune response and confirm that this 
response is not different when using unlabeled SIINFEKL-presenting BMDC. The 
experimental approach is outlined in Figure 2-11. On day -2, C57Bl/6 mice were inoculated 
with 2x105 B16-F10 luciferase+ ovalbumin+ cells. Two days later, using flow cytometry, 
19F-PFC-labeled and unlabeled control BMDC SIINFEKL peptide presentation was 
confirmed (Fig. 2-11, grey and black histograms, respectively) and compared to the third 
injection group that consists of BMDC without SIINFEKL peptide (Fig. 2-11, blue 
histogram). BMDC from each of the aforementioned conditions were formulated into 
3x106 BMDC doses for injection into the hind footpads of tumor-bearing mice. Mice that 
received 19F-PFC-labeled BMDC injections underwent 19F/1H MRI two days later. In a 
preliminary experiment, 19F/1H MRI detected 2.2x104 19F-PFC-labeled BMDC in the 
popliteal lymph node (Fig. 2-11, yellow arrow), with 2.2x106 injected cells persisting at 
the injection site (Fig. 2-11, red arrow). Tumor-bearing mice then underwent 
bioluminescence imaging every second day to determine the viability and size of the tumor 
in each BMDC vaccine condition. Currently, two mice in each condition have been 
completed and popliteal lymph node signal was quantified in the popliteal lymph nodes of 
both mice. Bioluminescence imaging was performed until the pre-determined experimental 
endpoint was reached (tumor ³ 600 mm3). Whole body perfusion was performed after 
euthanasia and tumors were removed and placed in 4% PFA for future histological 
analysis. This experiment will be repeated such that a total of 10 mice per injection 
condition is achieved.    
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Figure 2-11. Correlating 19F-PFC-labeled SIINFEKL-presenting 
BMDC migration to the lymph node with the ensuing antigen-
specific immune response to a model tumor antigen OVA in a mouse 
model of melanoma.  
Figure 2-11. Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC migration to the 
lymph node with the ensuing antigen-specific immune response to a model tumor antigen 
OVA in a mouse model of melanoma. Two days prior to BMDC footpad injection (day -
2, green box), C57Bl/6 mice were inoculated with 2x105 B16-F10 Luc+ OVA+ cells (same 
cell line as Figure 2-10 ) subcutaneously on the back. The bone marrow from C57Bl/6 
mice was used to generate mature CD11c+ that were either labeled with 19F-PFC or are 
control unlabeled CD11c+ BMDC. On day 0, SIINFEKL loading was verified using flow 
cytometry (A). 19F-PFC-labeled and unlabeled BMDC were injected into tumor-bearing 
mice and tumor growth was monitored as presented in the timeline. Two days after BMDC 
injection, mice that received 19F-PFC-labeled BMDC underwent a 19F/1H MRI scan to 
detect and quantify migration to the draining popliteal lymph node (B). This migration was 
measured to be 2.2x104 19F-PFC-labeled cells in the popliteal lymph node (yellow arrow), 
with 2.2x106 19F-PFC-labeled cells remaining at the injection site (red arrow). From day 2 
onwards, all tumor-bearing mice undergo bioluminescence imaging until experimental 
endpoint is reached (tumor volume ³ 600 mm3), which is denoted in the timeline by Day 
X (C). 
59 
 
2.5 Discussion 
2.5.1 BMDC can be labeled with 19F-PFC without affecting 
viability, phenotype and in vivo migration capacity 
Initial experiments were conducted using BMDC prepared using an enrichment step for 
CD11c+ immature BMDC (Fig. 2-1) prior to labeling with 19F-PFC. After labeling, the 
immature BMDC underwent a maturation step in the presence of a cytokine and TLR 
agonist cocktail207, 211, 212, 213. This maturation step was confirmed through phenotyping 
analysis of the cocktail-cultured BMDC prior to adoptive transfer to ensure they are 
migration competent (CCR7) and mature (CD86). In addition to phenotyping, the viability 
of BMDC was measured over a range of concentrations of 19F-PFC (2.5-7.5 mg/mL) and 
compared to unlabeled control BMDC. BMDC that were co-cultured with 5 mg/mL 19F-
PFC labeled efficiently at approximately 1.78x1012 19F spins/cell on average, which is 
comparable to labeling observed for BMDC with a 19F perfluoropolyether emulsion299 
(~5x1012) and also comparable to labeling observed in human DC ranging from 1012 19F 
spins/cell to 1.73x1013 19F spins/cell291, 310. As demonstrated previously, labeling of 
therapeutic cells with 19F-PFC plateaus at a certain label concentration, for example 10 
mg/mL for a PLGA-encapsulated 19F-PFC141, and any increase in label concentration 
thereafter results in decreased viability without increased label incorporation. For BMDC 
labeling in this chapter, we believe the saturation point was reached at 5 mg/mL 19F-PFC, 
as the 7.5 mg/mL culture condition did not significantly increase label incorporation but 
did result in a viability decrease. Therefore, BMDC were able to efficiently incorporate 
19F-PFC label without affecting maturation status and viability, which is important to note 
as 19F-PFC label incorporation is directly related to in vivo detection sensitivity using 19F 
cellular MRI. Lastly, within the context of APC-based cancer vaccine immunotherapies, 
BMDC maturation status must be known prior to adoptive transfer as immature DC are not 
efficient at migrating to secondary lymphoid organs, can result in tolerogenic immune 
responses towards a TAA and even prevent a future successful immune response from 
being launched against that same TAA139, 202, 212, 213.  
19F-PFC is added to immature BMDC to take advantage of its high endocytic capacity 
compared to mature BMDC, which excel more at antigen presentation and migration119, 139, 
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140, 167, 338. Although efficient labeling of BMDC was observed in vitro, it was yet to be 
determined if 19F-PFC labeling of murine BMDC was sufficient enough to allow for in vivo 
detection and migration to a lymph node at 9.4 T without compromising the inherent 
migration and immunological capacity of these professional APC. The only other previous 
study using primary murine BMDC and 19F cellular MRI was conducted using a vertical-
bore 11.7 T MRI299. More importantly, as mature BMDC express CCR7167, and because 
iron oxide MRI cell labeling agents, SPIO and MPIO, were found to physically impede the 
ability of DC to migrate to lymph nodes322, 339, it was important to demonstrate that 19F-
PFC did not inhibit BMDC migration. Adoptive transfer of 19F-PFC-labeled BMDC into 
the footpad of mice permitted the detection and quantification of 19F signal using a 9.4 T 
MRI scanner in the draining popliteal lymph node, the inguinal lymph node and the iliac 
lymph node. Detection of 19F-PFC-labeled BMDC in multiple lymph nodes from one 
injection was an infrequent occurrence. Although 19F-PFC-labeled BMDC are migration-
competent in vivo, their migration capacity must be compared to unlabeled BMDC from 
the same source to ensure that migration is equivalent between both BMDC conditions. 
Direct in vivo migration comparisons between 19F-PFC-labeled and unlabeled DC has not 
been conducted in previous studies77, 302 and thus, these studies failed to address the 
immunological issues associated with differences in migration capacities of therapeutic 
cells between unlabeled and labeled conditions.  
To compare in vivo migration capacities, BMDC from both 19F-PFC-labeled and unlabeled 
control conditions were labeled with an intracellular fluorophore, CFSE, immediately prior 
to adoptive transfer performed via footpad injection. Thus, quantification of fluorescence 
in the draining lymph node as a result of BMDC migration 48 hours post injection was 
used as an accurate means of comparing migration between both cell conditions. For both 
low and high injection dose conditions, the migration of 19F-PFC-labeled BMDC and 
control BMDC was not statistically different, suggesting that 19F-PFC does not physically 
impede migration of therapeutic cells to secondary lymphoid organs. Furthermore, note 
that BMDC from both conditions reach the central paracortical regions of the lymph node 
where high concentrations of T cells are located217. Migration to these in vivo locations is 
essential for DC-based vaccine immunotherapy to be successful, as stable cell-cell 
interaction between DC and T cells is required to initiate a cell-mediated adaptive immune 
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response. To control for any type of interaction between an externally introduced 
fluorophore (CFSE) and 19F-PFC that could alter migration, a similar in vivo migration 
experiment was performed; however, transgenic mice that express DsRed in all cells were 
used to generate fluorescently-labeled BMDC337. The results from this experiment 
determined that 19F-PFC did not interfere with BMDC migration to a lymph node nor does 
it interfere with intranodal migration to immunologically relevant locations, which 
coincides with previously published data regarding intranodal DC localization196. Finally, 
19F-PFC and intracellular fluorescent labels do not interfere with each other or hinder 
migration of BMDC from a distal location to a secondary lymphoid organ. 
Taken together, detection and quantification of in vivo migration of 19F-PFC-labeled 
BMDC to immunologically-relevant locations are feasible using pre-clinical 19F cellular 
MRI. With the current clinically available MRI technology, 19F cellular MRI is a superior 
means of quantifying therapeutic cell migration. In comparison to other cell labeling 
agents, such as iron oxide-based contrast agents, it is difficult to quantify the signal and 
relate it directly to the cell number as not all cells uptake label and the relation of in vivo 
signal to cell quantification is not always linear297, 298. Furthermore, the chemical shift 
artifact created by the surrounding fat pad that interfaces with the edge of the lymph node 
often confounds the interpretation of what is and what is not iron-induced signal loss 
observed in standard 1H MRI scans. Lastly, if relying solely on 1H MRI to detect iron 
oxide-labeled DC in the lymph node, some lymph nodes can be overlooked due to the lack 
of contrast with surrounding tissues340.  
2.5.2 Increasing DC in vivo migration 
As the main limiting factor hampering the effectiveness of DC-based cancer vaccines is 
the sub-optimal percentage of cells that migrate to secondary lymphoid organs post 
injection183, 198, 199, 215, 216, 217, a study was designed to attempt to increase BMDC migration 
to the lymph node.  Subcutaneous footpad injections were administered to two groups of 
mice, a control group and one in which the popliteal lymph node area was pre-treated 3 
hours prior with the pro-inflammatory cytokine, IL-1b. Previous research has shown that 
using pro-inflammatory cytokines like TNFa and IL-1, or TLR agonists such as LPS that 
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induce pro-inflammatory cytokine secretion, to pre-condition tissue in close proximity to 
the injection site stimulates and/or increases DC migration to draining lymph nodes. It also 
promotes DC retention within the lymph node, which further increases DC:T cell 
interactions that contribute to effective induction of subsequent antigen-specific immune 
responses199. TNFa pre-conditioning greatly improves the migration capacity of DC when 
a low dose injection number is used (105 cells). Although, increasing the number of 
migrating DC by injecting higher cell numbers (³106 cells) diminishes the effect pre-
conditioning has on increasing migration as DC migration reaches a plateau at which point 
the lymph node appears unable to accept further migrating DC199, 341, 342. Pre-conditioning 
with IL-1b did not significantly increase the amount of 19F-PFC-labeled BMDC that 
reached the popliteal lymph node two days post injection (Fig. 2-7). A possible explanation 
is that the injection number in this study was 3x106 19F-PFC-labeled BMDC, which could 
be too high of a dose to observe the benefits associated with tissue pre-conditioning with 
pro-inflammatory cytokines. Tissue pre-conditioning increases migration to the lymph 
node by causing the up-regulation of CCL21199, 343, which is one of the main ligands that 
drives DC migration in vivo, the other being CCL19168, 169, 170, 344. Pre-conditioning with 
combinations of pro-inflammatory cytokines, or even a pre-conditioning injection of DC 
that produce similar cytokines would be of interest considering that this increase in 
migration could be immunologically significant, as it has been shown to contribute to a 
greater antigen-specific CD4+ T cell response in the lymph node four days after injection. 
The other alternative is the injection of cytokines to pre-condition the tissue such that 
resident or injected DC are surrounded by a pro-inflammatory environment that is 
conducive to promoting DC migration168, 199, 345. Although not addressed in this chapter as 
19F MRI was only performed at one timepoint, tissue pre-conditioning has been reported 
to accelerate DC migration to a secondary lymphoid organ and was associated with an 
increased number of activated CD4+ TH cells in the lymph node capable of secreting TNFa 
and IFNg199. Therefore, even though increased BMDC migration was not observed 
following IL-1b pre-conditioning in our study, it remains to be elucidated if it resulted in 
enhanced pro-inflammatory cytokine secretion. 
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2.5.3 19F-PFC labeling of BMDC does not hinder subsequent 
antigen-specific immune response 
The effectiveness of BMDC-based immunotherapies to elicit an antigen-specific immune 
response is dictated by the number of antigen-presenting BMDC that reach a lymph 
node199. Therefore, it is important that we track and quantify peptide-presenting 19F-PFC-
labeled BMDC migration to the lymph node using 19F cellular MRI. Furthermore, this 
study is unique in that antigen-specific immune responses were directly measured and 
compared following immunization with either antigen-presenting 19F-PFC-labeled BMDC 
or antigen-presenting unlabeled BMDC using the well-characterized MHC Class I (H-2Kb) 
immunogenic peptide (OVA257-264, SIINFEKL) derived from ovalbumin protein, a model 
pseudo-tumor antigen261, 346, 347, 348, 349. Although not included in the research described in 
this chapter, a well-defined MHC Class II peptide (OVA323-339) also exists for ovalbumin, 
which allows for possible examination of TAA-specific CD4+ T cells if deemed 
necessary350, 351. After confirming that 19F-PFC-labeled BMDC and control unlabeled 
BMDC have a similar mature BMDC phenotype as measured through CCR7 and CD86 
cell surface expression, a fluorescent antibody that specifically recognizes SIINFEKL in 
the context of H-2Kb352, 353 cell surface presentation was used to confirm surface 
presentation of peptide using flow cytometry prior to adoptive transfer via footpad 
injection. The percentage of SIINFEKL-specific CD8+ T cells in the draining lymph node 
using tetramer staining revealed that compared to unlabeled BMDC, 19F-PFC did not affect 
BMDC H-2Kb presentation of SIINFEKL peptide and yielded the same SIINFEKL-
specific CD8+ T cell-mediated immune response in vivo. This demonstrated that the ability 
of BMDC to initiate an antigen-specific immune response is unaffected as a result of 19F-
PFC label incorporation. Also, the percentage of SIINFEKL-specific CD8+ T cells for both 
unlabeled and 19F-PFC-labeled BMDC was significantly higher than in the control 
condition in which BMDC not presenting SIINFEKL peptide were adoptively transferred 
into the footpads. This confirmed that an immune response was launched as a result of 
BMDC injection and set the stage to investigate that 19F-PFC-labeled BMDC and unlabeled 
control BMDC both presenting SIINFEKL peptide launch and effective and equivalent 
anti-tumor response in mice bearing an ovalbumin-expressing B16-F10 melanoma tumor.  
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Prior to conducting experiments in tumor-bearing mice, the B16-F10 cancer cell line was 
modified via introduction of three transgenes: ovalbumin as a pseudo-tumor antigen and 
luciferase and GFP as imaging biomarkers to monitor tumor growth. A western blot was 
performed on B16-F10 cell lysate to confirm ovalbumin expression, and flow cytometry 
revealed that this cell line does not down-regulate H-2Kb and thus, is able to present 
SIINFEKL peptide on the cell surface in the context of H-2Kb. With bioluminescence 
imaging, tumors implanted on the back of mice were visualized after intraperitoneal 
administration of luciferin substrate and tumor growth/regression was monitored 
quantitatively until the pre-determined experimental endpoint was reached. This tumor 
experiment was designed such that correlating the quantification 19F-PFC-labeled BMDC 
migration to immunologically relevant locations with objective tumor response is possible 
upon completion. With the current study design, metastases were not observed or measured 
using BLI before the tumor volume endpoint was reached. The B16-F10 cell line appears 
to grow too fast to conduct an in-depth analysis of metastases, which are commonly seen 
in the lungs323, 354, 355. Therefore, future experiments can include removing the primary 
tumor as it approaches an endpoint volume and continuing to monitor the animals for 
metastases thereafter356.  
The B16-F10 melanoma cell line was chosen for this murine tumor experiment as it is an 
immunogenic cancer that has previously been shown to respond to IL-2 therapy333 and cell-
based cancer vaccine immunotherapies targeted against B16-F10 melanoma have resulted 
in both tumor-specific humoral and cell-mediated immune responses357. With respect to 
B16-F10 melanomas expressing ovalbumin as a pseudo-tumor peptide, many studies have 
taken advantage of the OT-I mouse model. These mice are transgenic such that all CD8+ T 
cells express a TCR that specifically binds SIINFEKL peptide in the context of H-2Kb 358, 
359. The tracking of CD8+ SIINFEKL-specific T cells to a lymph node has been observed 
if that lymph node contains ovalbumin and incomplete Freund’s adjuvant307. With 19F 
cellular MRI, 19F-labeled OT-I T cells have been detected in the liver, lung and spleen 
following injection, but not in an ovalbumin-expressing B16 tumor261. Moreover, naïve 
CD8+ SIINFEKL-specific T cells do not inhibit tumor growth in a tumor-bearing mouse 
unless they are properly activated360, for example with a professional APC, like a DC, 
presenting SIINFEKL peptide361. 19F cellular MRI failed to detect ex vivo-activated OT-I 
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CD8+ T cell migration to a tumor, most likely as a result of the combination of poor 19F-
labeling of T cells and extensive T cell proliferation diluting 19F label below in vivo 
detection threshold261. 19F-labeled NK cells ex vivo-stimulated with IL-2 also could not be 
detected migrating to a tumor post injection314.  
DC-based immunotherapies in B16-F10 tumor-bearing mouse models have also been 
extensively investigated. DNA vaccination of B16-F10-specific TAA that resulted in DC 
uptake and antigen presentation were associated with delayed B16-F10 tumor growth, 
reduced lung metastases and extended overall survival of C57Bl/6 mice362, 363. DC cultured 
with B16-F10 cell lysate and poly(I:C) have induced B16-F10-specific CD8+ T cells and 
decreased tumor growth333; however, without a TLR agonist, DC culture with B16-F10 
cell lysate did not inhibit melanoma progression. These sub-optimal results, in combination 
with the notion that a DC-based immunotherapy has not been monitored using 19F cellular 
MRI in B16-F10 tumor bearing mice, outline the need for further research to elucidate the 
in vivo fate of injected therapeutic cells following injection109, 264. This newly acquired 
knowledge can then be used to improve upon the effectiveness of cell-based 
immunotherapies and non-invasively predict tumor outcome without issues such as T cell 
division and low labeling of lymphocyte lineages. 
2.5.4 Conclusions 
Data presented above demonstrates that murine BMDC can be efficiently labeled with 19F-
PFC to permit detection and quantification of their in vivo migration using 19F cellular 
MRI. 19F-PFC labeling incorporation occurs without affecting viability, phenotype, in vivo 
migration and ability of BMDC to function as an adjuvant in initiating tumor-specific 
immune responses in the context of APC-based cancer immunotherapies. Future research 
should focus on confirming that 19F cellular MRI is a suitable platform for quantifying 
differences in therapeutic cell migration between different cancer vaccine formulations as 
it relates to anti-tumor immune responses. Also, investigating if this imaging technique can 
serve as a suitable non-invasive surrogate marker for assessing the effectiveness of 
combination therapies can only aid in the battle between up-regulating the immune system 
to combat a tumor and tumor immune evasion strategies. 
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Chapter 3  
3 Mixed APC-based cancer immunotherapies 
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67 
 
and quantification of in vivo signal. JMG and CF processed all cell samples required for 
NMR and NMR spectroscopy was performed at J.B. Stothers NMR Facility, Department 
of Chemistry, Western University, London, ON.  
Following imaging, all experiments that required organ removal, manipulation, histology 
or digestion with subsequent immunological analysis were performed by CF. 
Acknowledgments to Dr. Craig Meagher, Dr. Nadeem Sheikh and Jason Chinn for 
assistance with assay development, experimental design and direction.  
For murine PBMC studies, CF performed all mouse PBMC isolation, tissue culturing, and 
fluorescence labeling of PBMC. CF performed all flow cytometry data acquisition and 
analysis described in Appendix II. Murine PBMC injections and post-imaging lymph node 
and organ removal was performed by CF. JMG conducted MRI scanning, data acquisition 
and quantification of in vivo signal. Acknowledgments to Dr. Natalie Kozyrev for confocal 
imaging of murine lymph node cryosections.   
3.2 Introduction and Rationale 
Prostate cancer is the third leading cause of cancer death in men364. Traditional therapies 
utilized during early stage cancer are surgical resection and radiation therapy, followed by 
further surgical and radiological interventions along with androgen deprivation therapy 
(ADT) during late stage treatment241, 365. Unfortunately, patients who progress to metastatic 
hormone-refractory prostate cancer, which is the stage responsible for virtually all prostate 
cancer-related deaths6, have few treatment options and as a result, the 5 year survival rate 
for metastatic prostate cancer is 28%366. Docetaxel is a possible treatment option available 
at the metastatic stage; however, treatment with this chemotherapeutic agent is not suitable 
for all prostate cancer patients. This highlights the need for novel approaches and strategies 
to combat metastatic prostate cancer5, 6.  
Previous research has found that basal immune responses to PAP, a TAA, have been 
detected in prostate cancer patients prior to immunotherapeutic-related interventions242, 367, 
368. This, in combination with the knowledge that prostate cancer progresses slowly and 
has well-defined TAA, makes prostate cancer a platform well-suited for cancer 
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immunotherapy development8, 40, 41, 42, 44.  Multiple immunotherapies have been 
investigated, such as DCVAC/PCa which consists of mature DC pulsed with PSA-
expressing LNCaP cancer cells369, 370, 371, PROSTVAC, a pox viral-based PSA 
immunotherapy delivered in conjunction with co-stimulatory molecules and GM-CSF372, 
373, 374, and BDCA-1+ BDC-01+, a CD1c+ blood-derived DC-based vaccine pulsed with 
PAP- and PSA-based peptides375. Although these immunotherapies have demonstrated 
promising pre-clinical results, a mixed APC-based immunotherapy, Sipuleucel-T, is the 
only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer 
(CRPC)7.  
Sipuleucel-T functions by potentiating established basal immune responses a prostate 
cancer patient has to PAP to level that overcomes tumor-induced immunosuppression and 
results in tumor recognition and destruction120, 241, 242, 243. It is formulated by ex vivo-
culturing PBMC with a proprietary fusion protein containing PAP, a TAA present in the 
vast majority of prostate cancer tumors and primarily restricted to prostate tissue376, 377, 
fused to GM-CSF, a cytokine that activates APC contained within PBMC7, 241, 249, 378. In 
this manner, APC are rendered TAA-specific via PAP and activated as a result of GM-CSF 
upon fusion protein internalization379. Surface expression of CD54 is used as a readout to 
determine APC activation43, 246 and upon autologous reinfusion, APC are properly 
activated to boost existing responses as well as launch an anti-tumor immune response, 
which includes activation of naïve CD4+ and CD8+ T cells192, 241, 251. Sipuleucel-T 
prolonged overall survival of prostate cancer patients by 4.1 months in a phase III clinical 
trial; however, further research and improvements to this immunotherapy must take place 
in order to reach a therapeutic level whereby significant prolongation of progression-free 
survival takes place244, 245.  
As Sipuleucel-T is derived from prostate cancer patient PBMC, it contains a heterogeneous 
mixture of immune cells, each with their own in vivo function and own propensity to home 
to a specific in vivo location and exert their function120, 247. Not only is in vivo CD54+ large 
APC migration important when considering Sipuleucel-T, but other cell lineages, such as 
B and T lymphocytes, are contained within the infusion product and can be activated during 
ex vivo-culture120. TNFa produced as a result of B and T cell activation can further 
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potentiate APC activation following administration and lead to the production of IL-1b120, 
380, 381. Therefore, knowledge acquisition pertaining to in vivo migration and persistence of 
all cell lineages within therapeutic PBMC preparations can aid in fully understanding and 
thus, improving upon this APC-based immunotherapy. In this chapter, we aimed to 
efficiently label the main cell lineages contained within both murine and human PBMC 
formulations with a 19F-PFC cell labeling agent without affecting PBMC viability or 
phenotype. Research then focused on detecting and quantifying 19F-PFC-labeled murine 
PBMC in vivo migration in an immunocompetent mouse model and detecting and 19F-PFC-
labeled human PBMC in vivo migration in an immunocompromised mouse model using 
19F cellular MRI.  
Considering the data we present in this chapter, 19F cellular MRI has the potential to be 
applied to non-invasively detecting and quantifying the migration of T, NK or NKT cells 
to the tumor, which has been histologically-associated with increased survival in previous 
studies125, 129, 162, 163, 185, 382, 383, 384, 385. Furthermore, as the proportions of immune cell 
lineages within a heterogeneous APC-based cancer immunotherapy vary greatly between 
apheresis patient products42, 246, 19F cellular MRI can potentially be used to observe which 
cell lineage proportions are best-suited for this immunotherapy. This non-invasive imaging 
modality can also be employed to compare in vivo migration competencies between 
freshly-prepared or frozen vaccine formulations (APC8015F), which have been used as 
salvage therapies in Sipuleucel-T clinical trials and demonstrated to be biologically active7, 
43. 19F cellular MRI can possibly help answer fundamental questions hindering the 
advancement of Sipuleucel-T from an immunotherapy that induces T cell activation7, 
mobilizes tumor-specific immune cells to the tumor83 yet does not result in progression 
free survival245, 386 to an immunotherapy that induces long-term protection against prostate 
cancer.  
3.3 Materials and Methods 
3.3.1 Animal Care 
Male nu/nu mice (Crl:NU-Foxn1NU) were purchased from Charles River Laboratories Inc. 
(Saint Constant, Canada) at 8-10 weeks old and housed at Robarts Research Institute at the 
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University of Western Ontario (London, Canada) in a high efficiency particulate air-
filtered (HEPA-filtered) barrier cage system. All experiments were pre-approved by the 
Animal Use Subcommittee at the University of Western Ontario and conducted in 
accordance with an approved protocol from University of Western Ontario’s Council on 
Animal Care (Protocol #2015-046). When required, mice were anaesthetized with 2% 
isoflurane in oxygen unless specified otherwise.   
3.3.2 Participants 
The University of Western Ontario Health Sciences Research Ethics Board (REB) pre-
approved this protocol (REB Protocol #104593). Each healthy volunteer involved in this 
study protocol received a REB-approved Letter of Information and provided a signed 
Letter of Informed Consent before entering into the study and provided between 50 mL-
150 mL of peripheral blood. For inclusion in the study, healthy participants had to be 18 
years of age or older and free of Human Immunodeficiency Virus (HIV), Hepatitis B or C 
Virus or other transmissible diseases. Commercially-available peripheral blood or 
leukapheresis cell products (Stemcell Technologies, Seattle, USA) were also used as a 
source of PBMC for certain experiments. Certificates of analysis were provided to confirm 
a viability of >90% of cell product and each donor was negative for HIV, Hepatitis A and 
Hepatitis B. Cell count, volume and type of anti-coagulant used for each sample was 
provided as well.  
3.3.3 Reagents 
Aim V® Medium CTS (GMP-grade, Gibco, Burlington, Canada) was supplemented with 
100 U/mL of penicillin, 100 µg/mL of streptomycin and 0.3 mg/mL L-Glutamine 
(ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, human AB serum, Trypan 
Blue, CellTraceTM CFSE, CellTraceTM Violet and CellTraceTM Far Red cell proliferation 
kits and LIVE/DEAD™ fixable aqua dead cell stain were purchased from ThermoFisher 
Scientific and BSA was obtained from Calbiotech (Spring Valley, USA). Lymphoprep™, 
human CD3, human B cell and human monocyte negative selection kits were purchased 
from Stemcell Technologies (Vancouver, Canada). NGS was purchased from Jackson 
ImmunoResearch (West Grove, USA) while human GM-CSF and murine IL-1b were 
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obtained from PeproTech (Montreal, Canada). CD15-PE/Cy7 (clone W6D3), CD11c-APC 
(3.9), CD16-Alexa Fluor 700 (3G8), CD19-APC/Cy7 (HIB19), CD56-BV605 (HCD56), 
CD3-PE (HIT3a), CD19-PE (HIB19), CD20-PE (2H7), CD45-FITC (HI30), CD3-
APC/Cy7 (SK7), CD11b-Alexa Fluor 647 (M1/70), CD20-PE/Cy5 (2H7), CCR7-PE/Cy7 
(G043H7), CD40-BV421 (5C3), CD54-PE (HA58), CD83-Alexa Fluor 488 (HB15e), 
CD86-PerCP/Cy5.5 (IT2.2) and FITC Annexin V Apoptosis Detection kit with 7-AAD and 
were purchased from Biolegend (San Diego, USA), while anti-human CD14-eFluor450 
(61D3) and UltraComp eBeads were acquired from eBioscience (San Diego, USA).  The 
19F-PFC cell labeling agents used in this study, Cell Sense CS-1000 and the red fluorescent 
version, CS-ATM DM Red (excitation 596 nm, emission 615 nm), were both purchased 
from Celsense, Inc. (Pittsburgh, USA). Lastly, PBMC were cultured in ThermoFisher 
Scientific Nunc Hydrocell plates (ThermoFisher Scientific).  
3.3.4 Human PBMC isolation and 19F-PFC labeling 
Following venipuncture and collection of peripheral blood from volunteers or receiving of 
purchased cell products collected in the presence of heparin sulfate, samples were diluted 
1:1 with room temperature HBSS and subject to density gradient centrifugation using 
LymphoprepÔ (Stemcell Technologies, Vancouver, Canada) to isolate PBMC.  To assess 
uptake of 19F-PFC, PBMC were labeled at varying cell (2, 5, 10x106 cells/mL) and red 
fluorescent 19F-PFC (2.5, 5.0, 7.5 mg/mL) concentrations (Celsense, Inc., USA) at 37ºC, 
5% CO2 for 24h in AIM V® Medium CTS™ media. Labeled PBMC (as well as unlabeled 
control PBMC) were collected, washed in HBSS and then resuspended in HBSS+0.1% 
BSA with 5% (v/v) NGS for 30 minutes on ice. Following washing, surface staining for 
lineage markers (CD3/CD19, CD11c, CD14) in HBSS+0.1% BSA was conducted on ice 
(4°C) for 25 minutes. Stained PBMC were then washed and resuspended in HBSS+0.1% 
BSA, with data being acquired immediately on an LSRII analytical flow cytometer (BD, 
Mississauga, Canada) to determine 19F-PFC label uptake in each cell lineage. Data was 
analyzed using FlowJo software (Tree Star, Ashland, USA). Upon completion of 
measuring 19F-PFC uptake at a range of label concentrations and cell culture 
concentrations, it was determined that 5x106 cells/mL labeled with 5.0 mg/mL 19F-PFC 
produced the best results with respect to viability and label incorporation and thus, were 
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the conditions used for the remainder of experiments. In addition, a 48 hour cell culture 
with 19F-PFC-labeled or control unlabeled PBMC was adopted, which included the 
addition of human GM-CSF (PeproTech) at 20 ng/mL for the last 24 hours of culture except 
to control conditions that did not receive GM-CSF.  
3.3.5 Cell viability 
Cell viability was measured during the process of PBMC isolation, culturing and labeling 
with 19F-PFC using the trypan blue exclusion assay. The viability of PBMC cell products, 
regardless of cell concentration or 19F-PFC label in culture and the addition of GM-CSF 
(20 ng/mL) or not was measured using FITC-Annexin V apoptosis detection kit with 7-
AAD and acquired on a LSRII analytical flow cytometer (BD Biosciences) immediately 
after the addition of 7-AAD at room temperature.  
To assess the activation, co-stimulation and maturation state of 19F-PFC-labeled and 
unlabeled PBMC cultured in the presence or absence of GM-CSF, PBMC from each 
condition were collected and washed in PBS. Two microliters of LIVE/DEAD™ fixable 
aqua dead cell stain stock solution (reconstituted in 50 µL DMSO) was added per mL of 
room temperature PBS. Next, 250 µL of this diluted solution was added to each FACS tube 
and incubated at room temperature for 20 minutes, followed by surface staining (detailed 
below) and acquisition using a LSR II analytical flow cytometer (BD Biosciences).  
3.3.6 Flow cytometry 
The following antibodies were used for phenotyping human PBMC: CD15-PE/Cy7, 
CD11c-APC, CD16-Alexa Fluor 700, CD19-APC/Cy7, CD14-eFluor450, CD56-BV605, 
CD3-PE, CD19-PE, CD20-PE and CD45-FITC.  
In addition to the lineage phenotyping and red fluorescent 19F-PFC incorporation into 
PBMC, further phenotyping was conducted in order to compare between 19F-PFC-labeled 
and unlabeled control PBMC, as well as assess phenotypic differences that may arise as a 
result of GM-CSF addition to culture. Activation, migration and co-stimulation 
phenotyping was first conducted using LIVE/DEAD™ fixable dead cell stain (described 
above), followed by surface staining with the following antibodies: CD3-APC/Cy7, 
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CD11b-Alexa Fluor 647, CD20-PE/Cy5, CCR7-PE/Cy7, CD40-BV421, CD54-PE, CD83-
Alexa Fluor 488 and CD86-PerCP/Cy5.5. Irrespective of cell surface markers being 
phenotyped, cultured PBMC were blocked on ice for 30 minutes with 5% NGS (v/v) in 
HBSS+0.1% BSA and then washed in HBSS. Following washing, cell surface staining of 
PBMC was conducted in HBSS+0.1% BSA on ice (4°C) for 25 minutes. Lastly, stained 
PBMC were washed in cold HBSS and re-suspended in HBSS+0.1% BSA and 4% 
paraformaldehyde for data acquisition on a LSRII analytical flow cytometer (BD 
Biosciences).  
3.3.7 Adoptive cell transfer of PBMC 
Three hours prior to PBMC injection, nu/nu mice were anesthetized and received an 
injection in the left popliteal lymph node area of 300 ng murine IL-1b (PeproTech) to 
facilitate increased migration of injected cells to the lymph node. To generate 19F-PFC-
labeled PBMC injections, cells were washed twice in PBS and formulated into a 3x106 
injection in 40 µL PBS into both footpads of anesthetized mice. The same injection 
procedure was followed for 19F-PFC-labeled PBMC co-cultured with GM-CSF (20 ng/mL) 
for the last 24 hours of culture.  19F cellular MRI was conducted 48 hours post injection 
and 19F-PFC-labeled PBMC migration to the draining lymph node was detected and 
quantified upon overlay with an anatomical proton scan to provide anatomical context to 
observed in vivo 19F signal. 
3.3.8 MRI of PBMC migration 
Mouse imaging was performed with a 9.4 T Varian small-animal MRI scanner (Santa 
Clara, CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging. 
Animals were imaged alongside a reference tube containing a known 19F concentration 
(3.33x1016 19F/μL or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with 
2% isoflurane, with breathing rate and temperature monitored throughout the scan. MRI 
was performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), 
tuned to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively.  For proton 
imaging the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°, 
PC = 4, averages = 3 and resolution = 200x200x200 μm3.  For 19F imaging the parameters 
74 
 
were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC = 4, averages = 200 and 
resolution = 1x1x1 mm3. To avoid 19F present in isoflurane confounding the 19F-PFC 
signal, imaging was performed by centering on the 19F-PFC Cell Sense-specific frequency 
as was previously described270. The total protocol time for both proton and 19F imaging 
was under 90 minutes.   
3.3.9 19F-loading efficiency and signal quantification 
The mean intracellular 19F content of human PBMC was determined by NMR spectroscopy 
using a 400 MHz Varian vertical spectrometer.  First, a known number of 19F-PFC-labeled 
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a 
solution containing 100 µL of 5% Triton X-100.  After lysing, the cells were transferred to 
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with 
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA 
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal 
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters 
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm. 
The number of PBMC detected within MR images was determined with Voxel TrackerTM 
software (Celsense Inc, Pittsburgh, PA) 270, 308.  Prior to analysis, a signal correction was 
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest 
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal 
contained within a hand-drawn ROI was compared to the average signal produced by the 
reference tube containing a known 19F concentration. This information was used alongside 
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at 
the ROI.   
3.3.10 Lineage-specific adoptive cell transfer 
As PBMC are composed of a heterogeneous mixture of immune cells, the three main 
lineages found in PBMC were isolated into homogeneous cultures, differently labeled with 
an intracellular fluorescent label and reconstituted back as a heterogeneous population at 
physiologic proportion prior to injection and draining popliteal lymph node removal 48 
hours later. Briefly, PBMC were isolated from healthy volunteers as described previously 
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and subject to negative magnetic selection kits (Stemcell Technologies) and 
manufacturer’s instructions such that homogeneous cultures of CD3+ T cells, 
CD19+/CD20+ B cells and CD14+CD16+ monocytes could be obtained. These cell lineages 
were resuspended at 5x106 cells/mL in AIM V® Medium CTS™ media AIM V and 
cultured for 48 hours with 19F-PFC (5 mg/mL), with GM-CSF (20 ng/mL) being added to 
all wells for the last 24 hours of culture. All cell conditions were collected separately and 
resuspended at 1x106 cells/mL in warm PBS+0.5% human AB serum (ThermoFisher) and 
labeled with a unique intracellular fluorophore for 10 minutes at 37°C (T cells were labeled 
with CellTrace™ Far Red (1 µM), monocytes with CellTrace™ CFSE (1 µM), and B cells 
with CellTrace™ Violet (1 µM) (ThermoFisher Scientific). The reaction was quenched 
with ice cold AIM V® Medium CTS™ media and cells were washed in HBSS. 
Immediately prior to injection, all 3 cell lineages for both 19F-PFC-labeled and control 
PBMC were recombined back into a heterogeneous population at physiological proportions 
(as determined by flow cytometry above) and 3x106 cell footpad injections were performed 
as stated above into the left and right hind footpad of anesthetized nu/nu mice. Forty-eight 
hours later, draining popliteal lymph nodes were removed from sacrificed mice, fixed with 
4% PFA and cryopreserved in sucrose solutions. Upon completion of cryopreservation, 16 
µm sections were placed on VWR Microslides Superfrost® Plus (VWR), coverslipped with 
PBS and imaged to detect the unique fluorescence of each of the 3 main lineages found 
within PBMC. 
3.3.11 Statistical analysis 
All data was presented as the mean with the standard error of the mean. A paired t-test 
(Graph Pad Prism, Version 7, La Jolla, USA) and two-way ANOVA were used and was 
defined when statistics were reported. Multiple comparisons were conducted for two-way 
ANOVAs.  Significance was considered if p ≤ 0.05. When written, the number of 
independent experiments is denoted by (N) while the number of replicates per independent 
experiment is defined by (n).  
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3.4 Results 
3.4.1 Human PBMC cell lineages important for antigen 
presentation efficiently label with 19F-PFC without affecting 
viability 
As human PBMC are composed of multiple cell lineages such as B and T lymphocytes, 
monocytes and dendritic cells, initial experiments to determine red fluorescent 19F-PFC 
incorporation into a heterogeneous cell mixture were conducted, as the vast majority of 
19F-PFC labeling is performed on homogeneous cell cultures141, 270, 307, 314, 387, 388, 389, 390. A 
range of cell (2-10x106 cells/mL) and 19F-PFC (2.5-7.5 mg/mL) culture conditions were 
used to elucidate the optimal concentrations that provide the most efficient 19F-PFC 
labeling without having a deleterious effect on cell viability. After 48 hours in culture, 
PBMC were first gated on singlet, live cells using forward-/side-scatter properties and 
FITC-Annexin V/7-AAD staining (Fig. 3-1A-C). Regardless of cell lineage or 19F-PFC 
concentration employed, CD11c+CD14-CD16- dendritic cells (Fig. 3-1D/G) CD14+ 
monocytes (Fig. 3-1E/G) and B and T cell lymphocytes (Fig. 3-1F/G) all label with red 
fluorescent 19F-PFC at a high percentage (>70%, Fig. 3-1). However, CD14+ monocytes, 
lymphocytes and CD11c+CD14-CD16- dendritic cells all label equivalently at a high 
percentage (>88% for each replicate) when a cell concentration of 5x106 cells/mL and 5 
mg/mL 19F-PFC was used while also maintaining a high viability at 89.47% ± 2.39% (mean 
± SEM, n=3) (Fig. 3-1G). Therefore, the latter culture condition was chosen for all 
subsequent experiments presented in this chapter.   
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 Figure 3-1. All cells important to antigen presentation and 
ensuing antigen-specific immune response label efficiently with 
red fluorescent 19F-PFC.  
Figure 3-1. All cells important to antigen presentation and ensuing antigen-specific 
immune response label efficiently with red fluorescent 19F-PFC. Following incubation for 
48 hours with red fluorescent 19F-PFC, live, singlet cells were gated based on scatter and 
7-AAD/FITC-Annexin V staining as shown in (A-C) using fluorescent minus one (FMO) 
controls and further gated using appropriate FMO control to identify CD11c+ DC (D), 
CD14+ monocytes (E) and CD3+ T cells/CD19+ B cells (F). All lineages label to a high 
degree when compared to unlabeled control PBMC from th  same donor, regardless of the 
concentrat on of 19F-PFC and oncentration of cells in culture used (G). Data is shown as 
means ± SEM (two-way ANOVA, p > 0.05) for 5x106 cells/mL cell concentration 
condition used in all subsequent experiments.  
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3.4.2 19F-PFC-labeled PBMC can be cultured with GM-CSF 
without affecting viability, phenotype and 19F-PFC loading 
After establishing that human PBMC can be efficiently labeled with 19F-PFC, we next 
sought to determine what effect GM-CSF in culture has on 19F-PFC-labeled PBMC. This 
was investigated because our research is modeled after the APC-based immunotherapy, 
Sipuleucel-T246, which is generated by co-culturing PBMC with the cytokine GM-CSF 
fused to a tumor-associated antigen. First, PBMC were isolated from the blood of healthy 
volunteers and cultured at the optimal cell concentration and 19F-PFC concentration, which 
are 5x106 cells/mL and 5 mg/mL, respectively. GM-CSF (20 ng/mL) was added to half of 
19F-PFC-labeled PBMC for the final 24 hours of a total 48 hour culture. Upon completion 
of culture, PBMC were collected and counted for viability. It was determined that the 
viability after GM-CSF addition to 19F-PFC-labeled PBMC culture (85.7 ± 2.31%) did not 
significantly differ from the viability of control 19F-PFC-labeled PBMC (88.73 ± 1.87%) 
(Fig. 3-2A). The viability between PBMC cultures treated with GM-CSF or left as control 
were further analyzed by looking at lineage-specific viability. The viability of CD3+CD20-
CD11b- T cells, CD20+CD3-CD11b- B cells and CD11b+CD3-CD20- myeloid cells 
remained unchanged with the addition of GM-CSF into culture for both 19F-PFC-labeled 
PBMC lineages and unlabeled PBMC lineages (Fig. 3-2B).   
After assessing the viability of T cells as well as two APC lineages, CD20+ B cells and 
CD11b+ myeloid cells in Figure 3-2B, flow cytometry was used to measure surface 
expression of activation markers such as CD40, CD54, CD83, migration marker CCR7, 
and co-stimulation markers CD83 and CD86. This phenotyping was conducted such that 
CD20+ B cells were analyzed for percent expression of the aforementioned surface antigens 
(Fig. 3-3A), and CD11b+ cells were analyzed for percent expression following the same 
approach (Fig. 3-3B). Furthermore, the intensity of cell surface expression of these markers 
was analyzed by using mean fluorescence intensity (MFI) of the positively stained 
population for both CD20+ B cells (Fig. 3-3C) and CD11b+ myeloid cells (Fig. 3-3D). The 
percentage of cells presenting these markers for both B cell and myeloid cell lineages did 
not significantly change as a result of GM-CSF addition to both 19F-PFC-labeled and 
unlabeled conditions. However, the intensity of expression of activation, migration and co-
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stimulation does trend towards increasing upon GM-CSF addition, with significant 
increases being observed for CD86+ MFI for CD20+ B cells and CD11b+ myeloid cells as 
well as CD54+ MFI for CD11b+ myeloid cells (Fig. 3-3C/D).   
The amount of 19F-PFC loading on average per cell was also investigated with cell pellets 
from 19F-PFC-labeled PBMC that were cultured in either the presence or absence of GM-
CSF. NMR spectroscopy was conducted to quantify PBMC loading with 19F-PFC using 
the spectra obtained for both control 19F-PFC-labeled PBMC (Fig. 3-4A) and GM-CSF-
treated 19F-PFC-labeled PBMC (Fig. 3-4B) and the equation previously described in 
Appendix I, Figure 6-8. Quantification of average 19F-PFC loading (2.17x1011 ± 9.25x1010 
19F atoms/cell) remained unchanged with the addition of GM-CSF in culture (2.27x1011 ± 
1.08x1011 19F atoms/cell) (Fig. 3-4C).  
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. 19F-PFC labeling and the addition of GM-CSF in cell 
culture does not affect the viability of human PBMC.  
Figure 3-2. 19F-PFC labeling and the addition of GM-CSF in cell culture does not affect 
the viability of human PBMC. Following a 24 hour incubation with 19F-PFC (5 mg/mL), 
GM-CSF was added (20 ng/mL) to half of cells and PBMC (5x106 cells/mL) were 
incubated for 24 more hours. GM-CSF-treated 19F-PFC-labeled PBMC did not differ in 
viability when compared to control 19F-PFC-labeled PBMC with data shown as means 
± SEM (t-test, p>0.05) (A). A more rigorous analysis of viability using flow cytometry 
and LIVE/DEAD™ fixable dye to determine the viability of CD3+CD20-CD11b- T 
cells, CD20+CD3-CD11b- B cells and CD11b+CD3-CD20- myeloid cells was conducted. 
Culture conditions were the same as in (A) with the inclusion of an unlabeled condition. 
Human PBMC labeled with or without 19F-PFC or treated with or without GM-CSF 
(control) were gated on T cells, B cells and myeloid cells to assess viability of each 
lineage. Data is shown as means ± SEM (two-way ANOVA, p>0.05) (B). 
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Figure 3-3. Human CD20+ B cells and CD11b+ myeloid cells appear 
to up-regulate their expression of maturation and activation 
markers following GM-CSF addition.  
Figure 3-3. Human CD20+ B cells and CD11b+ myeloid cells appear to up-regulate 
the expression of maturation and activation markers following GM-CSF addition. 
Viable B cells (A) and viable myeloid cells (B) were further phenotyped to identify 
cells that stain positively for markers of activation, migration and co-stimulation. The 
intensity of staining for each surface marker was also measured using the MFI of the 
positively-gated population for CD20+ B cells (C) and CD11b+ myeloid cells (D) 
cultured with or without 19F-PFC and with or without GM-CSF (20 ng/mL). Data is 
shown as means ± SEM (two-way ANOVA, * p<0.05). 
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Figure 3-4. GM-CSF addition to PBMC culture does not increase 19F-PFC 
loading.  
Figure 3-4. GM-CSF addition to PBMC culture does not increase 19F-PFC loading. 
The individual nuclear m gnetic resonance spectra for co trol PBMC (A) and GM-
CSF-treated (20 ng/mL) PBMC (B) are required for quantification of the average 
number of 19F atoms per cell (C). Data shown as means ± SEM (t-test, p > 0.05). 
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3.4.3 GM-CSF addition to PBMC culture allows for consistent 
detection and quantification of 19F-PFC-labeled PBMC 
migration in vivo 
After demonstrating that PBMC efficiently label with 19F-PFC in the presence of GM-CSF 
without significantly affecting viability, the next logical step was to assess the in vivo 
migration of GM-CSF-treated 19F-PFC-labeled PBMC compared to 19F-PFC-labeled 
PBMC not cultured with this cytokine. In addition to GM-CSF treatment, the left popliteal 
lymph nodes of all mice were pre-treated 3 hours prior to PBMC injection with murine IL-
1b. Forty-eight hours after hind footpad injection of 3x106 19F-PFC-labeled PBMC 
cultured with or without GM-CSF, mice underwent 19F/1H MR imaging. Figure 3-5 
displays the detection and quantification of 10.1 ± 0.88x104 GM-CSF-treated 19F-PFC-
labeled PBMC in the left popliteal lymph node that received IL-1b pre-treatment (Fig. 3-
5, orange arrow) and 12.8 ± 0.3x104 GM-CSF-treated 19F-PFC-labeled PBMC in the right 
popliteal lymph node that did not receive IL-1b (Fig. 3-5, yellow arrow) upon overlaying 
a pseudocoloured 19F MRI to a standard 1H MRI. This experiment was conducted using 
PBMC obtained from 4 different healthy volunteers, with each repeat including footpad 
injections into 2 immunocompromised mice for both cell culture conditions. Mice injected 
with GM-CSF-treated 19F-PFC-labeled PBMC have the right popliteal lymph nodes 
identified by 19F/1H MRI (Fig. 3-6A/C/E/G/I/K/M/O, blue arrows) and the left popliteal 
lymph nodes that was pre-treated with IL-1b identified by red arrows (Fig. 3-
6B/D/F/H/J/L/N/P). The right popliteal lymph nodes from mice that received 19F-PFC-
labeled PBMC not cultured with GM-CSF are identified by blue arrows (Fig. 3-
6Q/S/U/W/Y/a/c/e) and the left popliteal lymph nodes that were pre-treated with IL-1b are 
identified by red arrows (Fig. 3-6R/T/V/X/Z/b/d/f). The detection and quantification of 19F-
PFC-labeled cells in the lymph node is summarized in Table 3-1 and organized identically 
to the lymph nodes displayed in Figure 3-6.  Upon completion of in vivo migration studies 
using 19F/1H MRI for both cell conditions, GM-CSF increases the migration of 19F-PFC-
labeled PBMC above the detection threshold of 19F MRI such that this migration can be 
readily detected, unlike the situation observed for 19F-PFC-labeled PBMC that were not 
cultured with GM-CSF. Moreover, IL-1b pre-treatment of the popliteal lymph node area 
appears to increase migration of 19F-PFC-labeled PBMC not cultured with GM-CSF such 
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that this migration is above the detection threshold and thus, can be quantified (Table 3-1). 
As IL-1b pre-treatment does not increase the migration of GM-CSF-treated 19F-PFC-
labeled PBMC, it appears that these two cytokine pre-treatments do not act synergistically.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. A representative 19F cellular MR image of human 19F-PFC-
labeled-PBMC detected in the popliteal lymph nodes of a nude mouse two 
days following injection.  
Figure 3-5. A representative 19F cellular MR image of human 19F-PFC-labeled PBMC 
detected in the popliteal lymph node of a nude mouse two days following injection. 19F/1H 
MRI overlay images were obtained two days post footpad injection of 3x106 19F-PFC-
labeled PBMC that were co-cultured with GM-CSF (20 ng/mL) during the last 24 hours of 
a 48 hour culture. The 19F signal, rendered in “hot-iron” colour scale, detected 10.1 ± 
0.88x104 19F-PFC-labeled cells (orange arrow) in the left popliteal lymph node (which was 
treated 3 hours prior to injection with 300 ng of murine IL-1b) and 12.8 ± 0.3 x104 19F-
PFC-labeled cells (yellow arrow) in the right popliteal lymph node. 
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(Figure 3-6 continues on next page) 
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Figure 3-6. Proof of concept MR imaging approach to 
increasing PBMC migration to draining target lymph nodes 
following adoptive cell transfer.  
Figure 3-6. Proof of concept MR imaging approach to increasing PBMC migration to 
draining target lymph nodes following adoptive cell transfer. Data is presented as 4 separate 
experiments with 2 immunocompromised mice per condition. For PBMC labeled with 19F-
PFC and cultured with GM-CSF (20 ng/mL), the right popliteal lymph node 
(A,C,E,G,I,K,M,O) is indicated by the blue arrow.  The left popliteal lymph node 
(B,D,F,H,J,L,N,P) is indicated by the red arrow and was pre-treated 3 hours prior to injection 
of cells with 300 ng of mIL-1β. For control PBMC labeled with 19F-PFC in the absence of 
GM-CSF, the right popliteal lymph node (Q,S,U,W,Y,a,c,e) is indicated by the blue arrow. 
The left popliteal lymph node (R,T,V,X,Z,b,d,f) is indicated by the red arrow and was pre-
treated 3 hours prior to injection of cells with 300 ng of mIL-1β. Area defined by R (in green) 
and outlined in white indicates the location of a reference tube that is required to quantify in 
vivo cell migration. The quantification of popliteal lymph node 19F signal is summarized in 
Table 3-1. 
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Table 3-1. GM-CSF in cell culture and IL-1b pre-treatment of draining popliteal lymph 
node area increase migratory capacity of 19F-PFC-labeled human PBMC. 
 
GM-CSF-treated PBMC* 
19F MRI Quantification 
 
 
Control PBMC* 
19F MRI Quantification 
 
 
Right Lymph 
Node 
 
 
Left Lymph Node 
(IL-1b pre-
treated) 
 
 
Right Lymph 
Node 
 
 
Left Lymph Node 
(IL-1b pre-
treated) 
 
 
(Figure 3-6 A-D)              Experiment 1        (Figure 3-6 Q-T) 
 
(n=2)                                                                    (n=2) 
 
13 ± 3x104 10 ± 3x104 15 ± 2x104 11 ± 2x104 
--- 19 ± 5x104 --- --- 
                 
(Figure 3-6 E-H)             Experiment 2        (Figure 3-6 U-X) 
 
(n=2)                                                                   (n=2) 
 
6.3 ± 1x104 5.4 ± 1x104 --- 10 ± 2x104 
3.3 ± 0.8x104 --- --- 9.8 ± 1.3x104 
                 
(Figure 3-6 I-L)               Experiment 3        (Figure 3-6 Y-b) 
 
(n=2)                                                                   (n=2) 
 
9.6 ± 1.5x104 5.2 ± 1.3x104 --- 7.7 ± 2x104 
7.2 ± 1.2x104 5.7 ± 1.1x104 --- 6.7 ± 1x104 
                 
(Figure 3-6 M-P)            Experiment 4        (Figure 3-6 c-f) 
 
(n=2)                                                                   (n=2) 
 
7 ± 3x104 --- --- 12 ± 3x104 
--- --- --- 13 ± 5x104 
* 19F-PFC-labeled PBMC detected at each injection site 48 hours after injection 
--- denotes lymph nodes in which 19F-PFC-labeled PBMC migration was below the 
detection threshold for 19F cellular MRI 
 
 
88 
 
3.4.4 All three main cell lineages within control and 19F-PFC-
labeled PBMC can be detected in the draining lymph node 
two days after injection 
As PBMC are heterogeneous and composed of different cell lineages with varying 
immunological functions in vivo, it was important to determine which cell lineage(s) 
contained within control unlabeled PBMC and 19F-PFC-labeled PBMC are migrating to 
the popliteal lymph node and producing the observed in vivo signal. To conduct this 
experiment, human PBMC were isolated and then subject to flow cytometric analysis to 
determine the percentages of each of the 3 main cell lineages present within PBMC. Cells 
were first gated for live, singlet, CD45+ PBMC (Fig. 3-7A-C). Further gating ascertained 
the composition of PBMC in this representative sample to be 70% CD3+ T cells (Fig. 3-
7D), 3.87% CD19+CD20+ B cells (Fig. 3-7E) and 22.5% CD14+/CD16+ monocytes (Fig. 
3-7F, red arrow points to monocyte population). It is important to note that these 3 lineages 
represent greater than 96% of total CD45+ PBMC from this donor.  Using magnetic bead 
negative selection, CD3+ T cells (Fig. 3-8A), CD19+CD20+ B cells (Fig. 3-8B) and 
CD14+/CD16+ monocytes (Fig. 3-8C) were isolated from a heterogeneous PBMC cell 
suspension with greater than 95% purity. Each lineage was then cultured with 19F-PFC or 
left as control unlabeled cells and cultured for 48 hours. GM-CSF (20 ng/mL) was added 
to all wells for the final 24 hours of culture. Immediately prior to injection, each of the 3 
isolated cell lineages described above was labeled with a different intracellular, membrane-
intercalating fluorophore. CD3+ T cells were labeled with CellTrace™ Far Red (control 
Fig. 3-8D, 19F-PFC Fig. 3-8d), CD19+CD20+ B cells incorporated CellTrace™ Violet 
(control Fig. 3-8E, 19F-PFC Fig. 3-8e), while CD14+/CD16+ monocytes were labeled with 
CellTrace™ CFSE (control Fig. 3-8F, 19F-PFC Fig. 3-8f). Regardless of the cell lineage or 
culture condition, >99% of cells were successfully labeled with an intracellular fluorophore 
(Fig. 3-8D-f, black histograms) compared to an aliquot of cells removed before fluorescent 
labeling (Fig. 3-8D-f, blue histograms). Following cytospins of homogeneous cell 
populations, fluorescence microscopy images were taken to verify fluorescent cell labeling 
of B cells (Fig. 3-9A, pseudocoloured white), T cells (Fig. 3-9B) and monocytes (Fig. 3-
9C). Each of the fluorophore-labeled homogeneous cell preparations was mixed back 
together in physiologic proportion based on the data obtained from Figure 3-7D-F to re-
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establish the original heterogeneous PBMC population prior to footpad injection. Either 
3x106 control, 19F-PFC unlabeled CellTrace+ recombined PBMC or 3x106 19F-PFC-labeled 
CellTrace+ recombined PBMC were injected into the hind footpads of nude mice. Two 
days later, the popliteal lymph nodes were removed, underwent cryosectioning and were 
examined by digital fluorescence imaging. For both control unlabeled CellTrace+ 
recombined PBMC (Fig. 3-9D) and 19F-PFC-labeled CellTrace+ recombined PBMC (Fig. 
3-9E), all 3 cell lineages were identified in the popliteal lymph node.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7. Flow cytometric analysis of human PBMC to determine 
cell lineage composition. 
Figure 3-7. Flow cytometric analysis of human PBMC to determine cell lineage 
composition. Viable (A), singlet (B), CD45+ (C) PBMC were phenotyped using flow 
cytometry to determine the percentages of CD3+ T cells (D), CD19+CD20+ B cells (E) and 
CD14+/CD16+ monocytes (F), which are the three main lineages found within PBMC. 
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Figure 3-8.  Enrichment and differential fluorophore labeling of T 
cells, B cells and monocytes from human PBMC.  
Figure 3-8. Enrichment and differential fluorophore labeling of T cells, B cells and 
monocytes from human PBMC. After gating for singlet, viable, CD45+ cells as illustrated 
in Figure 3-7A-C, CD3+ T cells (A), CD19+CD20+ B cells (B) and CD14+/CD16+ 
monocytes (C) were negatively enriched to a purity >95%. Half of each enriched cell 
lineage was labeled with 19F-PFC and the other half served as the control unlabeled 
condition. GM-CSF (20 ng/mL) was added for the last 24 hours of culture. Homogeneous 
cell populations were labeled with an intracellular membrane-intercalating fluorophore 
both when serving as control cells (top panel, D-F) and 19F-PFC-labeled cells (bottom 
panel, d-f). CD3+ T cells labeled with the intracellular fluorophore Far Red to >99% (D,d; 
black histograms). CD19+CD20+ B cells labeled with the intracellular fluorophore Cell 
Trace Violet (CTV) to >99% (E,e; black histograms).  CD14+/CD16+ monocytes label 
with the intracellular fluorophore CFSE to >99% (F,f; black histograms). Corresponding 
non-fluorescent controls are represented by blue histograms (D-F/d-f). 
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Figure 3-9. All 3 main cell lineages within PBMC reach the draining 
popliteal lymph node two days following adoptive cell transfer.  
Figure 3-9. All 3 main cell lineages within PBMC reach the draining popliteal lymph 
node two days following adoptive cel  transfer. B cells (A, pseudo oloure  white), T cells 
(B) and monocytes (C) were negatively se ected for from PBMC nd ach lineage was 
labeled with a unique fluorophore (A-C, yellow scale bar represents 50 µm). Then, these 
3 lineages were recombined at physiological proportions and a footpad injection of 3x106 
unlabeled PBMC or 19F-PFC-labeled PBMC was performed. Following removal of 
popliteal lymph nodes and cryosectioning, all 3 cell lineages can be detected in the lymph 
node for both control PBMC (D) and 19F-PFC-labeled PBMC (E). 
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3.5 Discussion 
3.5.1 Prostate cancer diagnosis, current treatment options and 
progression 
Prostate cancer is the most common cancer in men with over 20 000 Canadian males being 
diagnosed in 2017391, with frequencies expecting to rise in the coming years given the 
ageing population in developed countries and slow progression associated with this 
disease392. In the early stages of disease, prostate cancer is diagnosed using an increase in 
blood PSA levels and evidence of disease pathology in tissue biopsies8. If detected during 
a stage of low aggression, active surveillance is preferred393, 394, 395, 396, followed by surgery 
and radiotherapy397, 398, 399, 400, 401, with the latter two options being associated with 
decreased quality of life and sexual dysfunction364. Upon disease progression, ADT is 
initiated402, 403, 404, 405 and continues until the prostate cancer develops into metastatic 
CRPC406, 407, which usually occurs 12-18 months after initiation of ADT408. During the 
metastatic stage, few therapies have proven effective, such as the chemotherapeutic agent 
docetaxel. Newly emerging hormone agents and bone-targeting agents to combat 
metastatic spread have also been utilized at this stage8, 364.   
At various stages of prostate cancer treatment, anti-tumor immune responses have been 
observed, albeit at sub-optimal levels11, 12, 63. Biopsies collected from patients undergoing 
ADT have identified uncharacterized tumor-infiltrating T lymphocytes409, 410, 411, 412, while 
other studies have characterized infiltrating lymphocytes as being CD56+ NK cells, 
CD3+CD8+ CTL and CD68+ macrophages, indicating the presence of both innate and 
adaptive anti-tumor responses243, 413, 414. Basal TAA-specific immune responses to PAP 
have also been measured in prostate cancer prior to any immunotherapy being 
administered242, 367, 368. Also, 53.9% and 35.2% of metastatic CRPC patients have 
previously undergone radiotherapy and surgery, respectively. Tumor cell death as a result 
of these treatments can contribute to the anti-tumor immune response present prior to 
immunotherapeutic intervention 246. As a result of lymphocyte infiltration into prostate 
cancer tumors and TAA-specific immune responses being detected, multiple cancer 
immunotherapy strategies have been employed to potentiate the pre-existing anti-tumor 
immune responses observed in vivo to a therapeutic level. In fact, prostate cancer is one of 
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the few cancers in which immunotherapy is included as standard of care treatment8. 
However, unlike melanoma and NSCLC, many gaps in knowledge exist that are hindering 
the full understanding of immunotherapy in the context of prostate cancer246, 258. 
3.5.2 Sipuleucel-T 
In 2010, Sipuleucel-T became the first immunotherapy to gain FDA approval for the 
treatment of asymptomatic or minimally symptomatic metastatic CRPC43, 415. PBMC from 
prostate cancer patients are enriched using leukapheresis of 1.5-2 blood volumes246 and ex 
vivo-cultured with a proprietary fusion protein encoding PAP and GM-CSF for 36-44 
hours7, 42, 250, 379. Ex vivo-culturing and subsequent autologous intravenous infusion 
occurred 3 times over the course of 4-6 weeks7, 241, 249, with each infusion required to 
contain at minimum 40x106 large cells surface expressing CD54+ 246. Both humoral and 
cell-mediated TAA-specific adaptive immune responses have been measured in peripheral 
blood and are associated with Sipuleucel-T administration120, 260; however, in a phase III 
clinical trial this immunotherapy extended overall survival by 4.1 months and improved 
overall 3 year survival to 31.7% compared to 23.0% in the control arm of the study43, 246. 
These modest results clearly highlight the need for improvement of this therapy such that 
progression free survival can be established in patients. As this immunotherapy is an APC-
based vaccine, 19F cellular MRI can non-invasively track and quantify APC migration to 
secondary lymphoid organs post injection as a surrogate marker of immunotherapeutic 
effectiveness. Furthermore, as Sipuleucel-T is derived from PBMC, tracking and 
quantification of other cell lineages contained within the vaccine, such as T cells and NK 
cells82, 83, 133, 385, 416, 417, 418, 419, 420, 421, to the tumor could also provide valuable information 
with respect to better understanding and improving the immunogenicity of this therapy. 
3.5.3 Labeling of human PBMC with 19F-PFC 
As all previous studies investigating successful 19F-PFC cell labeling were conducted on 
homogeneous cell cultures77, 283, 299, 314, 388, 422, red fluorescent 19F-PFC labeling of human 
PBMC isolated from peripheral blood of healthy volunteers was conducted to confirm that 
the main cell lineages within heterogeneous PBMC incorporate label. A range of cell 
culture concentrations and 19F-PFC culture concentrations were employed, and nearly 
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100% of PBMC (5x106 cells/mL in culture) labeled with 19F-PFC at 5 mg/mL. Similar to 
what was observed in Chapter 2 with BMDC, 19F-PFC labeling plateaued and further 
increases in 19F-PFC culture concentration did not result in increased label uptake but did 
result in increased cell death. It is also important to note that cell lineages contained within 
PBMC important for antigen presentation, such as CD11c+ DC, CD14+ monocytes and 
CD3+/CD19+ T and B lymphocytes, all labeled with 19F-PFC to a high percentage (Fig. 3-
1). This is important to note as a prior study has discussed the potential complexity 
associated with labeling cells from different sub-populations and how this may affect 19F-
PFC labeling387. For example, different cell lineages within PBMC may require longer co-
culture with 19F-PFC to reach maximum labeling. It is also known that larger and highly 
phagocytic cells like monocytes uptake more label than smaller cells such as B and T 
lymphocytes; however, it is unknown if highly phagocytic cells indirectly interfere with 
label uptake by smaller, less phagocytic cells in heterogeneous PBMC culture. Even 
considering this added complexity, our results that show near 100% label incorporation 
suggest that in vivo tracking of PBMC is possible using 19F cellular MRI. In stark contrast 
to the data presented here, one other published study investigated labeling of a 
heterogeneous murine splenocyte population with 19F-PFC261. Following 18 hours of 
labeling with 19F-PFC (10 mg/mL), 3.70 ± 0.21% of CD3+ cells and 44.93 ± 3.76% of CD3- 
cells contained within splenocyte cell culture incorporated fluorescent 19F-PFC label261. 
Although a different source of cells than human PBMC, murine splenocytes after Ficoll-
Paque™ gradient centrifugation contain the same 3 main cell lineages, CD3+ T cells, 
CD19+ B cells and CD11b+ myeloid cells. Furthermore, murine PBMC were also labeled 
with red fluorescent 19F-PFC in a preliminary experiment in our laboratory (see Appendix 
II) and >72% of CD3+ T cells and >96% of CD3- cells (containing CD11b+ myeloid cells 
and CD19+ B cells) incorporated red fluorescent 19F-PFC following overnight culture. This 
low labeling percentage observed by Gonzales et al. could be due to increased death caused 
by using a 40 µm cell strainer to generate splenocyte cell suspensions compared to a 70 
µm strainer used in the methods described in this chapter. Additionally, Ficoll-Paque™ 
centrifugation was used to remove dead cells; however, splenocytes that incorporated large 
amounts of 19F-PFC could have an altered cell density that results in these cells pelleting 
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alongside dead cells. Lastly, a 19F-PFC concentration of 10 mg/mL, when used for murine 
splenocytes labeling, resulted in increased cell death (unpublished data).     
Heterogeneity within cell populations labeled with 19F-PFC is an important concept to 
discuss as ideally, a cell labeling agent should serve to label all cells to a high percentage 
without affecting viability, phenotype and function203. On average, Sipuleucel-T infusions 
contain 62.3% CD3+ T cells, 18.3% APC of which the majority are CD14+, 11% CD56+ 
NK cells and 4.7% CD19+ B cells. The relative proportions of cells between infusions from 
the same patient were consistent120; however, large differences in cell lineage proportions 
have been observed between patients (our own unpublished data). This observation is in 
agreement with a previous study that found PBMC lineage ranging from 18.7-71.4% for T 
cells, 7.14-45.3% for monocytes, 3.36-27.7% for B cells and 2.26-21.8% NK cells238. With 
respect to 19F-PFC incorporation, labeling can be up to 10 000 times greater in large cells 
such as monocytes/macrophages and DC when compared to smaller cells containing very 
little cytoplasm, such as T cells423. In the context of cellular immunotherapy, this labeling 
difference has been reported to be much lower, with small cells like T, B and NK cells 
labeling on the low end of 1012 19F spins424 per cell and larger cells like CD14+ monocytes 
and DC labeling on the high end of 1012 to the low end of 1013 19F spins per cell291, 299 (and 
unpublished data).  Although labeling human PBMC with 19F-PFC as a whole is near 
100%, differences in lineage composition between patients must be taken into account 
when considering the sensitivity and location of 19F cellular MRI in vivo detection. At 
present, it must be assumed that the relative cell lineage proportions in a participant’s 
PBMC NMR sample prior to adoptive cell transfer remain unchanged compared to the cell 
lineage proportions of migrated PBMC detected in the lymph node. While experiments to 
determine lymph node-migrated PBMC cell lineage composition are ongoing, this 
assumption represents a limitation of this non-invasive imaging modality with respect to 
accuracy of in vivo cell quantification.  
3.5.4 Human 19F-PFC-labeled PBMC cultured with GM-CSF as a 
model of Sipuleucel-T 
Following the observation of near 100% labeling of human PBMC from healthy volunteers 
with 19F-PFC, GM-CSF was added to culture medium to mimic Sipuleucel-T ex vivo 
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culture and verify that it did not interfere with 19F-PFC incorporation. By adding GM-CSF 
in culture to PBMC, simulation of PA2024 fusion protein uptake seen in Sipuleucel-T that 
induces efficient antigen presentation, activation and up-regulation of co-stimulation 
molecules250, 425 can be studied.  
GM-CSF exerts its function by binding its receptor, CD116, which is expressed on myeloid 
and epithelial cells, such as both professional and non-professional APC. The receptor is 
composed of a unique alpha chain and a common beta chain that is shared with the IL-3 
and IL-5 receptor251 and has been demonstrated to enhance the tumoricidal function of 
monocytes426. Immunogenic cancers, such as melanoma, NSCLC, pancreatic cancer, renal 
cell carcinoma and prostate cancer have been found to secrete GM-CSF427 and formed the 
premise for the early immunotherapy strategy in which tumors were genetically modified 
to secrete GM-CSF, known as GVAX428, 429. A prostate cancer-specific therapy (prostate 
GVAX) was developed by modifying LNCaP and PC3 cell lines to secrete GM-CSF and 
was met with limited success430, 431. GM-CSF is superior to fms like tyrosine kinase 3 
(FLT3) for promoting DC expansion and CD80 up-regulation, yet if administered in high 
doses can result in a blockade of an immune response mediated by myeloid-derived 
suppressor cell (MDSC) expansion that induce regulatory T cells (Treg) and defects in DC 
function427, 432, 433. With Sipuleucel-T, GM-CSF interaction with its cognate receptor 
initiates the activation of APC and also, with each subsequent infusion, APC activation 
increases further, with a 6.2 fold activation being measured upon first infusion and a 10.5 
fold activation observed after the third infusion120. Along with increased antigen processing 
and presentation as a result of APC activation, up-regulation of co-stimulatory surface 
markers, such as CD54, occurs.  
CD54, also known as intracellular adhesion molecule-1 (ICAM-1) is a member of the IgG 
superfamily, participates in immune surveillance and by binding with LFA-1, facilitates 
and provides stability to the immunological synapse between an APC and T cell42, 379, 427, 
434. The stability of the peptide:MHC complex within an immunological synapse is related 
to the immunogenicity of the ensuing peptide-specific immune response435 and thus, CD54 
serves as a predictor of APC activation and their capacity to induce a potent in vivo immune 
response.  
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Prior to 19F cellular MRI in vivo imaging studies, the effect of GM-CSF in culture on 19F-
PFC-labeled human PBMC was investigated. First, the viability of 19F-PFC-labeled bulk 
PBMC was unaffected by GM-CSF addition in culture. Further data analysis demonstrated 
the viability of the main three lineages contained within PBMC, CD3+ T cells, CD20+ B 
cells and CD11b+ myeloid cells, did not differ as a result of GM-CSF addition for both 
unlabeled control PBMC and 19F-PFC-labeled PBMC.  
Following PBMC viability assessment with respect to 19F-PFC and/or GM-CSF addition 
in culture, the percentage expression and intensity of expression (determined using MFI) 
of activation, co-stimulation and migration cell surface markers were measured for both 
CD20+ B cells and CD11b+ myeloid cells cultured in or without 19F-PFC and GM-CSF. In 
all culture conditions evaluated, the activation marker CD40 and co-stimulatory marker 
CD86 were present on both B cells and myeloid cells and is in agreement with a previously 
published report42 that demonstrated CD54+ APC express CD40 and CD86 as well as HLA-
A,B,C and HLA-DR. The latter two are required for peptide presentation that induce CD8+ 
and CD4+ T cell activation and proliferation, respectively42, 436. GM-CSF results in modest 
but similar increases in activation, co-stimulation and migration marker expression for both 
control unlabeled and 19F-PFC-labeled PBMC, with significant up-regulation being 
observed for CD86 in CD20+ B cells and for CD86 and CD54 in CD11b+ myeloid cells. 
Therefore, this suggests that GM-CSF in culture is biologically active in our current system 
as evidenced by CD54 up-regulation in CD11b+ myeloid cells following GM-CSF 
addition. Lastly, CD11b+ CD54+ myeloid cells in our culture system closely resemble the 
CD54+ large APC population within Sipuleucel-T infusion products246.    
As expected, given inter-patient variability in relative cell lineage compositions in PBMC, 
a range of average 19F-PFC labeling per cell was noted for different participant samples; 
however, GM-CSF addition to the culture did not result in significant changes to 19F-PFC 
incorporation. PBMC were ex vivo-cultured for a total of 48 hours, with GM-CSF being 
added 24 hours into culture. It was presumed that maximum label incorporation would be 
reached prior to GM-CSF addition and the associated changes in the activation state of 
APC did not hinder 19F-PFC label incorporation. Thus, this permitted the consistent 
detection and quantification of a therapeutically relevant cell number in the draining 
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popliteal lymph node of immunocompromised mice two days post footpad injection using 
19F cellular MRI. 
3.5.5 Implications of 19F-PFC-labeled PBMC in vivo migration to 
lymph nodes 
GM-CSF addition to 19F-PFC-labeled PBMC in ex vivo culture increased migration such 
that consistent detection and quantification of cell migration to the draining popliteal lymph 
node was possible. As described previously in Chapter 2, tissue pre-treatment with IL-1b 
three hours prior to 19F-PFC-labeled cell injection was included in 19F cellular MRI 
imaging studies in an attempt to increase cell migration to the lymph node199. IL-1b pre-
treatment did not work synergistically or additively with GM-CSF to consistently improve 
migration of 19F-PFC-labeled cells to popliteal lymph nodes; however, this pre-treatment 
did appear to increase 19F-PFC-labeled PBMC not cultured with GM-CSF above the 
detection threshold for in vivo 19F cellular MRI detection. Considering that GM-CSF in co-
culture did not increase the percentage of CCR7+ cells or the intensity of CCR7 expression 
(as measured by MFI), GM-CSF may have activated APC such that when they reach the 
draining lymph node, they remained there longer without undergoing apoptosis or leaving 
via the lymphatics. Also, a positive feedback loop has been demonstrated whereby GM-
CSF-induced maturation of APC results in IL-12 and IFNg secretion by APC, which then 
activate NK and T cells, promoting IFNg and TNFa release. Increased IFNg and TNFa can 
then function in a paracrine manner to further activate APC437, 438, 439, 440, 441. To further 
elucidate this positive feedback loop, cytokine secretion profiles of culture supernatant as 
well as cytokine secretion upon APC reaching the lymph node would need to be analyzed. 
Nonetheless, increased activation and secretion of pro-inflammatory cytokines could 
present as increased quantification of migration 48 hours after injection and would be 
expected to result in the induction of a more potent TAA-specific immune response 
compared to control 19F-PFC-labeled PBMC. With respect to consistent and efficient 
quantification of therapeutic cell migration following injection, 19F cellular MRI appears 
to be a suitable, non-invasive imaging technique for use within the context of cell-based 
immunotherapies.  
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Detection and quantification of 19F-PFC-labeled PBMC in the draining lymph node post 
injection led to discussion as to which cell lineage contained within PBMC were 
responsible for producing the observed in vivo signal. From an imaging standpoint, 
questions arose relating to whether 19F-PFC labeling altered the relative cell proportions 
within PBMC when compared to control unlabeled PBMC from the same participant. From 
an immunological perspective, the proportion of cell lineages reaching the lymph node 
compared to pre-injection proportions was important to learn such that deficiencies in 
migration of certain cell lineages could be assessed. Also, as B and T lymphocytes, 
monocytes, DC and NK cells vary with respect to their in vivo functions, knowledge of 
which cells reach the draining lymph node is necessary to understand the immunological 
implications of this measured migration83, 378, 385. For example, with APC-based cellular 
immunotherapies, APC migration is absolutely necessary as the quantification of lymph 
node migration is directly proportional to the ensuing immune response199. Other cells 
within this formulation, like T cells, are also important in the context of immunotherapy as 
CD4+ TH1 cells have been shown to release cytokines that can lead to further APC 
activation and cytokine release, affecting both the strength, persistence and type of immune 
response that is subsequently launched380, 381.  
Differential intracellular fluorescent labeling of CD3+ T cells, CD19+CD20+ B cells and 
CD14+/CD16+ monocytes prior to footpad injection and recombination at physiologic 
proportions permitted lymph node removal and fluorescence microscopy analysis 
following detection of 19F-PFC signal in the popliteal lymph node. Although not yet 
quantified for measurement of relative proportions of cell lineages, qualitatively it can be 
said that each fluorescently-labeled cell lineage was observed to be present in the draining 
popliteal lymph node 48 hours post injection for both 19F-PFC-labeled and control 
unlabeled PBMC co-cultured with GM-CSF. A more rigorous, quantitative analysis could 
be conducted by flow cytometry. Taken together, this data suggests that 19F-PFC labeling 
does not affect the viability or in vivo migration capacity of the 3 main PBMC lineages and 
can be conducted with GM-CSF activation of APC in culture without any deleterious 
effects.   
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As fluorescence microscopy was employed to confirm which cells were producing the 
observed in vivo 19F signal in the lymph node, tissue sectioning revealed that B and T 
lymphocytes reach the lymph node and were dispersed across the central regions of this 
organ. Secondly, fluorescence microscopy detected monocytes in the central lymph node 
regions as well. This led to considerations regarding whether these fluorescent cells were 
still CD14+ monocytes or whether culturing with GM-CSF induced differentiation into 
CD11c+ CD123- moDC that were capable of migrating into paracortical lymph node 
regions. The biological implications of this potential differentiation are promising from an 
immunological perspective, as moDC are professional APC known to stimulate potent and 
long-term immune responses upon interacting with and activation of naïve T cells125, 285.  
3.5.6 Conclusions 
This chapter demonstrated that a high percentage of human PBMC, which are the source 
of cells for mixed-APC based cancer vaccine immunotherapies, incorporated 19F-PFC cell 
labeling agent without affecting PBMC viability and phenotype. GM-CSF can also be 
added to culture to mimic the culture conditions of mixed APC-based cancer vaccine 
immunotherapies without having any deleterious effect on viability, phenotype or in vivo 
migration. In fact, we reported that GM-CSF addition to culture activated APC contained 
within human PBMC such that their migration to secondary lymphoid organs following 
injection was reliably above the detection threshold of 19F cellular MRI and permitted the 
quantification of in vivo migration. Post-19F cellular MRI analysis of draining lymph nodes 
illustrated that all main cell lineages within PBMC are migration-competent and are 
responsible for the detected in vivo 19F signal.  Therefore, we propose that this imaging 
technique can be used in conjunction with an established APC-based cancer 
immunotherapy model83 to serve as a surrogate marker for assessing and improving upon 
the therapeutic benefit that this immunotherapy currently provides. For example, 19F 
cellular MRI can be employed to non-invasively determine the enhanced effect of APC-
based immunotherapies in combination with other immunotherapies or previously 
established anti-tumor treatment strategies442, 443, 444. It is also broadly applicable such that 
19F cellular MRI can serve as a non-invasive imaging technique to measure and improve 
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upon the effectiveness of other emerging APC-based cancer vaccine immunotherapies for 
metastatic breast, ovarian and colorectal cancer445, 446 as well as renal cell carcinoma447, 448. 
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Chapter 4  
4 Clinical translation and GMP-compliant processing of 
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4.2 Introduction and Rationale 
Cancer immunotherapy is an emerging research area that relies on one’s own immune 
system to combat the cancer. Early research focused on non-specific up-regulation of the 
immune system using interleukins or adjuvants in an effort to elicit an anti-tumor 
response449. More recently, specific anti-tumor immune responses have been developed 
using TAA-specific vaccine approaches450, 451. An example of such an immunotherapy is a 
TAA-specific APC-based cancer vaccine. In order for APC, such as B cells, monocytes, 
macrophages and DC452 to function as adjuvants in cancer vaccines, they must seed 
secondary lymphoid organs such as a lymph node or spleen in order to interact with and 
activate CD4+ and CD8+ T cells203. With such therapies, it is advantageous to prepare 
properly matured, activated and TAA-loaded APC ex vivo to avoid the harsh 
immunosuppressive environment induced by a tumor in vivo that prevents proper APC 
priming, maturation and activation192, 453. Following completion of ex vivo culture, APC 
are infused back into the patient and exert their anti-tumor function upon reaching 
secondary lymphoid organs. This ex vivo approach has proven safe and non-toxic7, 72 and 
has led to improvements in quality of life and overall survival times73, 74, 76, 454; however, 
improvements to this type of immunotherapy are needed in order for long-term progression 
free survival to be achieved in cancer patients455, 456. 
Previous research has demonstrated that only 3-5% of originally injected therapeutic APC 
reach the lymph node post injection, which is a major factor limiting the effectiveness of 
mixed APC- and DC-based cancer vaccines183, 198, 199, 215, 216, 217. As the quantity of TAA-
presenting APC that reach a secondary lymphoid organ and interact with T cells is directly 
proportional to the ensuing TAA-specific T cell response elicited in vivo199, there is a 
pressing need to confirm and non-invasively quantify this migration. Knowledge gained 
through in vivo tracking of therapeutic cells to and persistence in secondary lymphoid 
organs109, 264 can function to predict immunotherapeutic effectiveness and also alert 
researchers of cell migration to unexpected in vivo locations, which could explain the sub-
optimal effectiveness currently associated with APC-based immunotherapies.  
MRI is a promising approach for tracking APC in vivo203, 278. Various types of cell labeling 
agents are available for pre-clinical cell tracking by MRI that include iron oxide, 
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gadolinium, manganese and 19F457. However, only 19F incorporated into a 19F-PFC is a 
commercially available formulation designed specifically for in vivo cell tracking that can 
stably label many cell types141, 270, 307, 314, 388, 389, 390. This 19F-PFC has been approved as an 
investigational new drug by the U.S. Food and Drug Administration for human use as a 
cellular MRI tracking agent308 and has been employed to track human DC in mice291, 310 
and in one human clinical trial77. This type of cellular MRI labeling agent is attractive 
because it provides a quantifiable, positive signal in the absence of any endogenous 19F 
signal following an in vivo 19F MRI scan. This allows for the unambiguous detection of 
greater than 104 19F-PFC-labeled cells per voxel291 and when combined with 1H MRI, the 
anatomical 3-dimensional location of this observed 19F signal can be determined307, 308, 310.  
Previous research from our laboratory that is presented in Chapter 3 demonstrated that 
nearly 100% of human PBMC, which is the source of leukocytes used in a FDA-approved 
mixed APC-based cancer vaccine246, 458 can incorporate 19F-PFC in a pre-clinical setting. 
Moreover, 19F-PFC labeling did not affect human PBMC viability, phenotype or function, 
and 19F-PFC incorporation was sufficient to permit the in vivo detection and quantification 
of a therapeutically-relevant number of human PBMC in secondary lymphoid organs in an 
immunocompromised murine model. 
Although we reported efficient 19F-PFC labeling of human PBMC in a pre-clinical setting, 
our intent is to conduct a clinical trial to detect and quantify autologous 19F-PFC-labeled 
human PBMC following injection using 19F cellular MRI. Therefore, human PBMC 
isolation, culture and 19F-PFC labeling must be performed under GMP-compliant 
conditions, which are a set of standards and reagents with respect to processing cell 
products intended for injection into humans that must be met. Additionally, all quality 
assurance, sterility and purity tests mandated by Health Canada before autologous infusion 
takes place must be passed with respect to 19F-PFC labeling. Therefore, we designed a 
protocol to label human PBMC under GMP-compliant conditions that included all 
associated quality assurance tests required for autologous reinjection; however, until 
clinical trial approval, imaging GMP-cultured 19F-PFC-labeled human PBMC was 
conducted in a pre-clinical immunocompromised mouse model. The nearest GMP-
compliant cell manufacturing facility is nearly 3 hours away from where patients will have 
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their blood drawn and undergo MR imaging upon clinical trial approval. Therefore, it was 
necessary to also test the effect of a lengthy transportation on 19F-PFC-labeled PBMC and 
compare these results to unlabeled cells that were cultured under GMP-compliant 
conditions. Finally, in a parallel experiment, optimization of 19F cellular MRI detection 
using a clinical MR set-up and hardware was performed in preparation for imaging patients 
following autologous injection.  
This study investigates the suitability of using a 19F-PFC as a MRI cell labeling agent for 
a heterogeneous APC population, as found in a PBMC-based cancer vaccine platform, such 
that they are detectable in vivo. Successful labeling of individual leukocyte and non-
leukocyte lineages has been reported307, 310, 388. However, while 19F-PFC labeling of all 
cells in a heterogeneous population might be anticipated, it has not been successfully 
reported in the literature261 until our lab demonstrated near 100% labeling (Chapter 3). 
Vaccines composed of a heterogeneous mixture of leukocytes, like PBMC, which form the 
basis of a FDA-approved therapy for prostate cancer246, 458, contain both non-professional 
APC (T and NK cells) in addition to professional APC, such as B cells, monocytes and 
circulating DC459, 460. This pre-clinical validation study was performed as a step towards a 
clinical trial. The main purpose of this chapter was to determine if we could label the major 
blood leukocyte lineages within PBMC with 19F-PFC under GMP-compliant conditions 
while maintaining viability, functionality and 19F-PFC label retention that meets the pre-
determined criteria for autologous re-injection. We demonstrate that 19F-PFC-labeled 
human PBMC processed under GMP-compliant conditions are detectable and migration-
competent in a pre-clinical murine model. Lastly, translation to a 3 T clinical MRI scanner 
using a dual-tuned 1H/19F switchable RF coil suitable for use in human studies permitted 
the detection and quantification of 19F-PFC-labeled human PBMC in a mock human in vivo 
system. 
4.3 Materials and Methods 
4.3.1 Animal care 
Male nu/nu mice (Crl:NU-Foxn1NU) were purchased from Charles River Laboratories Inc. 
(Saint Constant, Canada) at 8-10 weeks and housed in a pathogen-free barrier at Robarts 
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Research Institute at the University of Western Ontario (London, Canada). All experiments 
were pre-approved by the Animal Use Subcommittee at the University of Western Ontario 
and conducted in accordance with an approved protocol from the University of Western 
Ontario’s Council on Animal Care (Protocol #2015-046). Mice were anaesthetized with 
2% isoflurane in oxygen.  
4.3.2 Participants 
The University of Western Ontario Health Sciences REB pre-approved this protocol (REB 
Protocol #104593). Each participant involved in this study protocol received a REB-
approved Letter of Information and provided a signed Letter of Informed Consent before 
entering into the study. For inclusion in the study, healthy participants were required to be 
18 years of age or older and free of medical conditions that precluded participation in the 
study. Potential participants who were undergoing treatment with an immunosuppressive 
drug (eg. steroids) or infected with Human Immunodeficiency Virus, Hepatitis B or C 
Virus or other transmissible diseases were excluded from the study. Participants with 
prostate cancer were required to have castrate resistant, non-metastatic prostate cancer with 
normal or rising PSA levels. Prostate cancer patients on hormone therapy were permitted 
to participate but were excluded from the study if they were undergoing active 
chemotherapy and radiation therapy, being treated with immunosuppressive drugs (eg. 
steroids), were infected with HIV, Hepatitis B or C or other transmissible disease. 
4.3.3 Reagents 
Aim V® Medium CTS (GMP-grade, Gibco, Burlington, Canada) was supplemented with 
100 U/mL of penicillin, 100 µg/mL of streptomycin and 0.3 mg/mL L-Glutamine 
(ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, LIVE/DEAD® Fixable Aqua 
Dead Cell Stain Kit and CellTrace™ CFSE cell proliferation kit and human AB serum 
were purchased from ThermoFisher Scientific and BSA was obtained from Calbiotech 
(Spring Valley, USA). Ammonium chloride lysis buffer, human CD3+ positive selection 
kit and human CD3+ negative selection kits were purchased from Stemcell Technologies 
(Vancouver, Canada). Ficoll-Paque™ PREMIUM (GMP-grade) was acquired from GE 
Healthcare Bio-Sciences (Pittsburgh, USA) and NGS was purchased from Jackson 
109 
 
ImmunoResearch (West Grove, USA). Anti-human CD45-FITC (Clone HI30), CD45-PE 
(HI30), CD3-PE (HIT3a), CD3-APC/Cy7 (SK1), CD4-PerCP (RPA-T4), CD8-PE (SK1), 
CD19-PE (HIB19), CD20-PE (2H7), CD11b-Alexa Fluor 488 (M1/70), CD16-Alexa Fluor 
700 (3G8), CD11c-APC (3.9), CD56-BV605 (HCD56), purified anti-human CD3 antibody 
(OKT3) and FITC Annexin V Apoptosis Detection kit with 7-AAD were purchased from 
Biolegend (San Diego, USA), while anti-human CD14-eFluor450 (61D3) and UltraComp 
eBeads were acquired from eBioscience (San Diego, USA).  The 19F-PFC cell labeling 
agents used in this study, Cell Sense CS-1000 (suitable for clinical use) and the red 
fluorescent version, CS-ATM DM Red (excitation 596 nm, emission 615 nm), were both 
purchased from Celsense, Inc. (Pittsburgh, USA). Lastly, PBMC were cultured in 
ThermoFisher Scientific Nunc Hydrocell plates (ThermoFisher Scientific). 
4.3.4 Pre-clinical 19F-PFC-labeled PBMC functional and in vivo 
migration assessment 
In Chapter 3, human PBMC were isolated, viability assessed and labeled efficiently with 
19F-PFC such that they can be detected in vivo in a murine model. Before progressing to 
GMP-compliant 19F-PFC-labeling, experiments to determine PBMC functionality and 
verification of in vivo signal were conducted.   
4.3.5 Mixed lymphocyte reaction (MLR) 
PBMC were obtained from a healthy volunteer (as described in Chapter 3 methods) and 
using a human CD3 positive selection kit (Stemcell Technologies) and manufacturer’s 
instructions, T cells were removed from cell suspension. The remaining cells were cultured 
overnight as previously described with or without 19F-PFC (5 mg/mL). Following 
overnight culture, cells were collected and washed in HBSS. Cells were then re-suspended 
in AIM V® Medium CTS™ media at 2.5x106 cells/mL and serially diluted starting from 
2.5x105 cells per well in triplicate. Then, PBMC were obtained from different volunteers 
(n=3) and using a human CD3 negative selection kit (Stemcell Technologies) and 
manufacturer’s instructions, T cells were enriched from PBMC. Isolated T cells were re-
suspended at 1x106 cells/mL in warm PBS+0.5% human AB serum (ThermoFisher 
Scientific) and labeled with CellTrace™ CFSE (1 µM) for 10 minutes at 37°C. The reaction 
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was quenched with ice cold AIM V® Medium CTS™ media and cells were washed in 
HBSS. Lastly, T cells were re-suspended at 3x106 cells/mL in media and 100 µL was 
aliquoted to each well and a MLR was carried out for four days at 37°C/5% CO2 (positive 
control wells were coated overnight with anti-CD3 antibody (2 µg/well). After four days 
of incubation, wells were washed in buffer and following the same staining procedure as 
listed above, cells were stained for CD4 and CD8 and CFSE dilution was used as a readout 
to assess allogeneic T cell proliferation.  
4.3.6 T cell proliferation assay 
T cells from healthy volunteers (n=3) were enriched from PBMC as described previously 
and cultured with or without 19F-PFC (5 mg/mL) overnight at 5x106 cells/mL in AIM V® 
Medium CTS™ media. The following day, T cells were collected and labeled with CFSE 
as outlined above. Lastly, T cells were re-suspended at 3x106 cells/mL in AIM V® Medium 
CTS™ media and 100 µL was plated in triplicate. Negative control wells were uncoated 
while positive control wells were coated overnight with anti-CD3 antibody (2 µg/well).  
4.3.7 Pre-clinical confirmation of 19F MRI popliteal lymph node 
signal 
Although 19F MRI signal detection in the draining popliteal lymph node has been presented 
in Chapter 3 with human PBMC, verification that this signal is the result of originally 
injection PBMC was still to be determined.  PBMC were isolated from healthy volunteers 
and labeled with 19F-PFC as described above. However, immediately prior to injection, 
PBMC were labeled with CFSE as described previously. Dual-labeled 19F-PFC+ CFSE+ as 
well as CFSE+ control PBMC were then wash and formulated into a 3x106 cell injection in 
40 µL of PBS into the left and contralateral footpad of anesthetized nude mice, 
respectively. Immediately following 19F cellular MRI 48 hours later, draining popliteal 
lymph nodes were removed from sacrificed mice and either fixed with 4% PFA and 
cryopreserved in sucrose solutions or pushed through a 70 µm strainer (VWR) to obtain a 
single cell suspension. Cell suspensions were then re-suspended in HBSS+0.1% BSA, 
surface stained with human CD45-PE for 25 minutes on ice (4°C) and data was acquired 
immediately on a LSRII analytical flow cytometer (BD Biosciences) to identify CFSE+ 
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CD45+ human PBMC. For lymph nodes that were cryopreserved, 16 µm sections were 
placed on VWR Microslides Superfrost® Plus (VWR) and coverslipped with Vectashield® 
Hard Set mounting medium with 4’,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, CA, USA) to stain nuclei. Fluorescence microscopy was then performed to 
confirm popliteal lymph node 19F signal was from originally injected 19F-PFC-labeled 
PBMC through CFSE detection, as well as confirm that these cells were intact via DAPI 
staining of nuclei.    
4.3.8 GMP-compliant human PBMC isolation 
PBMC were procured from a healthy volunteer (n=1, subject 4) and prostate cancer patients 
(n=4; subjects 1, 2, 3, 5) who consented to a protocol approved by the University of 
Western Ontario Health Sciences Research Ethics Board (London, ON, Canada). 
Approximately 100-160 mL of blood was drawn into sterile vacutainer tubes containing 
di-potassium ethylenediaminetetraacetic acid (EDTA). Each vacutainer was labeled with a 
unique identifier as well as harvest date and time. The vacutainers were placed in a 
transport container capable of maintaining a constant temperature between 15-25ºC for 
transport (2-3 hours) in accordance with the Transportation of Dangerous Goods Act from 
London, Ontario to a University Health Network (UHN, Toronto, Ontario) cell 
manufacturing facility that operates under GMP principles. Upon receipt, PBMC were 
isolated by a density gradient centrifugation using GMP-grade Ficoll®-Paque (GE 
Healthcare Cat # 17-1440-02 or equivalent). 
4.3.9 Cell safety 
The following safety tests were performed on each PBMC preparation.   
Fourteen-day sterility testing: Sterility was performed on the supernatant of 19F-PFC-
labeled PBMC. Briefly, 19F-PFC-labeled PBMC were collected in 15 mL conical tubes by 
gentle scraping using a cell scraper and were centrifuged at 300xg for 10 minutes at room 
temperature. One mL of the culture supernatant from the tubes was inoculated each into 
thioglycollate and tryptone Soya tubes. Inoculated tubes were sent to a certified 
microbiology laboratory (Mt. Sinai Hospital) for analysis as per United States 
Pharmacopeia (USP) Chapter 71461. 
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Endotoxin testing: The presence of endotoxin was measured by a Health Canada approved 
Endosafe®-PTS Portable Test System (Charles River). Briefly, a 1 mL aliquot of cell 
culture supernatant was collected after the final wash of 19F-PFC-labeled PBMC. Samples 
were processed as per manufacturer recommendations, including a reference standard 
spike-in (positive control).  
Mycoplasma Testing: Mycoplasma testing was done on final 19F-PFC-labeled PBMC using 
a validated qPCR method as per USP Chapter 63462. Testing was done on 2-3x106 cells/mL 
collected along with supernatant collected after harvesting but prior to washing.   
4.3.10 Human PBMC 19F-PFC labeling 
PBMC were labeled with the 19F cell labeling agent, a 19F-PFC having a total concentration 
of 120 mg/mL. The average nanoemulsion droplet size was 180 nm and was formulated 
with excipients that expedite entry of the nanomaterial into all cell types, regardless of their 
endocytic and phagocytic capacity. Approximately 50 million PBMC isolated by FicollÒ-
Paque density gradient separation were plated in 75 cm2 ultra low attachment flasks 
(Corning, NY, USA) in defined serum-free AIM V® Medium CTS™ media (GMP-
compliant). PBMC were labeled with 5 mg/mL of 19F-PFC by co-incubation for 16-24 
hours (overnight) at 37ºC, 5% CO2 in certified incubators at the UHN cell manufacturing 
facility. The 19F-PFC-labeled PBMC were collected in 15 mL conical tubes by gentle 
scraping using a cell scraper (BD Biosciences) and washed with PBS (ThermoFisher 
Scientific) 3 times.  
4.3.11 Cell viability 
Cell viability was measured during the process of PBMC isolation using the trypan blue 
exclusion assay. The injection-ready 19F-labeled PBMC viability was performed more 
rigorously by 7-AAD staining and flow cytometric analysis on a LSRII analytical flow 
cytometer (BD Biosciences). Alternatively, an aliquot of both 19F-PFC-labeled and 
unlabeled PBMC in HBSS+0.1% BSA were first stained on ice for 25 minutes with anti-
human CD45-FITC, then washed and re-suspended in buffer supplied in the apoptosis 
detection kit for staining with 7-AAD at room temperature. Data was acquired immediately 
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after addition of 7-AAD to the PBMC cell suspension.  Data was analyzed to ensure that 
the viability of final 19F-PFC-labeled PBMC was >70%.   
4.3.12 Flow cytometry 
To phenotype both 19F-PFC-labeled PBMC and unlabeled PBMC, analytical flow 
cytometry was performed on whole blood and isolated PBMC samples on the day of blood 
draw, as well as on 19F-PFC-labeled and unlabeled PBMC following overnight culture at 
the GMP-compliant facility and upon return to Robarts Research Institute. In this manner, 
cell lineage composition could be compared between labeled and unlabeled PBMC 
populations and between the lineage composition from the initial blood draw on day 0 to 
the PBMC post GMP-compliant processing. Isolated PBMC were blocked on ice for 30 
minutes with 5% NGS (v/v) in HBSS+0.1% BSA and then washed in HBSS and stained 
with LIVE/DEAD® dye for 20 minutes at room temperature. Following washing in HBSS, 
cell surface staining with the antibodies mentioned previously was conducted on PBMC in 
HBSS+0.1% BSA on ice (4°C) for 25 minutes. Lastly, stained PBMC were washed in cold 
HBSS and re-suspended in HBSS+0.1% BSA for data acquisition on a LSRII analytical 
flow cytometer (BD Biosciences). Staining of whole blood was performed as mentioned 
above without a blocking step. Also, red blood cells were lysed by the addition of 
ammonium chloride lysis buffer following antibody and LIVE/DEAD® staining. 
4.3.13 Adoptive cell transfer of PBMC 
For PBMC to be injected into mice, PBMC were washed twice in PBS and these final 
injection-ready PBMC, depending on yield post-GMP processing, were divided into a low 
(1x106) and high (4-6x106) injection number for both 19F-PFC-labeled and unlabeled 
PBMC. Labeled or unlabeled PBMC in 100 µL PBS were adoptively transferred 
subcutaneously into the upper left flank and contralateral flank of anaesthetized nude mice, 
respectively.  
4.3.14 MRI of PBMC migration 
Mouse imaging was performed with a 9.4 T Varian small animal MRI scanner (Santa Clara, 
CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging. Animals 
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were imaged alongside reference tubes containing a known 19F concentration (3.33x1016 
19F/μL or 7.3x1016 19F/μL) suspended in agarose. Mice were anaesthetized with 2% 
isoflurane, with breathing rate and temperature monitored throughout the scan. MRI was 
performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), tuned 
to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively.  For proton imaging 
the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°, PC = 4, 
averages = 3, resolution = 200x200x200 μm3, and number of excitations (NEX) = 3.  For 
19F imaging the parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC 
= 4, averages = 200, resolution = 1x1x1 mm3, and NEX = 200. To avoid 19F present in 
isoflurane confounding the 19F-PFC signal, imaging was performed by centering on the 
19F-PFC Cell Sense-specific frequency as was previously described270. The total protocol 
time for both proton and 19F imaging was under 90 minutes.   
4.3.15 Clinical MRI Protocol 
Optimization was performed with an array of PBMC pellet phantoms produced by 
centrifugation of 1, 3, 10, and 20 x106 19F-labeled PBMC in Eppendorf tubes. The 
supernatant was discarded and the remaining cell pellets were overlaid with 1% agarose to 
prevent dispersion.  Mock human imaging was performed by intradermal injection of 1.5, 
4.5, 10.5, and 20x106 PBMC into a ham shank. An additional 4.5x106 PBMC were 
administered intramuscularly 1.2 cm below the dermal layer to measure imaging depth 
sensitivity.  Samples were imaged with a GE MR750 (GE Healthcare, Milwaukee, WI, 
USA), 3 T MRI scanner equipped with a multinuclear pre-amplifier. Samples were first 
imaged with the built-in proton body coil to identify ROI.  Site-specific imaging was then 
performed by placing a dual proton/19F-tuned switchable surface coil (4.3 cm x 4.3 cm) 
manufactured by Clinical MR solutions (Brookfield, WI, USA), directly on the ROI for 
optimum sensitivity. The dual-tuned surface coil is approved for human use under 
Investigational Testing Authorization from Health Canada as well as approved by the 
University of Western Ontario Health Sciences Research Ethics Board as an investigational 
human MR imaging protocol (#2137).  A 2D fast gradient echo (Fast GRE) sequence was 
used for proton imaging with the following scan parameters: TE = 2.6 ms, TR = 100 ms, 
FOV = 15 cm x 15 cm x 5 cm, image matrix = 256x256, slice thickness = 5 mm, rBW = 
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83 kHz, NEX = 3, and FA = 20°. Following proton imaging, the coil was switched to 19F-
mode and the same FOV was scanned. The 19F images were obtained with a broad-banded 
3D bSSFP based on the GE FIESTA-C sequence.  The scan parameters were: TE = 2.2 ms, 
TR = 4.4 ms, FOV = 15 cm x 15 cm x 5 cm, image matrix = 46x46, slice thickness = 5mm, 
rBW = 10 kHz, NEX = 425 and FA = 70°. 19F imaging time was 15 minutes, with a total 
protocol time under 25 minutes. Images from the body coil were analyzed and lymph node 
volume was measured using OsiriX image analysis software (Pixmeo, Geneva, 
Switzerland). 
4.3.16 19F loading efficiency and signal quantification 
The mean intracellular 19F content of human PBMC was determined by NMR spectroscopy 
using a 400 MHz Varian vertical spectrometer.  First, a known number of 19F-PFC-labeled 
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a 
solution containing 100 µL of 5% Triton X-100.  After lysing, the cells were transferred to 
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with 
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA 
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal 
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters 
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm. 
The number of PBMC detected within MR images was determined with Voxel TrackerTM 
software (Celsense Inc, Pittsburgh, USA)270, 308. Prior to analysis, a signal correction was 
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest 
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal 
contained within a hand-drawn ROI was compared to the average signal produced by the 
reference tube containing a known 19F concentration. This information was used alongside 
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at 
the ROI.   
4.3.17 Statistical analysis 
All data was presented as the mean with the standard error of the mean. A one-way or two-
way ANOVA (Graph Pad Prism, Version 7, La Jolla, USA) was used with multiple 
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comparisons being assessed. Significance was considered if p ≤ 0.05. When written, the 
number of independent experiments is denoted by (N) while the number of replicates per 
independent experiment is defined by (n).  
4.4 Results 
4.4.1 The function of human PBMC is unaffected by the 
incorporation of 19F-PFC cell labeling agent 
In the previous chapter, we were able to establish the optimal cell concentration in culture 
and 19F-PFC concentration in culture such that human PBMC from healthy volunteers can 
be efficiently labeled with 19F-PFC without affecting viability and in vivo migration 
capacity. However, the effect of 19F-PFC on PBMC functionality and verification that in 
vivo signal is the result of originally injected 19F-PFC-labeled cells have yet to be 
elucidated. To address APC functionality, a MLR was conducted to compare the 
functionality between control and 19F-PFC-labeled APC. No significant differences in APC 
functionality were observed as a result of 19F-PFC labeling (Fig. 4-1A) with respect to 
stimulating allogeneic CD8+ (Fig. 4-1B) and CD4+ (Fig. 4-1C) T cell proliferation using 
CFSE dilution as a readout, regardless of the APC to T cell ratio. Next, the proliferative 
capacity of unlabeled and 19F-PFC-labeled T cells was compared using a T cell 
proliferation assay to assess function. Using anti-CD3 coated plates, no difference in T cell 
proliferation was measured for both CD8+ and CD4+ T cells (Fig. 4-1D) using CFSE 
dilution as a readout of proliferation (Fig. 4-1E/F).   
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Figure 4-1. APC and T cell functionality is not affected as a result of 19F-
PFC labeling.  
Figure 4-1. APC and T cell functionality is not affected as a result of 19F-PFC labeling. 
PBMC from healthy volunteers were either labeled with 19F-PFC overnight (5 mg/mL) or 
remained nlabeled and were th n subjected to CD3+ T c ll positive selection removal. 
Remaining l beled and unlabeled APC were then employed in a MLR (A) by co-culturing 
with allogeneic CFSE+ T cells obtained from 3 different healthy volunteers. Flow 
cytometry was used to assess CD3+ T cell proliferation using CFSE dilution as a readout 
for both CD8+ (B) and CD4+ T cells (C). Alternatively, CD3+ T cell functionality was 
assessed using CFSE dilution for 19F-PFC-labeled and unlabeled T cells as a result of CD3 
crosslinking (D) for both CD8+ (E) and CD4+ (F) T cells. Data shown as means ± SEM 
((A) two-way ANOVA, p > 0.05 and (D) one-way ANOVA, p > 0.05). 
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4.4.2 19F cellular MRI in vivo signal is the result of originally 
injected human PBMC 
Although detection and quantification of 19F signal has been measured in the popliteal 
lymph node, it cannot definitively be said that this observed signal is the result of originally 
injected intact, live 19F-PFC-labeled PBMC. Therefore, experiments were performed with 
human PBMC labeled with both 19F-PFC and CFSE prior to injection into nude mice to 
verify that in vivo 19F signal is the result of originally injected cells. Two days following 
injection of 3x106 human 19F-PFC-labeled PBMC into the footpad of nu/nu mice (N=3, 
n=4/experiment), 19F MRI detected 1.31 ± 0.2x105 cells (Fig. 4-2A, yellow arrow) in the 
draining popliteal lymph node. Following MR imaging, CFSE+ human 19F-PFC-labeled 
PBMC were detected in cryosections of the same popliteal lymph node (Fig. 4-2B, green 
arrows, counterstained with DAPI and pseudocoloured red).  In a similar experiment, two 
days after injection of 3x106 CFSE+ 19F-PFC-labeled PBMC, draining popliteal lymph 
nodes were removed, single cell suspensions prepared and subsequently counterstained 
with an antibody for human CD45. Flow cytometry identified CFSE+ human CD45+ cells 
(0.8778% ± 0.176%, N=3, n=4 per experiment) in the popliteal lymph node, with a 
representative figure being shown in Figure 4-2C. Therefore, cryosections of a lymph node 
after CFSE+ 19F-PFC-labeled PBMC and counterstaining with DAPI to detect nuclei 
demonstrates that originally-injected cells are producing the signal observed in vivo and 
furthermore, because CFSE+ cells in the lymph node were also human CD45+, this 
eliminates the possibility that originally-injected cells have died and been phagocytosed by 
resident lymph node phagocytes.  
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Figure 4-2. Human CFSE+CD45+ 19F-PFC-labeled PBMC are the 
source of 19F MRI signal in the popliteal lymph node.  
Figure 4-2. Human CFSE+CD45+ 19F-PFC-labeled PBMC are the source of 19F MRI signal 
in the popliteal lymph node. Two days after the injection of 3x106 human 19F-PFC-labeled 
PBMC into the footpad of nu/nu mice, mice were subjected to 19F MRI and positive 19F 
MRI signal detection of 1.31±0.2x105 cells (yellow arrow) resided within t e popliteal 
lymph node (N=3, n=4/experiment; scale bar=5 mm) (A). Following MRI, lymph nodes 
were removed, cryosectioned and fluorescent microscopy revealed the presence of CFSE+ 
19F-PFC-labeled human PBMC (representative of n=8 that did not undergo MRI). The 100X 
magnification sections were counterstained with DAPI to reveal nuclei (pseudocoloured 
red; scale bar =10 μm) (B). In a similar experiment, draining popliteal lymph nodes were 
removed two days after injection and single cell suspensions were prepared and 
counterstained with anti-human CD45 to reveal originally-injected cells in the draining 
popliteal lymph node using flow cytometry (C, representative of N=3, n=4 per experiment). 
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4.4.3 Human PBMC can be efficiently labeled with 19F-PFC cell 
labeling agent under GMP-compliant conditions without 
affecting viability 
Upon establishing that human PBMC from healthy volunteers can be labeled with 19F-PFC 
without affecting their viability, function or in vivo migration capacity, a protocol was 
developed whereby PBMC from prostate cancer patients would be obtained and labeled 
with 19F-PFC under GMP-compliant conditions at the UHN Cell Therapy Program Facility. 
During this processing as outlined in Figure 4-3, all quality control, safety and viability 
tests required by Health Canada for autologous re-injection into humans were conducted.  
While in the process of gaining approval from Health Canada to conduct a clinical trial in 
humans, human PBMC were processed under GMP-compliant conditions and instead of 
autologous injection back into the host, 19F-PFC-labeled PBMC injections into 
immunocompromised mice were imaged using 19F cellular MRI while other preliminary 
experiments were conducted to optimize a clinically-approved 19F MRI protocol in a 
human 3 T MRI.  
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Figure 4-3. Outline of events for GMP-compliant processing, safety testing and 
transport of 19F-PFC-labeled human PBMC. 
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As the nearest GMP-compliant cell therapy facility is located in Toronto and is 
approximately 2.5 hours away from Robarts Research Institute in London, the viability of 
cell product both before and after transportation was measured to confirm protocol 
suitability for approval of autologous cell injection into humans. 7-AAD staining for 
viability post-transport for the first two participant samples was less than 60%, revealing 
that the transportation conditions were sub-optimal and below the generally acceptable 
limit (70%) observed by Health Canada463. The incipient volume the GMP-processed cells 
were shipped in was increased to 15 mL in a tube filled with Plasma-Lyte A solution for 
participants 3-5 in this study. With this change in place, the viability of the last 3 participant 
post-transport samples for 19F-PFC-labeled and control PBMC was 88.75 ± 1.55% and 87.1 
± 4.57%, respectively (Fig. 4-4A). A small but non-significant decrease in viability was 
noted between pre- and post-transport between the cell manufacturing facility and Robarts 
Research Institute. Also, with respect to the viability of both pre-transport or post-transport 
time points, the viability between control and 19F-PFC-labeled PBMC is not statistically 
different, suggesting that when appropriate transport protocols and 19F-PFC labeling 
protocols are adhered to, the viability of PBMC cell products is suitable for autologous 
injection into humans (Fig. 4-4A).  
We next sought to qualitatively assess 19F-PFC labeling by mimicking GMP-compliant 
labeling and retention of this label during transportation as outlined in Figure 4-3. Using 
the red fluorescent version of 19F-PFC, an aliquot of PBMC was labeled overnight (~20 
hours). The shift in mean fluorescence intensity of the fluorescently-tagged 19F-PFC 
indicates that 99.8% of viable singlet PBMC were labeled and thus, all cell lineages 
contained within PBMC were labeled. In a separate set of experiments (N=3 different 
PBMC donors), labeling was conducted as described above but after overnight labeling 
with the fluorescent version of 19F-PFC, half of the cells were assessed immediately for 
fluorescent label incorporation, while the other half was left at room temperature to 
simulate the combined 2.5 hour transport time and post-arrival processing time. Flow 
cytometry revealed that 98.1 ± 1.2% of PBMC were labeled with red fluorescent 19F-PFC 
overnight (Fig. 4-4B) and that the percentage of labeled cells remains unchanged (98.3 ± 
0.76%) approximately 3 hours later (Fig. 4-4C). There was no significant difference 
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(p=0.43) in the median fluorescence intensity between pre- and post-transport samples for 
the 3 donors. A quantitative assessment to determine the average number of 19F atoms per 
cell was conducted for each participant using NMR spectroscopy (Fig. 4-4D). For all 5 
participants in this study, 19F loading values ranged from 5.14x1010 to 1.16x1011 19F atoms 
per cell. For the last three participants whose viability was greater than 87%, an average 
loading of 7.55x1010 19F atoms per cell was calculated.  
In addition to measuring the viability of all cell products both before and after transport 
using 7-AAD, a LIVE/DEAD™ vital dye can also be employed. Here, an aliquot of 
participant peripheral blood on day 0 of culture (Fig. 4-5A), PBMC on day 0 of culture 
(Fig. 4-5B) and then unlabeled and 19F-PFC-labeled PBMC post GMP-compliant 
processing (Fig. 4-5C) was first gated to identify CD45+ cells, followed by gating on live 
cells using the FMO control for LIVE/DEAD™ vital dye. Figure 4-5 is a representative 
image from one participant; however, a similar analysis was conducted for all participant 
samples.  
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Figure 4-4. Human PBMC labeled efficiently with 19F-PFC 
under GMP-compliant conditions and transported without 
significant loss of viability.  
Figure 4-4. Human PBMC labeled efficiently with 19F-PFC under GMP-compliant 
conditions and transported without significant loss of viability. Following overnight 
culturing of PBMC with and without the 19F-PFC cell-labeling agent (5 mg/mL) under 
GMP-compliant conditions, 19F-PFC-labeled and unlabeled PBMC were transported back 
to London, Canada. The viability of 19F-PFC-labeled PBMC and unlabeled PBMC was 
determined using 7-AAD staining before and after transport. There was no significant 
decrease in viability because of transport (approximately 2.5 hours or 250 km distance) as 
well as no significant difference in viability between 19F-PFC-labeled and unlabeled cells 
with data shown as means ± SEM (two-way ANOVA, p > 0.05) (A). PBMC were labeled 
overnight with the red fluorescent version of the 19F-PFC cell labeling agent. A flow 
cytometry analysis was performed on half of the cell suspension and it was determined that 
99.8% of PBMC were positively labeled with the red fluorescent version of the 19F-PFC 
agent compared to unlabeled PBMC from the same donor (blue histogram) (B). The second 
of half of the labeled PBMC were left for 3 hours to simulate the transportation process 
back to London, Canada. Flow cytometry revealed that 99% of the PBMC retained the red 
fluorescent 19F-PFC compared to unlabeled PBMC from the same donor (blue histogram) 
(C). In order to quantify in vivo cell migration, a quantitative assessment of 19F-PFC 
incorporation must also be ascertained using NMR spectroscopy on a known number of 
PBMC. For the last three participants, an average of 7.55x1010 19F spins were incorporated 
per cell (denoted by the white circles) and are the participants for which MR image data is 
provided (D). 
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Figure 4-5. Viability and CD45+ purity assessment of human peripheral 
blood and PBMC cell products using flow cytometry.  
 
Figure 4-5. Viability and CD45+ purity assessment of human peripheral blood and PBMC 
cell products using flow cytometry. An aliquot of peripheral blood is phenotyped to 
calculate the percentage of cells that are CD45+ on day 0 of culture (top left panel) and the 
FMO control for LIVE/DEAD™ aqua vital dye (top middle panel) was used to determine 
the viability of CD45+ cells (top right panel) (A). The same analysis for CD45+ and 
viability percentage was performed on day 0 after peripheral blood was subject to gradient 
centrifugation to enrich PBMC (B). Both day 1 control PBMC and 19F-PFC-labeled 
PBMC cultured under GMP-compliant conditions were also assessed for percentage of 
CD45+ cells and percentage viability (C). Representative flow cytometry gating is 
displayed for one participant sample; however, all 5 participant cell products were subject 
to a CD45+ and viability percentage flow cytometry analysis. 
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4.4.4 GMP-compliant processing of control and 19F-PFC-labeled 
PBMC meet all requirements outlined by Health Canada to 
permit autologous injection into humans upon clinical trial 
approval 
After ensuring that human PBMC can be labeled with 19F-PFC under GMP-compliant 
conditions without affecting viability, quality control and safety testing required for 
investigational, autologous use of PBMC in humans was evaluated. For all 5 participant 
samples, assessments were conducted for safety through rapid Gram staining, culture-
expanded sterility and mycoplasma testing. The purity and identity were also measured to 
ensure that the cell product for each participant contains greater than 80% CD45+ cells 
while confirming that impurities were not contained in any cell product as assessed via the 
absence of endotoxin. This data is summarized for each participant in Table 4-1.  
 
Table 4-1. Cell products from each participant passed all requirements outlined by Health 
Canada to allow for injection into humans upon clinical trial approval. 
 Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
Unlabeled 19F-PFC 
Labeled 
Unlabeled 19F-PFC 
Labeled 
Unlabeled 19F-PFC 
Labeled 
Unlabeled 19F-PFC 
Labeled 
Unlabeled 19F-PFC 
Labeled 
Stat Gram 
Stain 
Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
Endotoxin Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
CD45+ 
Percentage 
99.3% 99.7% 84.4% 92.5% 78.9% 96.0% 94.7% 97.1% 98.4% 98.2% 
14-day 
Sterility 
Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
Mycoplasma Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
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4.4.5 19F-PFC labeling does not alter the PBMC cell lineage 
composition 
Each cell lineage found in PBMC serves a different immunological purpose within a 
heterogeneous cell-based cancer vaccine. Therefore, the cell lineage composition and 
phenotype of individual participants’ PBMC preparations were characterized. Both whole 
blood and PBMC were examined to not only compare 19F-PFC-labeled and unlabeled 
PBMC populations, but also to verify that 19F-PFC labeling did not significantly alter cell 
lineage composition when comparing peripheral blood drawn on day 0 to PBMC after 
GMP-compliant processing. Single, live CD45+ unlabeled or 19F-PFC-labeled PBMC (Fig. 
4-6A-C) were analyzed. After debris removal (Fig. 4-6D), B and T cell lymphocytes were 
grouped together using antibodies to CD3, CD19 and CD20 that are all conjugated to the 
same fluorophore, while myeloid cells were gated on using CD11b+ selection (Fig. 4-6E). 
Myeloid cells were further analyzed using CD14 and CD16 surface expression (Fig. 4-6F) 
as well as CD11c+ surface expression (data not shown). NK cells were then analyzed using 
CD56 on cells negative for CD3/CD19/CD20 and CD11b (Fig. 4-6G).  The summary of 
cell lineage phenotyping for the last 3 participants after cell transportation optimization is 
presented in Table 4-2. The lymphoid cell lineage and the CD11b+CD16+ lineage of 
monocytes, although different between participants, appears to be similar for both labeled 
and unlabeled conditions within the same participant. However, within the myeloid lineage 
there was a decrease in the percentage of CD11b+CD14+ cell recovery post-labeling.  
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Figure 4-6. Phenotyping of GMP-compliant processed 19F-PFC-
labeled and unlabeled control human cell products.  
 
Figure 4-6. Phenotyping of GMP-compliant processed 19F-PFC-labeled and unlabeled 
control human cell products. Blood or isolated PBMC were analyzed for cell lineage 
composition using the gating strategy outlined. Briefly, hematopoietic cells were selected 
for using CD45+ (A), followed by gating on live (B), singlet cells (C). After debris removal 
(D), remaining cells were gated on CD11b for myeloid cells or CD3/CD19/CD20 for 
lymphoid cells (E). For CD11b+ and CD3/CD19/CD20- cells, further gating for CD16 and 
CD14 to analyze monocytes was conducted (F). For cells that are CD11b- and 
CD3/CD19/CD20-, gating for CD56 to identify NK cells was performed (G). Lastly, cells 
that are CD11b+ but CD14/CD16- were gated on CD11c to identify dendritic cells (data 
not shown). All cell surface marker gates were assigned based on their respective FMO 
controls. 
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Table 4-2. PBMC cell lineage comparison between 19F-PFC-labeled (L) and unlabeled 
control (UL) PBMC. 
 
 
 
Participant 
Sample 
Identifier 
Surface Antigen (percentage of live, singlet, CD45+ cells) 
CD45+ CD45+, 
CD11b-,  
CD3+,  
CD19+,  
CD20+  
 
CD45+, 
CD11b+,  
CD3-,  
CD19-,  
CD20-,  
 
CD45+, 
CD11b+,  
CD3-,  
CD19-,  
CD20-,  
CD16+ 
CD45+, 
CD11b+,  
CD3-,  
CD19-,  
CD20-,  
CD14+ 
 
CD45+, 
CD11b+,  
CD3-, CD19-
, CD20-,  
CD14-,  
CD16-, 
CD11c+ 
CD45+, 
CD11b-,  
CD3-, CD19-, 
CD20-,  
CD14-,  
CD16-,  
CD56+ 
UL L UL L UL L UL L UL L UL L UL L 
Participant 3 78.9 96.0 79.2 83.7 15.6 6.90 10.7 3.95 3.12 0.36 1.52 2.60 0.625 1.89 
Participant 4 90.5 95.0 83.8 87.7 13.6 8.96 0.22 0.42 9.12 0.53 ND ND 0.0002 0.08 
Participant 5 89.6 93.2 77.2 67.4 19.2 21.9 12.9 17.4 3.56 0.42 7.80 4.52 0.003 7.87 
Note: We reported the CD45+, CD11b+, CD3-, CD19-, CD20-, CD14-, CD16-, CD11c+ 
cell population percentage is displayed as a percentage positive from previous gate. ND 
not determined.  
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4.4.6 19F-PFC-labeled human PBMC can be detected using 19F 
cellular MRI in an immunocompromised mouse model  
The number of 19F atoms determined for each participant’s 19F-PFC-labeled PBMC 
preparation was generally lower (Fig. 4-4D) than reported for other cell types (1010-1011 vs 
1012)310, 387. To determine if the 19F-PFC-labeled PBMC preparations were detectable in 
vivo by cellular MRI, 19F-PFC-labeled PBMC from participants 3-5 were injected 
subcutaneously into the flanks of nude mice to mimic the location of autologous adoptive 
cell transfer pending clinical trial approval. 19F-PFC-labeled PBMC were formulated into 
low and high cell number injection preparations, in which cell numbers varied based on 
individual participant yield. This information and quantitative 19F MRI results are 
summarized in Table 4-3. MR images were obtained at ~2 hours and 2 days post injection. 
As expected, no 19F signal was detected at the unlabeled PBMC contralateral flank 
injection sites or in the draining lymph nodes. For the two mice injected with 1x106 and 
6x106 19F-PFC-labeled PBMC from participant 4 (healthy volunteer), MR imaging 
detected 6 ± 0.3x105 and 5.21 ± 0.2x106 19F-PFC-labeled cells at the injection sites on day 
0, with the 5.21 ± 0.2x106 injection being illustrated in Figure 4-7A, blue arrow). Also, in 
this mouse on day 0, 2 ± 0.3x105 cells were detected in the draining popliteal lymph node 
approximately 2 hours after subcutaneous injection (Fig. 4-7B, yellow arrow). On day 2, 
the number of detectable cells at both the injection site and draining popliteal lymph node 
decreased, with 4.11 ± 0.2x106 cells detected at the injection site (Fig. 4-7C, blue arrow) 
and the number of cells remaining in the popliteal lymph node fell below the detection 
threshold of 19F cellular MRI (Fig. 4-7D, lymph node identified by yellow arrow). For mice 
injected with 19F-PFC-labeled PBMC from participants 3 and 5 (both prostate cancer 
patients) 19F signal was detected only after the high cell dose injection on day 0 and day 2 
but not in any of the draining lymph nodes. Following high dose injection of 5.7 ± 0.1x106 
labeled PBMC from participant 3, 1.13 ± 0.3x106 and 7.5 ± 0.3x105 PBMC were detected 
at day 0 and day 2, respectively. With respect to participant 5, the high dose injection of 
4x106 labeled PBMC permitted the detection of 1.11 ± 0.2x106 PBMC at the injection site 
on day 0 and 5.9 ± 1.6x104 PBMC on day 2. The latter was the lowest cell number detected.  
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Table 4-3. 19F-PFC-labeled PBMC detection by 19F cellular MRI following subcutaneous 
injection into immunocompromised mice. 
 Participant 3 Participant 4 Participant 5 
Injection Cell 
Number  
Subcutaneous 
Flank 
 
1x106 
 
5.7x106 
 
1x106 
 
6x106 
 
1x106 
 
4x106 
Day 0 
Detection 
 
Injection Sitea 
No Yes 
 
(1.13x106) 
Yes 
 
(6x105) 
Yesb 
 
(5.21x106) 
No Yes 
 
(1.11x106) 
Day 2 
Detection 
 
Injection Site 
No Yes 
 
(7.5x105) 
Yes 
 
(2.0x105) 
Yes 
 
(4.11x106) 
No Yes 
 
(5.9x104) 
Note: aDay 0 scan completed ~2h post injection 
bDay 0 scan also detected 2x105 cells in the popliteal lymph node 
 
 
 
 
 
 
 
 
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. MRI detection of 19F-PFC-labeled human PBMC after 
subcutaneous flank administration in an immunocompromised 
murine model.  
Figure 4-7. MRI detection of 19F-PFC-labeled human PBMC after subcutaneous flank 
administration in an immunocompromised murine model. The overlay produced from 19F 
and 1H MR images following subcutaneous flank injection of 6x106 19F-PFC-labeled 
PBMC from participant 4 on day 0 permitted the detection of a 19F signal in both the 
flank (blue arrow, A) and at the popliteal lymph node (yellow arrow, B). Forty-eight 
hours after subcutaneous administration, the 19F signal was decreased but visible in the 
flank (C), but not detectable in the lymph node (D). The reference tube required to 
quantify the number of PBMC is marked with R in panel C. Scale bar = 5 mm. 
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4.4.7 MR imaging of 19F-PFC-labeled PBMC under clinical 
conditions at 3 T 
In an attempt to translate pre-clinical 19F cellular MRI at 9.4 T to a clinically-approved 
protocol at 3 T, PBMC were isolated from the blood of a healthy volunteer and labeled 
overnight with 19F-PFC. The next day, 1x106, 5x106 and 10x106 19F-PFC-labeled PBMC 
were pelleted in an Eppendorf tube and overlaid with 1% agarose to create 19F phantoms 
(Fig. 4-8A). To mimic MR scanning of a patient, these cell pellets were placed on the 
surface of the thigh of a volunteer and then scanned to optimize 19F imaging parameters at 
3 T. Under optimal labeling conditions with 4.2x1011 19F atoms per cell, as few as 1x106 
PBMC could be detected (Fig. 4-8B).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. Human 19F-PFC-labeled PBMC pellet phantoms as low 
as 1x106 cells can be detected at 3 T using a surface coil and clinical 
MR imaging protocols.  
Figure 4-8. Human 19F-PFC-labeled PBMC pellet phantoms as low as 1x106 cells can be 
detected at 3 T using a surface coil and clinical MR parameters. PBMC were obtained from 
a healthy volunteer and labeled with 19F cell labeling agent overnight (5.0 mg/mL). Cell 
phantoms were created by centrifuging 1x106, 5x106 and 10x106 19F-PFC-labeled PBMC 
and overlaying with 1% agarose in an Eppendorf tube (A). PBMC phantoms were scanned 
at 3 T using a clinically-approved surface coil and all 3 phantoms described in (A) were 
detected using 19F cellular MRI (B), with a hot-iron colour scale used to display 19F MRI 
signal. Point spread function artifact is visible from the largest cell phantom (10x106 
PBMC). 
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Further imaging optimization experiments were conducted on three volunteers to detect 
human inguinal lymph nodes, which appear as dark spheres within the bright fat pad in the 
upper thigh. A representative image (Fig. 4-9a/b) reveals that multiple inguinal lymph 
nodes can be detected with an average volume of 390 ± 290 mm3 and at an average depth 
of 1.5 ± 0.3 cm below the skin. These MR images were used to localize the target imaging 
area, after which a 1H/19F dual-tuned surface coil (Fig. 4-9c) would be placed in the centre 
of this area to detect in vivo 19F signal. As a proof on concept, 19F-PFC-labeled human 
PBMC were injected into a ham shank (of comparable size to an average human thigh). 
The 1H/19F dual-tuned surface coil was then placed on the surface of the ham shank above 
the target location (Fig. 4-9d). The 19F-PFC-labeled human PBMC (1.2x1011 19F atoms per 
cell) were administered intradermally in 3 doses: 1.5, 4.5 and 20x106. The two higher 
injection doses were detectable and quantifiable (Fig. 4-9e/f, yellow arrows) but not the 
lowest dose (1.5x106 cells). The subcutaneous injection of 4.5x106 19F-PFC-labeled PBMC 
that was administered 1.2 cm below the intradermal dose was also visible (Fig. 4-9f). 
Quantification of the number of cells indicated 4.11x106 cells at the site of the 4.5x106 
intradermal injection, 17.6x106 cells at the site of the 20x106 cell intradermal injection and 
3.76x106 cells at the site of the 4.5x106 subcutaneous injection (Fig. 4-9f, blue arrow). 
Human 1H images (n=2) of the inguinal lymph node area using the 1H/19F dual-tuned coil 
showed the location of a lymph node in the target area to be similar to that observed in the 
ham shank. A representative 1H human image shows a lymph node 0.71 cm below the 
surface (Fig. 4-9g).     
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Figure 4-9. Clinical 3 T MRI detection and quantification of 19F-PFC-
labeled human PBMC.  
Figure 4-9. Clinical 3 T MRI detection and quantification of 19F-PFC-labeled human 
PBMC. A T1-weighted, coronal orientation MR image obtained using a body coil reveals 
human inguinal lymph nodes as dark spheres (blue arrows) within the fat of the upper 
thigh (a). Th  red dashed line indicates the location of the axial MRI slice that identifies 
the depth of an inguinal lymph node to be approximately 1.5 cm below the skin (b, red 
scale bar). PBMC were obtained from a healthy volunteer and labeled overnight with the 
19F-PFC cell labeling agent before injection into a ham shank. Imaging was performed by 
placing the 1H/19F switchable RF (c) coil on the ham shank as shown in (d). 19F-PFC-
labeled PBMC were administered intradermally with the MR image shown for a 20x106 
injection (e, yellow arrow). 4.5x106 19F-PFC-labeled PBMC were injected both 
intradermally (f, yellow arrow) and subcutaneously (f, blue arrow). Both injections were 
detected and quantified, with the subcutaneous injection visible at a depth of 1.2 cm as 
measured from the MR image.  A representative human 1H image taken with the same 
parameters closely resembles the ham shank images with respect to tissue appearance, 
subcutaneous fat deposition and depth of inguinal lymph nodes (g). 
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4.5 Discussion 
4.5.1 19F-PFC labeling and label retention in human PBMC 
The aim of this investigation was to develop a clinical protocol to label therapeutic cells of 
a non-homogeneous nature, such as PBMC238, with a 19F-PFC cell labeling agent approved 
for use in humans. Other cell labeling and contrast agents were widely used in the past, 
such as iron-based labeling agents to track therapeutic cells in pre-clinical and clinical 
models196, 203. However, in contrast to 19F cellular MRI that employs a perfluorocarbon 
formulation, such iron-based labeling agents have not been reported to label all human 
leukocyte subsets, are difficult to quantify, and do not always provide unambiguous in vivo 
detection of labeled cells203. Previous work revealed that the quantity of APC that migrated 
to a lymph node following injection is directly proportional to the magnitude of the ensuing 
immune response199. By using 19F-PFC cell labeling agents, the quantitative distribution of 
a PBMC-based immunotherapeutic APC cancer vaccine to secondary lymphoid organs, 
such as a lymph node, may provide valuable biomarker information that is predictive of 
treatment efficacy. The labeling of a homogeneous cell population, such as DC that are 
naturally endocytic, with 19F-PFC-based cell labeling agents at levels that support in vivo 
detection by cellular MRI is easily achieved274, 291. In comparison, labeling non-
homogeneous populations of cells, such as PBMC, presents difficulties as each cell type 
has varying endocytic/phagocytic activity and inherent differences in cell volumes that 
limit 19F-PFC label uptake capacity.  
The cell density, 19F-PFC concentration and labeling time to achieve optimal 19F-PFC 
labeling of PBMC were based in part on previously published reports, advice from the 
manufacturer of the 19F-PFC cell labeling agent, as well as our own dose response 
experiments presented previously in Chapter 377, 261, 310, 314. Logistics planning in 
preliminary stages took into consideration that GMP-processed 19F-PFC-labeled PBMC 
needed to be shipped back from the manufacturing site to ensure that autologous infusion 
of PBMC product and subsequent 19F/1H MRI scan takes place at a reasonably convenient 
time of day. After accounting for this, our data demonstrate that the main leukocyte subsets, 
including those known to function as APC, are labelled with a 19F-PFC cell labeling agent 
under GMP-compliant conditions to a high percentage using cell culture conditions that we 
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have previously defined. Using a red fluorescent version of a 19F-PFC labeling agent and 
flow cytometry, 99% of PBMC were found to be labeled after the overnight labeling 
period. We also determined that 99% of the labeled PBMC retained 19F-PFC label over the 
approximate three hour period required to ship the labeled PBMC from the UHN 
manufacturing site (Toronto, ON) to Robarts Research Institute in London, ON and process 
them for flow cytometric analysis. The average MFI of samples from three donors was not 
different pre- and post-transport; however, one donor did exhibit a decrease in MFI. The 
reason for the apparent decrease in MFI is unclear as the manufacturer claims the 19F-PFC 
is stably retained in viable cells. As leukocytes are known to produce exosomes464, 465, 466 
it is possible that over time a portion of the 19F-PFC is lost in released exosomes. Additional 
experiments are required to resolve this issue and are considered outside the context of this 
thesis.  
4.5.2 Variability of 19F-PFC labeling of heterogeneous human 
PBMC 
As is important for all cell labeling agents, 19F-PFC incorporation occurred without 
affecting the functionality of the blood-derived APC or T cells within the PBMC mixture 
as assessed by a MLR and T cell proliferation assay. Although the PBMC labeling 
percentage was near 100% for each participant, some heterogeneity in the average amount 
of label incorporation was observed. This heterogeneity is attributable to the different cell 
lineages within PBMC. For example, smaller cells such as T cells and B cells with a small 
cytoplasmic volume have been shown to label with 19F-PFC labeling agents on the low end 
of 1012 19F spins per cell307. Larger leukocytes, such as monocytes and DC, label on the 
high end of 1012 to the lower end of 1013 19F spins per cell291, 299 (and unpublished data). 
Furthermore, the 19F-PFC labeling agent incorporates into multilamellar 
macropinosomes303, 307, so cells like DC and monocytes that are highly endocytic or 
phagocytic in nature accumulate more 19F-PFC label in culture. However, the 
aforementioned results were obtained in studies using homogeneous cell populations77, 283, 
299, 314, 388, 422 and thus, did not consider the effect of labeling of individual cell populations 
within a heterogeneous cell population. This likely explains why loading in these studies 
is higher than what is observed with our PBMC labeling method, as other preliminary 
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studies in our lab have shown increased labeling of each cell lineage (B cells, T cells, 
monocytes) following negative selection and culturing each separately as mono-cultures 
(unpublished data). The only other reported study on 19F-PFC labeling a heterogeneous 
hematopoietic mixture of cells was performed on murine splenocyte cell suspension and 
reported 3.70 ± 0.21% labeling of CD3+ T cells261. This is in stark contrast to labeling 
observed in a homogeneous T cell culture, in which 90% of CD3+ T cells incorporated 19F-
PFC422.   
Variability within the number of average 19F spins per cell was also observed between 
participants in this study, ranging from 5.14 × 1010 to 1.16 × 1011 19F spins per cell. A 
potential explanation for this is the differences that exist in relative cell lineage proportions 
between participant PBMC samples, which have been shown to be highly variable238. For 
example, a patient with a higher percentage of B and T cells and a lower percentage of 
monocytes would have a lower average loading than a patient with a higher percentage of 
monocytes in their PBMC. The age and/or health status of the donor may also be a factor 
as intracellular loading was highest within a younger, healthy control (Participant 4) 
compared to older (60–90 years of age) prostate cancer patients (Participants 1, 2, 3 and 
5). Considering the small number of participants in this study, a more extensive study is 
needed to verify this observation. 
4.5.3 GMP-compliant human PBMC processing 
After establishing protocols for labeling PBMC with 19F-PFC, it was necessary to consider 
the inter-city logistics in the design of a GMP-compliant processing protocol (Figure 4-3). 
This protocol involves drawing blood from patients in one location (London Regional 
Cancer Program, London, ON), transporting it to a GMP-compliant cell manufacturing 
facility (UHN, Toronto, ON) 2.5 hours (250 km) away and then returning the cell product 
back to Robarts Research Institute (London, ON) the next day. Furthermore, this study was 
designed to ensure GMP-compliant cell processing satisfies all requirements outlined by 
Health Canada for autologous injection back into humans463. All tests results passed Health 
Canada’s requirements, except for the PBMC viability of Participants 1 and 2. In the case 
of Participants 1 and 2, shipment of PBMC samples back to Robarts Research Institute post 
labeling were sent in small pre-determined volumes in individual vials intended to be used 
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directly for injection or for further safety testing. Thus, 19F-PFC-labeled PBMC recovery, 
in particular, was low and the viability fell below requirements for injection into humans. 
Cell loss greater than 35% during GMP culturing is an important concept as it is associated 
with significant increases in production cost467. While Participant 2 (prostate cancer 
patient) had a low lymphocyte count (predominant cell type in PBMC) and a low yield, the 
yield did not seem to be necessarily dependent on lower immune cell counts as Participant 
3 (prostate cancer patient) had a good yield but a low immune cell count. We rectified the 
yield problem by subsequently shipping all the PBMC in one 15 mL polypropylene Falcon 
tube fully filled with Plasma-Lyte A solution. This change alone greatly increased the 
viability of post-transport samples to levels deemed acceptable by Health Canada.  
PBMC viability was also not significantly affected by 19F-PFC labeling when compared to 
unlabeled PBMC and was unaffected by shipment time, distance traveled and the external 
temperature. The viability following 19F-PFC labeling in the current study is similar to 
what has been reported in other studies using DC and T cells77, 308. This is an important 
finding with respect to cell labeling agents and cell-based cancer vaccines as their purpose 
is to permit in vivo detection of cell migration without affecting viability and/or phenotype 
that could alter the immunogenic potential of the vaccine457, 468. FicollÒ-Paque density 
centrifugation has been used to pellet dead cells and debris from cell suspension such that 
the cell product meets or exceeds a pre-determined viability percentage required for 
injection388, 469; however, this additional step was not required in this investigation as the 
viability percentages reported for Participants 3-5 cell products exceeded the pre-
determined viability cut-off.  
With heterogeneous cell-based vaccines, each cell lineage within the PBMC mixture serves 
a different immunological purpose154, 470, 471, 472. Therefore, it was of interest to determine 
whether 19F-PFC labeling of PBMC affected any cell lineage within the PBMC 
formulation. Our flow cytometry analysis revealed that, although differences in 
percentages of lymphocytes and CD11b+CD16+ monocytes occurred between participants, 
the percentages between labeled and unlabeled PBMC for each participant was similar. A 
decrease in the CD11b+CD14+ monocyte population post labeling was noted in the current 
study. We have observed that 19F-PFC labeling tends to increase the propensity of 
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monocytes to adhere to plastic even when highly hydrophobic, non-adherent plastic was 
used, thereby resulting in a reduction of this cell type in the final cell suspension and not 
necessarily indicating CD11b+CD14+ cell death as a result of labeling. Alternatively, CD14 
receptor internalization may have resulted from uptake of the 19F-PFC nanoparticle 
emulsion, as has been suggested for CD36 on murine dendritic cells following iron oxide-
based labeling agent phagocytosis and CD14-mediated macropinocytosis339, 473. This could 
account for a transient decrease in CD14 on the cell surface of these monocytes. CD56+ 
NK cells exhibited differences between labeled and unlabeled populations in each of the 3 
participants PBMC assessed. The reason behind the decrease in the unlabeled population 
is not clear but may have to do with the lack of proper cytokine support needed for 
maintaining cultured NK cells474, 475, 476 as well as low CD56+ cell counts considering the 
extensive flow cytometry gating performed prior to gating for CD56 expression. Although 
broad cell lineage composition was assessed in this study, a detailed phenotypic assessment 
of individual leukocyte subsets was not assessed. 
4.5.4 Pre-clinical 19F cellular MRI 
Pre-clinical in vivo imaging studies in mice were conducted to determine the sensitivity of 
detection for 19F-PFC labeled PBMC and development of protocols in pre-clinical models 
prior to application in human studies. In a future clinical trial, autologous PBMC injection 
into patients is expected to follow the same processing and set-up protocols as the in vivo 
mouse imaging studies presented here. In all sites receiving 19F-PFC-labeled PBMC high 
dose injections and for one low injection (Participant 4), 19F-PFC labeled cells were 
detected on day 0. These are cells that have either not migrated in the 2 hour time frame 
following injection or could also represent a dead cell population as a result of shearing 
during expulsion through the 28G1/2 syringe needle. This will be of less relevance in 
corresponding human PBMC injections as the needle gauge will be increased and cells can 
be injected in a greater volume of excipient solution. Quantification at the site of injection 
2 days later was always possible if day 0 detection was present, albeit at a lower cell 
number. This can be attributed to two factors; cells migrating away from an area of 
quantified signal to a distal site and also to dying/dead cells releasing the 19F-PFC which 
will rapidly dissipate or be phagocytosed by murine macrophages261 and cleared from the 
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area of signal quantification. Only live cells retain the 19F-PFC387. In addition, migration 
from the flank injection site to a draining popliteal lymph node (quantified to be 2 × 105 
cells) was observed in one animal. This suggests that, although a small drop in viability 
occurs as a result of labeling and transport, 19F-PFC-labeled PBMC were still able to 
migrate to biologically-relevant sites after injection. This is the first demonstration of in 
vivo migration detected by 19F cellular MRI of 19F-PFC-labeled cells cultured under GMP 
conditions. This strengthens the case that 19F-PFC labeling in Biosafety Containment Level 
2-approved laboratory under pre-clinical conditions, as evidenced in Chapter 2, and 
labeling under clinical GMP-compliant conditions can be conducted and still render human 
PBMC migration competent in vivo. Also, migration to the lymph nodes likely occurred in 
additional cases, but in insufficient numbers to reach the threshold needed for 19F cellular 
MRI detection. Knowledge regarding in vivo migration after injection is important to note 
as lymphatic transport differs depending on the site of administration477, 478. Furthermore, 
differences in cell lineage proportions, such as DC subsets, exist not only between the 
spleen and lymph nodes but also between lymph nodes in different locations, such as the 
axillary, mesenteric, inguinal and popliteal lymph nodes200, 479, 480. This highlights the need 
to track therapeutic cells in vivo as it is predictive of the magnitude of an immune response 
as well as the type of immune response, which could depend on cell subset proportions 
present in the secondary lymphoid organ where 19F-PFC-labeled therapeutic cells were 
detected.  
We did not activate the PBMC in any way to stimulate migration to and, in particular, 
retention in secondary lymphoid tissues as has been done for the PBMC-based 
immunotherapy, ProvengeÒ, using granulocyte-macrophage colony stimulating factor246, 
481. This lack of activation due to the absence of GM-CSF in culture may also have resulted 
in a reduced number of detectable PBMC in any given draining lymph node. Furthermore, 
the injections were performed subcutaneously in the flank area, which can drain to multiple 
lymph nodes such as the popliteal and inguinal lymph nodes. This is in contrast to what we 
presented in vivo for human DC123 and as shown in Chapter 3 for PBMC, in which 
migration from footpad to popliteal lymph was observed as it is the only lymph node that 
drains immediately from the footpad. However, no migration to other more distant 
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secondary lymphoid tissues was detected by cellular MRI. This may be a limitation of 
the mouse model in which the number of leukocytes injected is much lower than what can 
be done in humans481, 482. Regardless, detection and quantification of cell migration 
observed following a low-dose injection in mice is a positive result when considering 
clinical translation.  
4.5.5 Clinical 19F cellular MRI optimization and detection 
The translational potential of 19F-cellular MRI was investigated with a clinical GE MR750 
3 T MRI scanner. Preliminary experiments were performed on 19F-PFC-labeled human 
PBMC cell pellets of known number, with imaging experiments progressing towards the 
use of a fresh ham shank as a mock human leg due to strong tissue similarities. The largest 
factor governing successful detection of PBMC was the number of 19F spins/cell. Mean 
intracellular loading of PBMC ranged from 1010–1011 between participants, representing 
an order of magnitude difference in cell detection threshold (107 vs 106 PBMC, 
respectively). While in the developmental stages of clinical 19F MRI, it may be necessary 
to pre-screen patients based on intracellular 19F-PFC loading. In comparison to other 
clinical 19F MRI studies, PBMC were observed to label on average one order of magnitude 
lower than dendritic cells (3.9 × 1012 19F spins/cell)310 and stromal vascular fraction cells 
(SVF) (2.8 ± 2 × 1012 19F spins/cell)387. This translates into a proportional decrease in signal. 
Yet, despite this inherent drawback, the minimum number of detectable cells in the current 
study was comparable to previous studies (DC: ~5 × 106, SVF: 2 × 106, PBMC: 4.5 × 106)77, 
387. The clinical protocol and hardware used when imaging the ham shank represents a 10 
times improvement in sensitivity compared to previously reported studies. This 
improvement is largely due to the small size and high sensitivity of the surface coil used, 
as well as the higher number of imaging averages employed compared to similar studies77, 
387. To provide higher detection sensitivity, we chose a MRI radiofrequency surface coil, 
but at the cost of limiting the imaging field of view compared to a volume coil. However, 
due to the superficial location of the proposed injection sites and shallow depth of the target 
lymph nodes, imaging at depths greater than 1.5 cm is currently not necessary. 
Improvements in acquisition with different MRI sequences, such as ultrashort echo time 
(UTE); advanced array coil configurations; post processing techniques, such as 
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compressed sensing; and novel 19F labeling agents141 will be required to increase sensitivity 
further than what we report here. 
4.5.6 Conclusions 
In this study, we present the highest sensitivity for 19F detection reported thus far in the 
literature using a clinical scanner and clinical protocol. Moreover, we demonstrate it is 
possible to quantify the signal of 19F-PFC-labeled PBMC at a depth of 1.2 cm using a 
clinical protocol and 19F MRI scanner hardware, as the only other study has detected signal 
of surface-injected cells77. This type of imaging is valuable when considering that it can be 
used as a non-invasive technique to track their anatomical location, their persistence and 
potentially lead to improvements in APC-based cancer vaccine efficacy. This imaging 
technique can potentially be applied to other types of cell-based cancer therapies, such as 
CAR T or NK cell immunotherapies. Furthermore, the in vivo cell tracking of 
immunosuppressive regulatory T cell-based therapies to their intended target locations for 
the treatment of autoimmune disease and organ transplantation is an unmet need required 
to verify the mechanism behind such immunosuppressive therapies483, 484. 
Immunomodulatory mesenchymal stem cell therapy trials also have a similar 
requirement387. Regulatory agencies are considering whether to require cell tracking to 
establish the anatomical fate(s) and persistence of the therapeutic cells as part of the process 
of establishing treatment efficacy. Thus, it is imperative to have a firm understanding of 
the advantages and disadvantages of different cell labeling agents such 19F-PFC 
formulations. 
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Chapter 5  
5 Thesis Discussion 
5.1 Data Summary 
In Chapter 2 and Appendix I, murine BMDC and human moDC were chosen as a 
professional APC therapeutic cell platform to determine if 19F cellular MRI is a suitable, 
non-invasive, longitudinal imaging technique sensitive enough to permit correlating 
quantification of 19F-PFC-labeled DC migration to the lymph node with the strength of the 
ensuing immune response. Greater than 95% of murine BMDC and human moDC labeled 
with 19F-PFC at a level capable of detecting and quantifying 19F-PFC labeled DC migration 
in vivo without affecting viability, phenotype and function. Moreover, 19F-PFC labeling of 
moDC did not affect phenotype or cytokine secretion profiles when compared to unlabeled 
moDC cultured under the same maturation cytokine cocktail conditions. 19F-PFC-labeling 
of murine BMDC did not alter in vivo migration capacity compared to unlabeled BMDC 
cultured under the same conditions nor did it affect the ability of TAA-presenting BMDC 
to elicit TAA-specific CD8+ T cell immune responses identified through tetramer staining 
of lymph node cell suspensions. A B16-F10 cell line stably expressing luciferase to monitor 
tumor growth kinetics and ovalbumin to serve as a model tumor antigen was generated 
such that future experiments to correlate the quantification of 19F-PFC-labeled BMDC 
migration to the lymph node with the objective tumor response in a tumor-bearing mouse 
model can be employed.   
Transitioning from a professional DC-based immunotherapy platform to a mixed APC-
based immunotherapy platform was first demonstrated in Appendix II through efficient 
labeling of the three main cell lineages found within murine PBMC (CD3+ T cells, CD19+ 
B cells and CD11b+ myeloid cells) without affecting viability or phenotype. In Chapter 3, 
a similar result was observed and measured with human PBMC. Detection and 
quantification of 19F-PFC-labeled murine PBMC in an immunocompetent mouse model 
(Appendix II) and detection of 19F-PFC-labeled human PBMC migration to the popliteal 
lymph node in an immunocompromised mouse model (Chapter 3) were both demonstrated. 
Further in vivo imaging studies using 19F-PFC-labeled human PBMC revealed that 19F 
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cellular MRI is not only capable of detecting and quantifying the migration of cells in vivo, 
but it is also sensitive enough to discern differences in migration associated with varying 
ex vivo culture and tissue pre-sensitization conditions. For example, increased migration of 
19F-PFC-labeled human PBMC to the popliteal lymph node was observed when human 
PBMC were ex vivo-cultured with GM-CSF as well as when 19F-PFC-labeled human 
PBMC were administered into tissue pre-sensitized with a pro-inflammatory cytokine, 
murine IL-1b. Finally, signal detected in vivo was confirmed to be the result of originally 
injected PBMC and through differential cell lineage fluorescent labeling, CD3+ T cells, 
CD19+CD20+ B cells and CD14+/CD16+ monocytes contained within PBMC were all 
detected within the popliteal lymph node.  
Previous studies in Chapter 3 outlined that efficient 19F-PFC labeling of human PBMC 
occurs without affecting viability or phenotype. In combination with MLR and T cell 
proliferation assays demonstrating no functional changes associated with 19F-PFC labeling 
of APC and T cells, respectively, a pre-clinical validation study was performed as a step 
towards a clinical trial. Human PBMC viability, function, 19F-PFC retention, regulatory 
authority-mandated quality control tests and associated transportation were all considered 
when designing a protocol to label human PBMC with 19F-PFC under GMP-compliant 
conditions.  After minor modifications, the protocol outlined in Chapter 4 was suitable for 
generating 19F-PFC-labeled human PBMC under GMP-compliant conditions that are 
migration competent in a pre-clinical murine model. In a parallel study, the translation of 
pre-clinical 9.4 T MRI knowledge to a 3 T clinical MRI set-up using a dual-tuned 1H/19F 
switchable RF coil approved for human use permitted the detection and quantification of 
19F-PFC-labeled human PBMC at an immunologically relevant depth in a mock human in 
vivo system.  
5.2 Cancer immunotherapy 
Cancer is the second most common cause of death in North America, trailing only heart 
disease485. In males, prostate cancer is the most prevalent malignancy and in 2018, is 
estimated to account for 19% of all male cancers, followed by lung cancer (14%) and 
colorectal cancer (9%). From birth until 49 years of age, prostate cancer affects 1 in 403 
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males, 1 in 58 males aged 50-59, 1 in 21 males aged 60-69 and 1 in 12 males over 70 years 
of age485, 486. Considering the increased prevalence of prostate cancer with age in 
combination with developed countries having ageing populations, research with respect to 
improving existing prostate cancer treatment options and the development of novel 
strategies is imperative to control and reduce the number of diagnoses in the coming 
years392. Research into novel chemotherapeutic, radiotherapeutic and surgical therapies, 
the three standard anti-cancer strategies, is currently being conducted and has demonstrated 
positive results; however, 30% of patients still progress to metastatic disease, which has a 
5 year survival rate of 28%4, 366. Nearly 100% of prostate cancer-related deaths are 
associated with metastatic disease, in which few treatment options are available5, 6, 487. 
Therefore, immunotherapeutic strategies to combat prostate cancer, along with other 
immunogenic tumors like melanoma and renal cell carcinoma31, 32 are becoming 
increasingly popular and represent personalized medicine approaches to harness the power 
of the immune system for patients unresponsive or refractory to standard treatments. 
In order for tumors to persist in vivo, they develop multiple strategies to evade the immune 
recognition9, 10. As these malignant cells are of host-origin, the immune system is naturally 
biased towards tolerance and thus, tumors continue to proliferate11, 12, which increases 
tumor burden and can potentially result in metastasis to distant organs4, 366. By down-
regulating MHC Class I expression on the cell surface, tumors are rendered nearly invisible 
to CD8+ cytolytic T cells as it cannot interact with a peptide:MHC Class I complex on the 
tumor cell surface19, 20, 21, 22.  In addition to preventing recognition by the immune system, 
tumors induce the surrounding microenvironment to be extremely immunosuppressive23 
such that if an anti-tumor immune response were to be initiated, it would quickly be 
dampened and skewed towards a tolerogenic response incapable of tumor destruction11, 12, 
212, 213, 488, 489.  
The tumor microenvironment establishes immunosuppression and tolerance through the 
release of immunosuppressive cytokines like IL-10490, 491 and pro-tumor cytokines such as 
transforming growth factor-b (TGFb) and vascular endothelial growth factor (VEGF)9, 492, 
493. Furthermore, the tumor microenvironment gives rise to cell subsets that are regulatory 
and suppressive in nature, primarily consisting of CD4+ CD25+ Foxp3+ regulatory T cells 
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(Treg) and MDSC338, 494, 495, 496, 497. Collectively, tumor-induced immunosuppression leads 
to APC and T cell dysfunction212, 213, 488, 489, 498 as well as the disruption of proper innate 
immune cell activation, such as seen with NK cells and macrophages9, 493, 499, 500, 501. 
Cancer immunotherapy serves to up-regulate the immune system to overcome one or more 
aspects of tumor-induced immune suppression such that a tumor can be recognized and 
drive an objective anti-tumor response, ultimately resulting in long-term immunological 
memory that prevents tumor re-emergence18, 31, 32. Cancer immunotherapy can be used to 
elicit anti-tumor immunity in a multitude of ways. First, non-specific up-regulation of the 
immune system can occur through systemic administration of pro-inflammatory cytokines 
like IL-263, 64 or through administration of checkpoint inhibitors that bind negative 
signaling molecules on an activated T cell, thereby prolonging their immunotherapeutic 
window at which to exert anti-tumor effects94, 502, 503, 504, 505. Alternatively, adoptive cell 
transfer of ex vivo-activated T cells can be employed. These T cells can consist of ex vivo-
expanded TIL87, 506 or genetically engineered CAR T cells and upon infusion back into the 
host, induce apoptosis in cancer cells108, 109, 507, 508. Although proven effective and capable 
of launching long-term anti-tumor responses, the broad, untargeted prolonging of the T cell 
activation state using checkpoint inhibitors and the “on-target off-tumor” destruction of 
healthy tissue associated with CAR T cell therapies can result in serious and even fatal 
toxicities14, 105, 108, 116, 241. Therefore, APC-based immunotherapeutic strategies have been 
employed as an alternative means to induce TAA-specific immune responses in vivo that 
led to both partial and durable responses in patients509, 510 and most importantly, are 
associated with excellent safety profiles511, 512, 513, 514.   
APC link the innate and adaptive immune systems and in the context of cancer 
immunotherapy, function as adjuvants120. APC are responsible for the uptake and 
processing of TAA in the periphery and presenting TAA to T cells upon migrating to 
secondary lymphoid organs in a manner that induces a TAA-specific T cell response62, 120, 
159. Professional APC, like DC, present TAA in conjunction with strong activation 
signaling through co-stimulatory molecules and pro-inflammatory cytokine secretion such 
that naïve T cells can be activated and proliferate into CD8+ CTL or CD4+ TH cells515, 516. 
Non-professional APC-based immunotherapies, for example mixed APC-based cancer 
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vaccines generated from PBMC, also exist and function by improving the strength of an 
existing basal anti-tumor response to a level that results in improved overall survival7. Due 
to the incomparable ability of DC to stimulate robust anti-tumor immune responses, they 
have been used extensively in immunotherapies for greater than 20 years210. Although safe 
and effective, the results of DC-based clinical trials are sub-optimal and thus, much effort 
has focused on improving the immunogenicity of DC-based vaccine formulations. Various 
strategies to improve immunogenicity have consisted of determining the ideal DC source, 
defining the optimal DC maturation and activation state, most appropriate administration 
route, increasing in vivo migration capacity and inducing cytokine secretion that promotes 
TH1-mediated CD4+ T cell, CD8+ T cell and NK cell responses517. 
As with any cell-based therapy, knowledge pertaining to in vivo migration and persistence 
following administration is largely unknown. With respect to APC, and more specifically, 
DC, previous research has shown that the number of APC that reach a lymph node 
following injection is directly proportional to the outcome of the immune response199, 518. 
This highlights the importance of developing a non-invasive imaging technique to 
quantitatively monitor in vivo cell distribution and thus, serve as a surrogate marker of 
vaccine effectiveness. This thesis outlines the use of 19F cellular MRI as a suitable non-
invasive imaging technique to quantify therapeutic cell migration in vivo such that it can 
serve as a surrogate marker or readout of effectiveness as a means to compare between 
different vaccine formulations or determine the effectiveness of emerging cell-based 
immunotherapies. Furthermore, we demonstrate that 19F cellular MRI is sensitive enough 
to permit in vivo detection of both human and murine therapeutic cells in a pre-clinical 
setting as well as in a clinical setting following GMP-compliant cell manufacturing.  
5.3 Source of DC and administration route 
Early studies pertaining to DC were conducted via direct isolation of blood-derived DC. 
Although possible, blood-derived DC represent a very small population of cells found in 
the blood (approximately 1%)519, 520, 521, and the technology at the time was not suitable for 
processing multiple blood volumes to obtain enriched DC apheresis products522. Therefore, 
monocytes, which are present at much higher proportions in peripheral blood than DC, are 
widely used as precursors to generate moDC523, which are then matured using a well-
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characterized standard cytokine maturation cocktail207, 211, 212, 213. Our laboratory 
involvement in a clinical trial evaluating an autologous DC-based cancer vaccine for non-
metastatic castrate-resistant prostate cancer patients with rising PSA123 created a platform 
from which we could generate moDC from patient samples. These moDC were then 
included in preliminary studies assessing 19F-PFC label incorporation as a means to detect 
moDC in vivo using 19F cellular MRI. In parallel to human moDC experiments, similar 
studies were conducted with murine BMDC, which closely resemble human moDC.  
DC were chosen for preliminary labeling studies firstly because they are commonly ex 
vivo-cultured to avoid tumor-induced immunosuppression523. Ex vivo culturing allows 
labelling agent incorporation to be controlled and consistent without concerns regarding 
other contaminating cell lineages incorporating signal and producing false positive signal. 
Secondly, they represent a terminally differentiated enriched cell population with a high 
endocytic capacity203. These characteristics enable DC to incorporate large volumes of cell 
labeling agent throughout the cytoplasm and labeling agent dilution due to proliferation is 
not a concern524, 525. Furthermore, previous studies had assessed different administration 
routes for DC as a means of improving immunogenicity. It was determined that intranodal 
administration was associated with the greatest number of DC in the lymph node. However, 
this did not result in an increased TAA-specific T cell response as intranodal injections 
bypass the natural maturation and activation that DC undergo during migration to a lymph 
node, resulting in both immature and incompletely matured and activated DC being 
injected in the lymph node64, 198. In the context of cancer immunotherapy, immature DC 
presenting TAA leads to tolerogenic responses, which is the opposite of the desired pro-
inflammatory response and in some instances can even be detrimental to the patient201. To 
avoid tolerogenic responses, peripheral administration of DC was widely adopted such that 
DC migration to the lymph node needed to take place and thus, only properly matured DC 
would reach the lymph node200. By incorporating peripheral subcutaneous or intradermal 
injection into DC-based immunotherapies, the need to track and quantify DC migration to 
secondary lymphoid organs became even more pertinent.  
An ideal cell tracking agent should label a high percentage of cells with enough agent to 
permit in vivo detection while not having any effect on viability, phenotype or function314, 
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526, 527, 528.  Therefore, both human moDC and murine BMDC were cultured with and 
without 19F-PFC and I determined, as presented in Appendix I and Chapter 2, that nearly 
100% of DC incorporated 19F-PFC label without affecting viability or phenotype when 
compared to unlabeled control DC. Furthermore, I established that the mature moDC 
phenotype was unchanged as a result of 19F-PFC labeling (Appendix I) with respect to 
human moDC activation and co-stimulation markers like CD80, CD83, CD86, CD40 and 
CD54, as signaling through these surface markers is absolutely required in addition to TAA 
presentation for the activation of naïve TAA-specific T cells160. Similar data was obtained 
for murine BMDC as presented in Chapter 2. Of equal importance to murine and human 
DC maturation is their in vivo migration competency, commonly assessed through surface 
up-regulation of CCR7 induced through addition of a maturation cytokine cocktail to ex 
vivo culture (Chapter 2 and Appendix I, respectively). 
5.4 DC migration 
One of the first rationales for conducting the projects presented in this thesis was the desire 
by clinicians involved in one of Canada’s first cell-based cancer vaccines clinical trials to 
know where injected DC tracked to within the patients following injection. Hence, 
assessing DC migration became an important issue as this trial progressed123. CCR7 
responds to CCL19- and CCL21-induced chemokine gradients that promote migration 
towards secondary lymphoid organs343, 344 and once within lymph nodes, directs migration 
towards paracortical T cell-rich regions529, 530, 531, 532. One of the main factors limiting the 
effectiveness of DC-based immunotherapies is that only 5% of injected cells reach the 
lymph node following injection183, 198, 199, 215, 216, 217. As the number of DC reaching the 
lymph node is predictive of the strength of the ensuing immune response199, 518, much focus 
has been directed towards increasing DC migration as a means of increasing vaccine 
potency. Even though CCR7 surface expression was unchanged for murine BMDC and 
human moDC following 19F-PFC labeling, 19F MRI imaging studies to detect in vivo 
migration from footpad injection to draining popliteal lymph node were conducted and 
presented in Chapter 2 and Appendix I123. For both human and murine DC, 19F-PFC-
labeled cells were detected and quantified in the lymph node. Furthermore, this experiment 
was designed to include the addition of a fluorescence marker to DC prior to injection such 
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that post 19F MRI digital morphometric analysis to compare the migration between 19F-
PFC-labeled DC and unlabeled DC could be conducted. No difference in in vivo migration 
capacity was associated with 19F-PFC labeling, which is a stark contrast to previously used 
cellular MRI SPIO- and MPIO-based labeling agents that physically impeded DC 
migration to secondary lymphoid organs322, 339, 533, 534. The moDC that I prepared from 
prostate cancer patients apheresis products in the aforementioned DC-based clinical trial 
were demonstrated to be migration competent using 19F cellular MRI123. This enabled 
clinical trial investigators to have some degree of confidence that the autologous vaccine 
moDC product administered to clinical trial patients were migration competent.  
Lipid mediators, such as PGE2, have been included in DC maturation cocktails to induce 
CCR7 up-regulation211 and were a component of maturation cocktails in this thesis for both 
murine BMDC and human moDC in Chapter 2 and Appendix I. Some controversy exists 
with the inclusion of PGE2 in DC culture because it can result in decreased production of 
IL-12p70 by DC when CD40 ligation also occurs535. In an effort to not dampen a 
subsequent immune response, I attempted to increase DC migration to the lymph node 
using a different method consisting of pre-sensitizing the lymph node region with IL-1b 
prior to DC injection. Although pro-inflammatory tissue pre-sensitization has resulted in 
increased DC migration at lower dose injections199, 341, 342, I believe our injection dose of 
3x106 BMDC was too high to observe the additive effects of tissue pre-sensitization. 
However, for both pro-inflammatory cytokine-treated and control injection conditions, 19F-
PFC-labeled BMDC were detected and quantified in the lymph node 48 hours post 
injection. Currently, it appears to be imperative that a DC-based vaccine be matured with 
PGE2; however, future research into alternative maturation procedures that do not 
compromise IL-12p70 production can use 19F cellular MRI to quantify migration as a 
measure of treatment effectiveness rather than relying on expensive and time-consuming 
immunoassays. 
5.5 Induction of TAA-specific T cell immunity 
For 19F cellular MRI to serve as a non-invasive surrogate marker for DC-based 
immunotherapeutic effectiveness, 19F-PFC labeling must not interfere with antigen 
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processing machinery and subsequent presentation to naïve CD8+ and CD4+ T cells via 
MHC Class I and II molecules in the lymph node. To assess TAA-specific immune 
responses in humans to a pre-determined well-characterized peptide, HLA-restriction must 
be considered536, 537, 538. Therefore, I chose to assess TAA-specific immune responses in a 
murine model of genetically identical mice expressing H-2Kb following administration of 
19F-PFC-labeled BMDC presenting SIINFEKL peptide and unlabeled BMDC presenting 
SIINFEKL peptide. The SIINFEKL peptide is the immunodominant H-2Kb-restricted 
peptide of the chicken ovalbumin protein (OVA257-264) and was chosen due to its extensive 
characterization and commercial availability of a tetramer to detect SIINFEKL-specific 
CD8+ T cells261, 346, 347, 348, 349. I determined that 19F-PFC labeling of BMDC did not alter 
the induction of a SIINFEKL-specific CD8+ T cell immune response compared to 
unlabeled BMDC. Hence, the immunogenicity of the SIINFEKL peptide-loaded cell-based 
vaccine was not affected by the presence of 19F-PFC. Additional studies using less 
immunogenic TAA in conjunction with 19F-PFC labeling of DC needs to be conducted. 
Although not utilized in this thesis, the immunodominant MHC Class II peptide of 
ovalbumin (OVA323-339) is also well characterized and could be used to assess whether 19F-
PFC labeling impairs CD4+ T cell responses in the context of ovalbumin as a surrogate 
tumor antigen in a cell-based cancer immunotherapy350, 351.  
In Chapter 2, I outlined a B16-F10 melanoma tumor cell line transfected to constitutively 
produce ovalbumin protein as a model tumor antigen and stably transduced to express 
luciferase. Therefore, this tumor model was designed to detect and quantify 19F-PFC-
labeled SIINFEKL-presenting BMDC migration to the lymph node using 19F cellular MRI 
and relate this quantification to the overall anti-tumor response, using bioluminescence 
imaging as a readout of tumor growth and persistence. Also, the plasmid selected for 
ovalbumin transfection is suitable for investigating the role of both CD4+ and CD8+ T cells 
in the context of cancer immunotherapy539, 540. The triple-expressing ovalbumin, luciferase 
and GFP B16-F10 cells are currently being used to determine whether 19F-PFC-labeled and 
unlabeled BMDC presenting SIINFEKL peptide induce the same anti-tumor response. 
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5.6 DC licensing 
Much attention related to DC-based vaccines is focused on their ability to induce TAA-
specific CD8+ T cells, which is the main cell type responsible for recognition and 
subsequent destruction of tumor cells250, 259, 260, 541, 542. However, DC need to interact with 
CD4+ TH cells to receive necessary signals and produce cytokines required for potent CD8+ 
T cell induction543. CD4+ TH cell responses last longer in vivo compared to CD8+ T cell 
responses and furthermore, play an integral role in creating an environment suitable for 
activating innate immune cells, maintaining TAA-specific CD8+ T cells and establishing 
long-term immunological memory435, 544, 545, 546, 547. In addition to DC needing CD4+ TH 
cells, moDC matured solely with pro-inflammatory cytokines did not produce sufficient 
amounts of polarizing cytokines to drive robust CD8+ T cell activation176, but rather were 
associated with an exhaustion phenotype capable of only weakly activating tumor-specific 
immune responses548, 549, 550. To generate DC resistant to promoting a T cell immune 
exhaustion phenotype and become properly activated, the high expression of PRR on DC 
cell surface or within DC has been exploited in an effort to further induce DC maturation 
and up-regulate polarizing cytokine secretion163, 551. In Appendix I of this thesis, I 
experimented with different TLR agonist combinations to include in a cytokine maturation 
cocktail for human moDC. Moreover, I also investigated if alterations to the maturation 
cytokine cocktail were affected by 19F-PFC labeling as ideally, 19F-PFC-labeled moDC 
migration to the lymph node could be compared between different vaccine formulations as 
a non-invasive means to measure DC migration as a surrogate marker of potential vaccine 
immunogenicity.  
As presented in Appendix I, TLR agonists such as CpG, poly(I:C), LPS and imiquimod, as 
well as combinations thereof, were included in the cytokine maturation cocktail. TLR 
agonist addition did not induce significant changes in moDC phenotype but did appear to 
increase moDC cytokine secretion with respect to IL-12p70, IFNg and IL-10. IL-12p70 
secretion is important in the context of immunotherapy as it skews an immune response in 
the TH1 direction and is a potent activator of NK and NKT cells552, 553. Signaling through 
TLR also induces IL-10 production, albeit to differing extents depending on the TLR 
participating in signaling554. For example, TLR2, TLR4, TLR7 and TLR9 signaling results 
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in strong IL-10 induction555, 556, 557 while TLR3 in combination with CD40 ligation yields 
minute quantities of IL-10558. With this information, further research is needed to 
determine the ideal maturation cocktail as well as research pertaining to how T cells 
respond to both pro- and anti-inflammatory secretion during an immune response. 19F-PFC 
labeling did not affect moDC phenotype or cytokine secretion when compared to control 
moDC cultured under similar conditions, suggest that this imaging modality is suitable for 
labeling therapeutic cells under different culture conditions and assessing their subsequent 
in vivo migration capacity and immunogenicity.  
Once DC reach the lymph node and begin interacting with naïve T cells, the signature of 
cytokines that they release during these immunological synapse interactions dictates the 
type of immune response launched in vivo176, 207, 211, 212, 213, 440. CD40 ligation of DC by 
CD4+ TH cells results in enhanced IL-12p70 and IFNg secretion555, 559, 560 that activates NK 
and T cells, promoting further secretion of IFNg and TNFa and induces TH1 pro-
inflammatory immune responses beneficial for anti-tumor immune responses437, 438, 439, 440, 
441. IL-4 production is important for TH2-mediated CD4+ T cell responses, while IL-5 and 
IL-13 contribute to induction of both TH1- and TH2-mediated immune responses 
simultaneously that lead to cell- and humoral-mediated adaptive immune responses120. IL-
17 is required for TH17 immunity that is commonly associated with autoimmunity561, 562; 
however, from a cancer perspective, it can be both pro-tumor by promoting angiogenesis563, 
564 and anti-tumor through enhancement of T and NK cell activity120, 565.   
The development of non-invasive imaging modalities to track therapeutic cells post 
injection are instrumental in better understanding cancer immunotherapies and can be 
exploited to compare the effectiveness of different vaccine formulations. Optimizations of 
DC-based vaccines are ongoing with respect to enhanced migration, polarizing cytokine 
secretion and involvement of CD4+ TH cells. Immunotherapy is currently at a crossroad in 
which cell-based immunotherapies that require little to no cell culture or are even 
allogeneic in nature are emerging and gaining popularity7, 387, 467 over potent professional 
APC associated with time-consuming and expensive protocols. With non-invasive imaging 
being included in immunotherapies, shorter culture times and labeling of large quantities 
of therapeutic cells is increasingly favoured.   
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5.7 Blood-derived DC 
Due to the improvement of techniques for isolating rare cell populations coupled with 
increased GMP-compliant grade cell isolation kits566, 567, 568, blood-derived DC-based 
immunotherapies are increasing in popularity. By enriching DC directly, an extended cell 
culture is not necessary and with fewer ex vivo manipulations, protocol standardization is 
easily achieved566, 569, 570, 571. Blood-derived DC primarily consist of CD1c+ or CD141+ 
mDC and CD123+ pDC146, 572, 573, 574, 575. Both subsets have been used to elicit robust anti-
tumor responses and can also function synergistically143, 144, 576. pDC are matured following 
IL-3 addition to culture while mDC are matured with GM-CSF, giving rise to type I IFN 
production by pDC in addition to IL-6 and TNFa production by both subtypes141. Type I 
IFN is beneficial in a cancer immunotherapy setting as it promotes tumor apoptosis, cell 
cycle arrest and enhances macrophage, lymphocyte and DC anti-tumor activity577, 578, 579, 
580.  
5.8 PBMC-derived mixed APC-based immunotherapies and 
19F-PFC labeling 
Instead of undergoing a lengthy apheresis procedure and enrichment for monocytes as was 
conducted in Appendix I, PBMC can be isolated directly from blood with relative ease581, 
582. Through co-culture with a fusion protein consisting of GM-CSF and PAP, APC within 
PBMC such as B cells, monocytes and DC can be activated by GM-CSF and rendered 
tumor-specific via uptake, processing and presentation of TAA derived from PAP245, 386, 
583, 584. This mixed APC-based immunotherapy, named Sipuleucel-T, can be manufactured 
and ready for autologous re-infusion within 48 hours of peripheral blood collection, is 
FDA-approved for the treatment of metastatic CRPC and is associated with significantly 
prolonged overall survival246. 
Mixed APC-based immunotherapies derived from PBMC function similarly to DC-based 
vaccines; however, a very small proportion of PBMC are professional APC, with the 
remaining non-professional APC populations consisting of monocytes and B cells238. 
Therefore, instead of predominantly eliciting a de novo immune response, they are 
designed to primarily enhance a pre-existing anti-tumor response to a level that is effective 
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at prolonging overall survival7. Mixed APC-based immunotherapies have yet to result in 
progression free survival, indicating the need for further research to increase potency445, 
446, 584, 585, 586, 587, 588, 589, 590, 591 but due to their short and relatively simple ex vivo culturing, 
there is potential for clinical translation. As this thesis focuses on in vivo cell tracking 
within the context of cancer immunotherapy, mixed APC vaccines derived from a 
heterogeneous cell population present new challenges with respect to 19F-PFC labeling as 
the vast majority of 19F-PFC labeling is performed using homogeneous cell cultures.   
19F-PFC is formulated as an emulsion such that all cells uptake label regardless of 
endocytic and phagocytic capacity314, 457, 468, 592. However, B cells, T cells and NK cells 
within PBMC have a low cytoplasmic volume and thus, are limited with respect to the 
amount of label they endocytose. In addition, the relative proportions of PBMC cell subsets 
vastly differ between patients238. Thus, depending on the relative proportions of B and T 
cells compared to larger cells like monocytes, the average 19F-PFC incorporation per cell 
can also differ significantly between patients. Although one may presume that if 19F-PFC 
labeling of the main cell lineages within PBMC have all labeled in a homogeneous culture 
that labeling in heterogeneous cultures should not differ; however, this is not the case. This 
is well demonstrated by comparing a study labeling human T cells with 19F-PFC, in which 
90% of cells incorporated label422, compared to less than 4% of CD3+ T cells that 
incorporated 19F-PFC when cultured as a heterogeneous splenocyte cell suspension261.  
In preliminary studies that I conducted in Appendix II, murine PBMC isolated from blood 
and splenocyte cell suspension following gradient centrifugation were cultured with 19F-
PFC. CD19+ B cells and CD11b+ myeloid cells labeled to a high percentage with 19F-PFC 
and in contrast to a previous study261, greater than 70% of CD3+ T cells incorporated 19F-
PFC. High 19F-PFC labeling observed with murine PBMC precipitated translation to 
determine human PBMC 19F-PFC incorporation in Chapter 3, which was conducted under 
a variety of cell culture conditions and found to be near 100% for CD14+ monocytes, 
CD19+ and CD3+ B and T lymphocytes and CD11c+ DC. By demonstrating that all cell 
lineages label with 19F-PFC to near 100%, similar labeling percentages should be observed 
for all human samples regardless of relative proportions of cell lineages within PBMC. 
This was clearly illustrated by the findings reported in Chapter 4 describing the labeling of 
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human PBMC under GMP-compliant conditions. Furthermore, for initial clinical studies, 
participants can be pre-screened and selected for based on average amount of 19F-PFC 
incorporation into PBMC, which presumably would increase with increasing percentage 
of CD14+ monocytes within PBMC. 
5.9 Mixed APC activation and functional assessment 
To better recapitulate culture conditions seen with Sipuleucel-T, GM-CSF was added to 
human PBMC cultures. GM-CSF addition occurred 24 hours into culture such that 19F-
PFC labeling of PBMC took place before activation with GM-CSF. As expected, GM-CSF 
did not alter 19F-PFC incorporation nor did it alter PBMC viability. In Sipuleucel-T, GM-
CSF serves to activate APC within PBMC and is measured through CD54 surface 
expression7, 435. In our labeling procedure, GM-CSF addition to unlabeled PBMC or 19F-
PFC-labeled PBMC resulted in as much as 40% and 60% up-regulation of CD54 MFI for 
CD20+ B cells and CD11b+ APC, respectively and as much as 120% and 55% up-regulation 
of CD86 MFI for both CD20+ B cells and CD11b+ APC, respectively. This demonstrates 
the bioactivity of GM-CSF in our human PBMC experiments. Moreover, murine and 
human APC functionality was assessed via a mixed lymphocyte reaction in Appendix II 
and Chapter 4, respectively, and was unaltered by 19F-PFC labeling. Interestingly, CCR7 
up-regulation did not occur in response to GM-CSF addition as demonstrated in Chapter 
3.  
5.10 Mixed APC migration 
As observed in DC-based immunotherapies, mixed APC-based immunotherapies exert 
their function through APC migration to secondary lymphoid organs to interact with and 
activate TAA-specific T cells83, 243, 593. Although GM-CSF did not result in CCR7 up-
regulation on human PBMC, in vivo 19F cellular MRI imaging revealed that 19F-PFC-
labeled PBMC cultured with GM-CSF were consistently detected and quantified in the 
popliteal lymph node 48 hours after footpad injection. In contrast, 19F-PFC-labeled control 
PBMC migration was mostly below the detection threshold. As the quantification of APC 
migration is indicative of the strength of the ensuing immune response199, 518, we 
investigated if tissue pre-sensitization with IL-1b increased both professional APC 
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(BMDC) and mixed APC migration. In contrast to what was observed in Chapter 2 with 
BMDC, pro-inflammatory tissue pre-sensitization appears to increase the migration of 19F-
PFC-labeled control PBMC above the detection threshold; however, it did not function 
synergistically with GM-CSF to further enhance migration. The results of this study 
demonstrate the feasibility of 19F cellular MRI as an appropriate non-invasive imaging 
modality than can discriminate differences in human PBMC migration to the lymph node 
associated with differing ex vivo culturing conditions as exemplified with GM-CSF as well 
as increased migration associated with tissue pre-sensitization using IL-1b (Chapter 3).  
5.11 Characterization of 19F-PFC-labeled PBMC in the 
popliteal lymph node 
A common question that arises following 19F-PFC detection in the lymph nodes is whether 
the signal is from intact, originally injected cells or if the signal is the result of phagocytosis 
of dying 19F-PFC-labeled cells by resident macrophages. If these resident phagocytes 
remain at this location, they produce a false positive signal as a result of bystander uptake. 
Co-labeling 19F-labeled therapeutic cells with an intracellular fluorophore aids in 
discriminating true positive from false positive signal using digital morphometry analysis 
when combined with lymph node digestion and counterstaining with human CD45 as 
described in Chapter 4. This ensures that originally injected therapeutic cells are producing 
the observed 19F in vivo signal and are not engulfed by resident phagocytes through positive 
human CD45+ staining. 
Seeing as my studies presented in Chapter 3 and Chapter 4 are centred around PBMC, 
additional questions that arise are which cell lineages from the originally-injected PBMC 
are producing the signal detected in the lymph node and how does the migrated relative 
proportion of cell lineages compare to pre-injection PBMC cell lineage relative 
proportions. From an immunological perspective, this information is vitally important 
considering the different roles T cells, B cells and monocytes have in cancer 
immunotherapy. 
Differential intracellular fluorescent labeling of T cells, B cells and monocytes within 
PBMC prior to injection for both 19F-PFC-labeled and unlabeled PBMC permitted post-
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imaging analysis of popliteal lymph node cryosections displayed in Chapter 3. Regardless 
of 19F-PFC labeling or not, all three main cell lineages were detected in the lymph node, 
with further research being required to compare relative proportions of PBMC lineages. 
This information, in combination with a similar experiment conducted in Chapter 4 in 
which intact CFSE-labeled cells counterstained with human CD45 were detected in the 
popliteal lymph node, implies that live, originally injected PBMC are the source of signal 
detected in the popliteal lymph node. Although we cannot definitively say these cells are 
alive, the detection of cell migration penetrating into the lymph node suggests that live 
cells responded to a chemokine gradient and directed their intralymphatic migration 
accordingly529, 530, 531, 532. To minimize quantification errors as a result of differences in 
relative cell lineage proportions between participant PBMC samples, NMR spectroscopy 
was conducted for each participant sample. This aided in minimizing interparticipant 
quantification errors; however, the lineage composition of cells that have migrated in vivo 
to immunologically-relevant locations has not been determined. Therefore, it is necessary 
to assume that relative cell proportions remain constant following in vivo administration 
but it is acknowledged that this represents a source of error with respect to 19F cellular MRI 
quantification. A future experiment in which lymph nodes are digested following migration 
of fluorescently-labeled cell lineages within PBMC and counterstaining with human CD45 
can be used to assess relative lineage proportions as well as confirm that these cells are not 
engulfed by murine resident phagocytes.   
5.12 Clinical translation 
Pre-clinical 19F-PFC labeling studies of human PBMC as well as murine BMDC and 
human moDC that demonstrated a high cell labeling percentage without deleterious effects 
on in vivo migration, viability, phenotype or function set the stage for clinical translation. 
The 19F-PFC cell labeling agent used throughout this thesis is suitable for use in humans 
and in combination with regulatory bodies expressing interest in non-invasive imaging 
technologies306, 594, 595, we decided to develop the methodologies whereby human PBMC 
are labeled with 19F-PFC under GMP-compliant conditions. In parallel, we also translated 
our pre-clinical cellular MRI knowledge to a clinical setting such that MR hardware and 
19F-PFC detection could be optimized prior to conducting a clinical trial.    
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5.13 GMP-compliant 19F-PFC labeling of human PBMC 
By incorporating a cell labeling agent into cell manufacturing protocols, it will be 
necessary to subject the labeled cells to the same quality control tests outlined by regulatory 
authorities that need to be met to obtain approval for infusion into patients. Therefore, in 
Chapter 4, we designed a protocol to obtain PBMC from prostate cancer patients and a 
healthy control that were labeled overnight with 19F-PFC under GMP-compliant 
conditions. Following 19F-PFC labeling, viability, phenotype and in vivo migration 
assessments were conducted and compared to unlabeled PBMC from the same participant. 
Lastly, all quality assurance tests that would be required for autologous injection were 
performed; however, murine injection studies were performed in our experimental design. 
In translational research, it is important to identify possible hurdles that may be faced 
during GMP-compliant cell manufacturing. Transportation was identified as a potential 
issue for two reasons. Firstly, the nearest GMP-compliant cell manufacturing facility is 
three hours away and secondly, the shipping conditions must be suitable to not result in 
significantly decreased viable cell yield. Greater than 35% cell loss during GMP-compliant 
manufacturing is associated with increased manufacturing costs467, 596. For example, in the 
first two participant samples, the cell yield, as well as viability, was low as a result of cells 
being transported in small, individual injection-ready aliquots. Fortunately, a simple 
protocol modification to transport all manufactured cells in a large media volume in one 
vial rather than small aliquots resolved this issue for remaining PBMC participant samples. 
Although not an issue in this thesis, shipping cryopreserved cell products would also result 
in decreased cell yields596. Finally, as stated in Chapter 4, we employed a short overnight 
labeling protocol and thus, minimized cell loss associated with extended cultures. This was 
balanced against a four-hour labeling protocol that requires using five times the amount of 
19F-PFC141 at five times the expense. However, with the 6 hours of total transportation time 
involved, the labeled cells would have required a future participant to come for their 
infusion at an evening time that generally would be inconvenient for most participants, 
particularly elderly men involved in a prostate cancer clinical trial. Hence, the protocol 
described in Chapter 4 represents the best compromise due to the distance between the 
study site and the cell manufacturing site. 19F-PFC labeling was maintained during 
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transport and after the aforementioned protocol modification with respect to transportation, 
all quality control tests, including viability, passed, suggesting that our current protocol is 
suitable for future clinical trials.  
5.14 19F-PFC-labeled PBMC in vivo migration 
To confirm the biological activity of GMP-processed PBMC and 19F-PFC uptake, I, in 
conjunction with Dr. Jeffrey Gaudet and Dr. Paula Foster, performed 19F MRI studies in 
immunocompromised mice. Previous studies in Chapter 2 and Chapter 3 utilized mouse 
footpad injections. As this is not an option in humans, we decided to modify the injection 
location. Earlier studies outlined in Appendix II using 19F-PFC-labeled murine PBMC 
injected intraperitoneally appeared to migrate to mesenteric as well as sacral lymph nodes. 
Unfortunately, the location of mesenteric lymph nodes can differ and could potentially be 
masked with injection site signal. Therefore, we performed subcutaneous flank injections 
as this closely mimics what will be conducted in a future clinical trial in which autologous 
cell injection will take place in close proximity to the inguinal lymph node area.  
Subcutaneous flank administration of GMP-processed 19F-PFC-labeled PBMC permitted 
injection site detection as well as migration to the popliteal lymph node approximately two 
hours after administration. Utilizing this approach, we demonstrated that GMP-processed 
human 19F-PFC-labeled PBMC were migration competent in vivo. It should be noted that 
as a proof of principle study, GM-CSF was not included as an additional variable. In 
Chapter 3, we showed that cell migration is increased with GM-CSF in culture, most likely 
as a result of increased retention of activated APC within the lymph node120, 379, 427, 435, 
suggesting that activation with GM-CSF during GMP-processing would have resulted in 
enhanced migration. 
5.15 Clinical MRI protocol 
When transitioning from 9.4 T pre-clinical MRI to a 3 T clinical MRI, the sensitivity of 
detection decreases linearly with decreasing magnetic field strength597. To balance the 
decrease in detected signal, a dual-tuned surface coil rather than volume coil can be 
employed as they are associated with a greater sensitivity of detection with respect to 
163 
 
imaging superficial locations77, 387, 598, 599, 600. Moreover, human lymph nodes are larger than 
murine lymph nodes and thus, the 19F-PFC voxel size can be increased accordingly. Lastly, 
human cell injection doses can be over an order of magnitude greater than injection doses 
employed in mouse studies.   
A previous clinical study was able to image 19F-PFC-labeled DC in humans at the injection 
site but was unable to detect cell migration77. In the context of APC-based cancer 
immunotherapies, migration from injection site to lymph node is absolutely required to 
achieve a clinical benefit168, 169, 170. Therefore, we designed an experiment using a clinical 
MRI set-up to not only detect a superficial intradermal injection but a deeper subcutaneous 
injection at a biologically relevant depth, being the depth of a human inguinal lymph node. 
Initially studies pertaining to 19F-PFC cell pellets were important to establish detection 
ranges; however, a much more biologically relevant set-up was required to provide 
meaningful information. Due to tissue similarities, a ham shank was used to detect and 
quantify both surface injected and subcutaneously administered 19F-PFC-labeled PBMC. 
The detection of an immunologically relevant number of cells at a biologically relevant 
depth highlights the importance of designing experiments that closely resemble what would 
occur in humans and allows for early identification of potential hurdles that may be faced 
in future clinical trials. It should be noted that the use of a refrigerated ham shank, although 
similar in size to a human thigh, would be associated with less cell dispersion following 
injection that what would occur in a live patient following autologous 19F-PFC-labeled 
PBMC injection. In conclusion, given the current outlined sensitivity of detection in a 
clinical setting and the notion that approximately 5% of therapeutic cells reach the lymph 
node following adoptive cell transfer, we can conservatively predict that an adoptive cell 
transfer of close to 90x106 19F-PFC-labeled PBMC would be required to detect migration 
to the draining inguinal lymph nodes.    
5.16 Conclusions and future directions 
Irrespective of the type of therapeutic cells employed for cell-based cancer 
immunotherapy, the development of novel immunotherapies and improvement to previous 
immunotherapies is contingent on knowledge gained regarding where and for how long 
cells remain at a given location post administration314, 601, 602, 603. With in vivo cell tracking, 
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the effectiveness of immunotherapies could be predicted as soon as hours or days after 
therapeutic cell infusion. Moreover, if the cell-based immunotherapy fails based on lack of 
cell migration or goes to unexpected locations, the patient could consider alternative 
treatment options sooner rather than waiting for lengthy periods of time to indirectly 
measure therapeutic outcome, for example using tumor growth at a follow-up 
appointment604.  
This thesis presented the usefulness of 19F cellular MRI in a pre-clinical setting that appears 
suitable for detection and quantification of BMDC migration to a draining lymph node and 
relating this migration to an antigen immunogenicity and soon to an anti-tumor response 
in a tumor-bearing mouse model. Fluorine cellular MRI is sensitive enough to detect 
differences in in vivo migration between GM-CSF-activated and control human PBMC in 
a mouse model while also being robust enough to be translated from pre-clinical murine 
BMDC studies to GMP-compliant processing and detection of human PBMC in a clinical 
MR setting.  
Future directions of 19F cellular MRI should be focused on comparing the effectiveness of 
GMP-compliant vaccine formulations, such as investigating whether frozen APC-based 
cell products, such as cryopreserved Sipuleucel-T (APC8015F) migrate similarly and as 
effectively as freshly prepared cell products7, 43. Secondly, 19F cellular MRI can be used to 
better understand existing immunotherapies, such as the in vivo migration signature 
associated with the first priming infusion of mixed APC-based immunotherapies like 
Sipuleucel-T as it compares to the in vivo migration signature of subsequent boost 
infusions120. Additionally, it can be easily translated to other immunogenic cancer 
platforms, such as a mixed APC-based cancer vaccine including HER2/neu-GM-CSF 
fusion protein for metastatic breast, ovarian and colorectal cancers445, 446 and a mixed APC-
based immunotherapy employing carbonic anhydrase 9 fused to GM-CSF for the treatment 
of renal cell carcinoma447, 448.  Knowledge gained through these described studies will help 
to shape the path taken to translate pre-clinical immunotherapies into the clinical setting in 
the most cost-effective manner without compromising the potent anti-tumor immune 
responses associated with cell-based immunotherapies.  
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Combination therapies of pre-existing immunotherapies or combination with standard 
treatment options are necessary for cancer immunotherapy to gain an advantage over the 
immunosuppressive tumor microenvironment and associated immune evasion605, 606. For 
example, the excellent safety profile associated with mixed-APC vaccinations83, 244, 246 can 
be combined with the potent anti-tumor activity of checkpoint inhibitors94, 503, 504, 505 to 
better recognize and subsequently eliminate a tumor. Moreover, the emergence of 
personalized medicine can be exploited to identify tumor neo-antigens that will improve 
the toxicity issues associated with CAR T cells14, 105, 315, 607, 608, 609, 610, 611, 612, which could 
potentially be measured using 19F cellular MRI by increased migration to tumors that 
coincides with decreased migration to unexpected in vivo locations containing normal 
tissue613, 614, 615. 
By incorporating a non-invasive imaging technique approved for clinical use that has 
demonstrated scale up capability422 and can efficiently label, track, and quantify in vivo 
therapeutic cell migration, the translation and development of novel GMP-processed 
immunotherapies can be better understood and thus, accelerated for clinical use435. The 
data presented in this thesis has now been translated into the pre-clinical component of a 
Phase I clinical trial application (NCT02921373616) to investigate the feasibility and safety 
profile associated with autologous injection of 19F-PFC-labeled PBMC in 6 healthy 
volunteers and 6 prostate cancer patients. In the first cohort of patients, a 3x106 19F-PFC-
labeled PBMC intradermal injection will be performed with subsequent monitoring for 
adverse effects as well as quality control tests mandated by regulatory authorities for 
autologous reinjection. If adverse effects are observed at the level of grade 1 or lower, a 
higher injection dose of 20-30x106 19F-PFC-labeled PBMC will be performed to detect 19F-
PFC signal at the injection site as well as detect and quantify 19F-PFC signal in the inguinal 
lymph nodes. The clinical trial will hopefully begin in July 2019, with completion being 
expected in June 2022.  
This imaging modality has broad implications not only for labeling immune cell types of 
varying origins but for being employed for therapeutic benefit in a multitude of 
immunogenic cancers. Fluorine cellular MRI can be applied to other cell-based therapies 
whose effectiveness is hindered by lack of knowledge of in vivo migration post injection. 
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For example, 19F-PFC has been used to label human mesenchymal stem cells617 as 
knowledge of their in vivo localization following administration is important when 
assessing treatment effectiveness. Furthermore, detection of tolerogenic DC after infusion 
can provide useful information with respect to the prevention of graft-versus-host disease 
and immune rejection commonly observed with hematopoietic stem cell transplant387, 618. 
Tolerogenic DC that are ex vivo-cultured to control maturation status and cytokine 
secretion profiles can be used to combat chronic immune system over-activation commonly 
observed in autoimmune disorders such as rheumatoid arthritis619. Improved knowledge 
regarding tolerogenic DC tracking can aid in improving this immunomodulatory 
therapeutic option. Current costs for cell-based imaging approved for clinical use is high; 
however, in an era with ever increasing technology, heightened demand for alternative and 
novel treatment options and broad usefulness across many disease states, the future of non-
invasive molecular imaging and the vital role it plays in advancing novel therapies is 
promising.  
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Appendix I- Human DC-based cancer immunotherapies 
6 Appendix I 
6.1 Materials and Methods 
6.1.1 Animal care 
Male Balb/c severe combined immunodeficiency (scid) mice (6-8 weeks) and male C.B17 
mice (6-8 weeks) were purchased from Charles River Laboratories Inc. (Saint Constant, 
Canada) and housed at Robarts Research Institute at the University of Western Ontario 
(London, Canada) in a pathogen-free barrier. All experiments were pre-approved by the 
Animal Use Subcommittee at the University of Western Ontario and conducted in 
accordance with an approved protocol from the University of Western Ontario’s Council 
on Animal Care (Protocol #2015-046). Where necessary, mice were anaesthetized with 2% 
isoflurane in oxygen unless stated otherwise. 
6.1.2 Participants 
Non-metastatic, castrate-resistant prostate cancer patients with rising PSA levels who were 
enrolled in a clinical trial of Tn-MUC1-DC vaccine (clinicaltrials.gov identification 
number NCT00852007) provided written consent to have elutriation samples enriched for 
PBMC drawn at McMaster University (Hamilton, Ontario) of which a portion was shipped 
to Robarts Research Institute at the University of Western Ontario (London, Ontario) for 
same day delivery. To be included in this study, prostate cancer patients must have been 
18 years of age or older and free of HIV, Hepatitis B or C Virus or other transmissible 
diseases and not undergoing steroidal or immunosuppressive therapy at the time of 
elutriation sample collection.   
6.1.3 Reagents 
CellGro® serum-free dendritic cell media (CellGenix®, Freiburg, Germany) was 
supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 0.3 mg/mL L-
Glutamine (ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, Trypan blue, 
human IL-1b, and Luminex® cytokine multiplex kit was purchased from ThermoFisher 
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Scientific, (Burlington, Canada).  BSA was obtained from Calbiotech (Spring Valley, 
USA) and NGS was purchased from Jackson ImmunoResearch (West Grove, USA). 
EasySepÔ human monocyte enrichment kit without CD16 depletion was obtained from 
Stemcell Technologies (Vancouver, Canada) and PeproTech (Montreal, Canada) was the 
source of human GM-CSF, human IL-4, human IL-6, and human TNFa. PGE2 was 
purchased from Sigma Aldrich (Oakville, Canada) while human CpG ODN 2216, Poly 
(I:C), LPS and Imiquimod (R837) were obtained from InvivoGen (San Diego, USA). 
CD11c-APC (Clone 3.9), CD15-PE/Cy7 (W6D3), CD123-BV421 (6H6), CD14-APC/Cy7 
(M5E2), CD54-PE (HA58), CCR7-PE (G043H7), CD80-PE (2D10), HLA-DR-PE (L243), 
CD40-PE (G28.5), CD83-FITC (HB15e), CD86-PerCP/Cy5.5 (BU63) and CD16-Alexa 
Fluor 700 (3G8) were purchased from Biolegend (San Diego, California). Vectashield® 
mounting media with DAPI was obtained from Vector Laboratories (Burlington, Canada). 
Lastly, Celsense, Inc. (Pittsburgh, USA) supplied both 19F-PFC cell labeling agents, CS-
1000 ATM and CS-1000 ATM DM Red, with the latter being the red fluorescent version 
of CS-1000 ATM.  
6.1.4 moDC generation and 19F-PFC labeling 
Samples from five non-metastatic castrate-resistant prostate cancer patients with rising 
PSA were received in this study, with one patient providing two elutriation samples on two 
separate occasions. Elutriation samples enriched for PBMC were collected at McMaster 
University (Hamilton, Ontario) and a portion was shipped to Robarts Research Institute, 
London, Ontario (day 0 of culture). Human monocyte magnetic negative cell enrichment 
without CD16 depletion (Stemcell Technologies) was performed in conjunction with 
manufacturer’s protocol to yield CD14+ and/or CD16+ monocytes. Monocytes were then 
counted using a hemocytometer and resuspended at 5x105 cells/mL in GMP-grade serum-
free media, CellGro® (CellGenix) supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.3 mg/mL L-Glutamine (all ThermoFisher Scientific). In order for 
monocytes to develop into immature moDC, GM-CSF and IL-4 was added to serum-free 
culture media at final concentrations of 0.1 µg/mL and 0.05 µg/mL, respectively.   
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Monocytes were plated at 5x105 cells/mL in serum-free media such that each well of a 6 
well plate contains 4 mL of cell suspension that can be exposed to different treatments 
conditions over the course of 6 day ex vivo culture. An aliquot of PBMC both before and 
after CD14+ CD16+ monocyte enrichment was collected for flow cytometry phenotyping. 
Monocytes were then left untouched for 72h in an incubator at 37°C and 5% CO2. 
After incubating for three days, half of the cell suspension was removed, centrifuged to 
pellet cells and resuspended in fresh media along with GM-CSF (0.1 µg/mL) and IL-4 
(0.05 µg/mL) at the same volume of cell suspension before centrifugation. This fresh cell 
suspension was combined with the other half of the cell suspension remaining in cell 
culture plates and incubated overnight. On day 4, one well was collected in order to 
phenotype the immature moDC. 19F-PFC cell labeling agent (Celsense, Inc.) was added to 
19F-PFC wells (2.5 mg/mL) while unlabeled moDC did not receive 19F-PFC and serve as 
control moDC.  
Twenty-four hours later on day 5, one 19F-PFC-labeled moDC well and one control moDC 
well was collected for phenotyping. All remaining moDC wells then received 1 of 4 
cytokine maturation cocktails in order to mature moDC. The standard maturation cytokine 
cocktail along with 3 modified cocktails are listed in Table 6-1. On day 6 of culture, all 
wells containing all culture conditions were collected individually and phenotyped using 
flow cytometry on a LSRII analytical flow cytometer (BD Biosciences).  
6.1.5 Human moDC viability assessment 
On day 0 of culture both before and after monocyte enrichment, as well as on day 4, day 5 
and day 6 of culture, an aliquot of moDC was removed for each culture condition and 
subject to a trypan blue exclusion assay (ThermoFisher Scientific) to count both viable and 
non-viable cells. 
6.1.6 Flow cytometry 
The following human antibodies were used for phenotyping: CD11c-APC, CD15-PE/Cy7, 
CD123-BV421, CD14-APC/Cy7, CD54-PE, CCR7-PE, CD80-PE, HLA-DR-PE, CD40-
PE, CD83-FITC, CD86-PerCP/Cy5.5 and CD16-Alexa Fluor 700.  
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An aliquot of PBMC both before and after negative selection for monocytes on day 0 were 
phenotyped using CD11c-APC, CD15-PE/Cy7, HLA-DR-PE, CD16-Alexa Fluor 700, and 
CD14-APC/Cy7. On day 4, 5 and 6 (prior to injection), phenotyping was performed on an 
aliquot from each culture condition using all the antibodies mentioned above. In addition 
to phenotyping, on day 6 of culture for the moDC sample labeled with red fluorescent 19F-
PFC, flow cytometry was used to qualitatively assess 19F-PFC labeling of moDC using a 
shift in mean fluorescence intensity as a result of fluorescent label incorporation when 
compared to unlabeled control cells from the same patient. All moDC samples were 
blocked on ice for 30 minutes with 5% NGS (v/v) in HBSS+0.1% BSA. Following washing 
in HBSS (ThermoFisher Scientific), cell surface staining of moDC with the appropriate 
antibodies for that day of culture was conducted in HBSS+0.1% BSA on ice (4°C) for 25 
minutes. Lastly, stained moDC were washed in cold HBSS and resuspended in 
HBSS+0.1% BSA and 4% PFA to fix samples. Phenotyping data acquisition for each day 
of culture was performed in one session using an LSRII analytical flow cytometer (BD 
Biosciences).  
6.1.7 Human moDC cytokine secretion 
On day 4, 5 and 6 of moDC culture, culture supernatants were collected for each cell culture 
condition and frozen in 500 µL aliquots and -20°C.  A Luminex® cytokine multiplex 
analysis (ThermoFisher Scientific) along with following manufacturer’s instructions was 
performed on supernatant samples that were thawed on ice immediately before use in this 
assay. All patient samples were included in the same Luminex® assay and data was 
acquired (in duplicate) all at once to minimize assay variability.  Supernatant samples were 
assayed for IL-2, IL-12p70, IL-10 and IFNg and analyzed using a Bio-PlexTM 200 readout 
System (Bio-Rad Laboratories, CA, United States), which utilizes Luminex® xMAPTM 
multiplexed immunoassay technology (Luminex Corp., TX, United States). Cytokine 
levels were automatically calculated from standard curves using Bio-Plex Manager 
software (v.4.1.1, Bio-Rad).  IL-2 served as a negative control for all moDC supernatants. 
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6.1.8 Adoptive cell transfer of mature moDC 
On day of culture, 19F-PFC-labeled moDC from one patient were washed extensively in 
PBS (ThermoFisher Scientific) and formulated into two high doses (2x106 moDC) and two 
low doses (0.5x106 moDC) for injection, each in 40 µL of PBS. Each C.B17 mouse 
received a subcutaneous hind footpad injection of the high dose condition and a 
subcutaneous hind footpad injection of the low dose condition in the contralateral footpad. 
Two days later, both mice were anaesthetized and 19F as well as 1H MRI scans were 
conducted.  
One of the five patient samples was co-cultured with a red fluorescent version of 19F-PFC 
cell labeling agent (2.5 mg/mL) on day 4 instead of the non-fluorescent labeling agent 
previously mentioned. All other procedural steps were identical to what was mentioned 
above for mature moDC generation. On day 6 of culture after an aliquot of each moDC 
culture condition was collected for phenotyping, the remaining red fluorescent 19F-PFC-
labeled mature moDC that received the standard cytokine maturation cocktail (Appendix 
I, Table 6-1) were counted, washed in PBS (ThermoFisher Scientific) and formulated into 
4, 2x106 moDC injections (high dose) and 4, 0.5x106 moDC injections (low dose) in 40 µL 
PBS.  Two days later, all 4 Balb/c scid mice were anesthetized and 19F as well as standard 
proton MRI scans were conducted followed by the immediate removal of draining popliteal 
lymph nodes that were fixed in 4% paraformaldehyde (PFA) and cryopreserved in sucrose 
solutions.  
6.1.9 MRI of moDC migration 
Mouse imaging was performed with a 9.4 T Varian small-animal MRI scanner (Santa 
Clara, CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging. 
Animals were imaged alongside a reference tube containing a known 19F concentration 
(3.33x1016 19F/μL or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with 
2% isoflurane, with breathing rate and temperature monitored throughout the scan. MRI 
was performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), 
tuned to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively.  For proton 
imaging the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°, 
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PC = 4, averages = 3, resolution = 200x200x200 μm3, and NEX = 3.  For 19F imaging the 
parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC = 4, averages 
= 200, resolution = 1x1x1 mm3, and NEX = 200. To avoid 19F present in isoflurane 
confounding the 19F-PFC signal, imaging was performed by centering on the 19F-PFC Cell 
Sense-specific frequency as we previously described270.  The total protocol time for both 
proton and 19F imaging was under 90 minutes.   
6.1.10 19F-PFC loading efficiency and signal quantification 
The mean intracellular 19F content of human moDC was determined by NMR spectroscopy 
using a 400 MHz Varian vertical spectrometer.  First, a known number of 19F-PFC-labeled 
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a 
solution containing 100 µL of 5% Triton X-100.  After lysing, the cells were transferred to 
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with 
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher Scientific). 
The TFA provides a reference peak for quantifying the number of 19F spins/ cell, since 
NMR signal is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy 
parameters were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm 
to -93 ppm. The number of moDC detected within MR images was determined with Voxel 
TrackerTM software (Celsense Inc, Pittsburgh, PA) 270, 308. Prior to analysis, a signal 
correction was applied to the 19F datasets by subtracting the signal value of the voxel 
containing the lowest signal in the dataset. Once the correction was applied, the total 19F-
PFC-labeled cell signal contained within a hand-drawn ROI was compared to the average 
signal produced by the reference tube containing a known 19F concentration. This 
information was used alongside the 19F spins/cell, measured by NMR, to quantify the 
apparent number of cells located at the ROI.   
6.1.11 Post-MRI lymph node histology 
Immediately following MRI imaging of Balb/c scid mice that received footpad injections 
of 2x106 and 0.5x106 red fluorescent 19F-PFC, both the left and right popliteal lymph nodes 
from each animal were removed and fixed in 4% PFA at room temperature. Cryoprotection 
of lymph nodes using sucrose gradients step of 10, 20 and 30% for a minimum of 24 hours 
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each were conducted at 4°C. The popliteal lymph nodes were then cryosectioned into 16 
µm sections (inguinal lymph nodes served as controls), digitally imaged on an Olympus 
IX50 phase contrast inverted microscope (Richmond Hill, Canada) and the red fluorescent 
19F-PFC-labeled moDC were quantified using Image-Pro® Plus 5.1 software (Media 
Cybernetics, Rockville, USA) and compared between 2x106 and 0.5x106 footpad injection 
conditions.  Lastly, representative lymph node sections were placed on VWR Microslides 
Superfrost® Plus (VWR) and coverslipped with Vectashield® Hard Set mounting medium 
with DAPI (Vector Laboratories) to stain nuclei. Overlay images were taken on a Leica 
DM IRE2 inverted brightfield microscope (Leica Camera Inc., Allendale, USA).     
6.1.12 Statistical analysis 
All data was presented as the mean with the standard error of the mean. A paired t-test 
(Graph Pad Prism, Version 7, La Jolla, USA) or two-way ANOVA was used. Multiple 
comparisons were assessed for all two-way ANOVAs. Significance was considered if p ≤ 
0.05. When written, the number of independent experiments is denoted by (N) while the 
number of replicates per independent experiment is defined by (n).  
 
Table 6-1. Composition of maturation cytokine cocktails added to moDC in culture to 
induce maturation on day 5. 
Standard 
Maturation 
Cytokine Cocktail 
(CC) 
Standard 
Maturation CC + 
CpG 
New Maturation 
CC 
New Maturation 
CC + LPS + 
Poly(I:C) + 
Imiquimod 
IL-6 (0.1 µg/mL) 
IL-1b (10 ng/mL) 
PGE2 (106 units) 
TNFa (25 ng/mL) 
IL-6 (0.1 μg/mL)  
IL-1β (10 ng/mL)  
PGE2 (106 units)  
TNFα (25 ng/mL)  
CpG (4 μg/mL)  
 
IL-1β (10 ng/mL)  
PGE2 (106 units)  
TNFα (25 ng/mL)  
 
IL-1β (10 ng/mL)  
PGE2 (106 units)  
TNFα (25 ng/mL)  
Poly(I:C)  
(5 µg/mL) 
LPS (20 ng/mL) 
Imiquimod  
(10 µg/mL) 
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6.2 Results 
6.2.1 An established 6 day protocol to generate human moDC in 
conjunction with 19F-PFC labeling yields efficiently labeled 
mature moDC 
Throughout the 6 day culture whereby human monocytes were enriched from prostate 
cancer patient elutriation samples and differentiated into immature and then mature moDC, 
an aliquot of cells at each step was collected for further analysis. A cytospin onto glass 
slides was performed on day 0 cells (both before and after monocyte enrichment), day 4 
immature moDC and day 6 mature moDC. Morphological changes associated with 
monocyte to moDC transition and immature to mature moDC can be observed in 
conjunction with brightfield microscopy (Fig. 6-1). When observing the morphological 
changes associated with immature to mature moDC, it is evident that moDC become 
slightly larger after addition of the cytokine maturation cocktail as well as develop long 
dendrites protruding outward from the central region of the moDC (Fig. 6-1, bottom right 
panel), which is consistent with previous reports298, 339. Thus, the 6 day culture of moDC 
appears to be sufficient in generating mature moDC; however, further experimentation is 
required to confirm this observation. Lastly, fluorescence microscopy was employed to 
visualize red fluorescent 19F-PFC incorporation into moDC after its addition to culture on 
day 4 (Fig. 6-1, bottom left panel). Near 100% labeling of moDC was observed, with 
fluorescent label incorporating throughout the cytoplasm of these cells.     
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Figure 6-1. Brightfield and fluorescent images of moDC following a 
cytospin to assess morphological changes.  
Figure 6-1. Brightfield and fluorescent images of moDC following a cytospin to assess 
morphological changes. Morphological changes associated with monocyte to moDC 
transition and moDC maturation are represented by increases in the amount and length of 
dendrites (bottom right image). Nearly 100% of human moDC are able to incorporate red 
fluorescent 19F-PFC (bottom left image). Scale bars in each image represent 25 µm. 
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Flow cytometry was employed to further confirm red fluorescent 19F-PFC incorporation 
into moDC prior to performing in vivo injections. In this experiment, cells were gated on 
viability based on forward and side scatter location, followed by doublet discrimination. 
These viable, singlet cells were then gated on CD11c+ and CD123- selection such that 
moDC were selected for and CD123+ pDC were excluded (Fig. 6-2). Then, a histogram 
overlay of moDC that incorporated red fluorescent 19F-PFC (black histogram) compared 
to control moDC (blue histogram) from the same patient was performed. Using a shift in 
mean fluorescence intensity as a result of fluorescent uptake, 95.3% of moDC incorporated 
19F-PFC cell labeling agent. Lastly, for the mature moDC that incorporated 19F-PFC, the 
majority of cells appear to be uniformly labeled as illustrated by one strong peak being 
observed (black histogram) rather than a broad peak extending over multiple decades.  
  
 
 
 
 
 
 
 
 Figure 6-2. Human moDC efficiently label with red fluorescent 19F-PFC.  Figure 6-2. Human moDC efficiently label with red fluorescent 19F-PFC. Human moDC 
were gated for live, singlet cells that are CD11c+ and CD123-. Following an overnight 
(20h) labeling with red fluorescent 19F-PFC (2.5 mg/mL), 95.3% of moDC label with 
fluorescent 19F-PFC (black histogram, bottom left image) compared to unlabeled control 
moDC (blue histogram). 
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6.2.2 Human moDC matured with a standard maturation cytokine 
cocktail are unaffected by the addition of 19F-PFC with 
respect to phenotype and viability 
A phenotypic analysis using flow cytometry was performed on day 6 moDC to ensure that 
there is no phenotypic difference as a result of 19F-PFC incorporation when compared to 
control moDC from the same patient for each of the four cytokine maturation cocktails 
used. First, gating for CD11c+/CD123- was performed to identify moDC for both 19F-PFC-
labeled (Fig. 6-3, blue bars) and control unlabeled (Fig. 6-3, white bars) conditions. No 
difference existed in the percentage of CD11c+/CD123- between 19F-PFC-labeled and 
unlabeled conditions regardless of the cytokine cocktail used to mature moDC. Co-
stimulatory markers such as CD80 and CD86 were analyzed, along with HLA-DR to 
confirm capacity to present antigen, CCR7 to verify that moDC are migration-competent 
and CD40, CD54 and CD83 served as maturation and activation markers (Fig. 6-3). 
Regardless of cell surface marker or cytokine maturation cocktail that was employed, no 
significant differences in expression exist between 19F-PFC-labeled moDC and control 
unlabeled moDC. This suggests that 19F-PFC-labeled moDC retain the same phenotype as 
control unlabeled moDC and thus, if used in an in vivo vaccine-based immunotherapy, they 
would be migration-competent, be capable of presenting antigen with appropriate co-
stimulatory markers as well as be properly activated to initiate an antigen-specific immune 
response.  
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Figure 6-3. Summary of human moDC phenotype cultured with or 
without 19F-PFC.  
 
Figure 6-3. Summary of human moDC phenotype cultured with or without 19F-PFC. Day 
6 matured CD11c+CD123- moDC were analyzed for markers of activation (CD83, CD40, 
CD54), antigen presentation (HLA-DR), migration (CCR7) and co-stimulation (CD80 and 
CD86). The percentage expression of these markers is shown for 19F-PFC-labeled moDC 
(blue bars) and control moDC (white bars) for all cytokine maturation cocktail derivations 
employed. Data shown as means ± SEM (two-way ANOVA, p > 0.05).  
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The viability of mature moDC that are labeled with 19F-PFC as well as control unlabeled 
moDC viability was assessed after moDC maturation with all four cytokines maturation 
cocktails took place. Although the viability of 19F-PFC-labeled moDC (Fig. 6-4, blue bars) 
is slightly lower than control moDC (Fig. 6-4, white bars), the difference is not statistically 
significant. For moDC matured with a traditional cytokine cocktail or new cytokine 
cocktail (defined in methods), a small, but in some cases, significant decrease in viability 
was associated with 19F-PFC labeling of moDC (Fig. 6-4). All in vivo moDC injections 
doses contained moDC that were cultured with the standard cytokine maturation cocktail 
as it most closely matched the moDC protocol used in the Tn-MUC1-DC vaccine 
immunotherapy clinical trial123.  
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Figure 6-4. Viability assessment of 19F-PFC-labeled and control unlabeled 
moDC on day 6 of culture by flow cytometry.  
Figure 6-4. Viability assessment of 19F-PFC-labeled and control unlabeled moDC on day 6 
of culture using flow cytometry. For moDC matured with the traditional cytokine cocktail, 
which was the maturation cocktail used for all in vivo moDC studies, no significant difference 
in viability is observed due to 19F-PFC incorporation. Howev r, the viability was significantly 
reduced by approximately 10-13% in the presence of 19F-PFC labeling for moDC matured 
with a traditional cytokine cocktail + CpG as well as for moDC matured with a new cytokine 
cocktail. Data shown as means ± SEM (two-way ANOVA, * p < 0.05). All abbreviations are 
defined as presented in Table 6-1. 
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6.2.3 Pro- and anti-inflammatory cytokine secretion by human 
moDC is unaffected by 19F-PFC labeling and appears to 
increase with increasing TLR agonists in culture 
Day 6 moDC culture supernatants were saved from the same moDC cultures described 
above and frozen until a Luminex™ cytokine multiplex analysis was performed. The 
supernatants were assayed for pro-inflammatory cytokines IL-12p70 (active form)620 and 
IFN-g as well as the anti-inflammatory cytokine IL-10173. IL-12p70 (Fig. 6-5A), IFN-g 
(Fig. 6-5B) and IL-10 (Fig. 6-5C) were all produced and secreted in varying degrees and 
appear to increase as more TLR agonists are included in the cytokine maturation cocktail. 
Importantly, there was no significant difference in cytokine production in the presence or 
absence of 19F-PFC regardless of which cytokine maturation cocktail was used. However, 
a more in-depth analysis is required to elucidate how an immune response would be 
affected by both pro- and anti-inflammatory cytokines being present.  
 
 
 
 
 
 
 
 
 
Figure 6-5. Luminex assay assessment 
of  moDC cytokine secretion profiles.  
Figure 6-5. Luminex assay assessment of 
moDC cytokine secretion profiles. The 
supernatants for each of the four maturation 
cytokine cocktail (both with a d without 19F-
PFC in culture) for each subject moDC 
preparation was measured for secretion of IL-
12p70 (A), IFN-γ (B) and IL-10 (C) using a 
Luminex assay. Data shown as means ± SEM 
(two-way ANOVA, p > 0.05). 
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6.2.4 19F-PFC-labeled moDC can be detected and quantified at 
the injection site and draining popliteal lymph node using 19F 
cellular MRI 
In vivo migration of matured and 19F-PFC-labeled moDC from one prostate cancer patient 
was then assessed using 19F cellular MRI 48h after hind footpad injections were performed. 
A 9.4T small animal scanner detected 19F signal in two locations (Fig. 6-6B), which were 
confirmed to be the footpad and draining popliteal lymph node (LN) upon 19F MRI signal 
being overlaid onto a standard proton MRI (Fig. 6-6A) and pseudocoloured to provide 
anatomical context to the in vivo signal observed (Fig. 6-6C). Quantification of in vivo 19F 
signal did not take place as 19F MRI signal detection was still being optimized at this point. 
Note that this 19F/1H MRI image is not processed and that there is a large artifact associated 
with high 19F signal in the footpad as well as 19F signal produced by TFA standards (Fig. 
6-6C). 
After optimizing in vivo 19F detection as well as improving the processing of 19F MRI 
images, moDC from a different prostate cancer patient sample were adoptively transferred 
and produced much more localized 19F signal in the footpad (Fig. 6-7A/B, blue arrow) and 
draining popliteal lymph node (Fig. 6-7A/B, green arrow) without 19F artifact and high 19F 
background signal. Upon overlaying a pseudocoloured 19F and 1H MRI, the in vivo signal 
can be quantified to be 1.1x105 ± 4x104 19F-PFC-labeled moDC (Fig. 6-7C, green arrow).  
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Figure 6-6. 19F/1H MRI detection of 19F-PFC-labeled moDC migration 
to the popliteal lymph node two days post adoptive cell transfer.  
Figure 6-6. 19F/1H MRI detection of 19F-PFC-labeled moDC migration to the 
popliteal lymph node two days post adoptive cell transfer. (A) The 1H MR image, (B) 
19F MR image and (C) 1H/19F MR image overlays (pseudocoloured and not corrected 
for 19F image shift are represented. A gold arrow in all three panels identifies the 
popliteal lymph node (LN). The white arrow indicates the 19F artifact generated by 
the TFA reference standard. 
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Figure 6-7. Fully processed 19F/1H MRI detection of 19F-PFC-labeled 
moDC migration to the popliteal lymph node two days post adoptive 
cell transfer.  
Figure 6-7. Fully processed 19F/1H MRI detection of 19F-PFC-labeled moDC migration 
to the popliteal lymph node two days post adoptive cell transfer. (A) The 1H MR image, 
(B) 19F MR image (after image processing) and (C) 1H/19F MR image overlays (not 
corrected for 19F image shift) are illustrated. A yellow arrow in the top panel identifies the 
popliteal LN. The blue arrow indicat s 19F-PFC-lab led moDC signal retain d at the 
injection site in the footpad.  The green arrow indicates the 19F signal in the popliteal 
lymph node from the injected 19F-PFC-labeled moDC. A “hot iron” colour scale is used 
to represent 19F signal in the bottom panel. The reference standard (R) and NMR 
spectroscopy of a moDC cell pellet is required to quantify the in vivo signal, which in this 
figure is calculated to be 1.1x105 ± 4x104 cells in the popliteal lymph node (bottom panel, 
green arrow). 
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In a parallel experiment, 48h after the footpad injection of 2x106 red fluorescent 19F-PFC-
labeled moDC into an immunocompromised mouse, 19F signal was detected in the draining 
popliteal lymph node after overlaying a 1H MRI with a pseudocoloured 19F MRI. This in 
vivo signal was quantified to be 1.25x105 19F-PFC-labeled moDC using information 
obtained from the reference tube (denoted by R in the MRI image of Fig. 6-8) and NMR 
spectra (Fig. 6-8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-8. 19F-PFC-labeled human moDC in vivo migration is 
quantifiable using 19F cellular MRI   
Figure 6-8. 19F-PFC-labeled human moDC in vivo migration is quantifiable using 19F 
cellular MRI. NMR spectroscopy is performed on a cell pellet of known cell number to 
determine the average number of 19F atoms per cell when compared to a TFA reference 
standard (top right). This information and the formula shown in the bottom right are 
required to accurately quantify in vivo 19F signal. 
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6.2.5 19F in vivo lymph node signal is the result of originally 
injected and intact moDC 
Once the in vivo 19F detection was optimized such that a number of cells in the popliteal 
lymph node could be readily calculated, we next sought to confirm that the signal detected 
in the lymph node was the result of the originally-injected moDC. Here, four 
immunocompromised mice were injected with 2x106 and 0.5x106 red fluorescent 19F-PFC-
labeled moDC into the left and right footpad, respectively. Forty-eight hours later, when 
19F MRI would be conducted, the popliteal lymph nodes were removed and processed for 
cryosectioning and subsequent fluorescence microscopy. Red fluorescent 19F-PFC-labeled 
cells were detected in the paracortex and cortex areas of the lymph node (Fig. 6-9A/B), 
which is where moDC would migrate to in order to interact with T cells and initiate a potent 
antigen-specific immune response181, 182. Digital morphometry analysis demonstrated that 
migration appears to increase in a dose-dependent manner; however, this difference is not 
significant between high and low injections (Fig. 6-9C). Lastly, counterstaining with DAPI 
to reveal nuclei demonstrates that red fluorescent signal in the lymph node is contained 
within intact cells (Fig. 6-9D).    
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Figure 6-9. Red fluorescent 19F-PFC-labeled moDC migration to the 
popliteal lymph node appears to increase in a dose-dependent manner.  
Figure 6-9. Red fluorescent 19F-PFC-labeled moDC migration to the popliteal lymph node 
appears to increase in a dose-dependent manner. Digital morphometry was used to quantify 
the degree of 19F-PFC-labeled moDC migration. Representative popliteal lymph node 
cryosections reveal red fluorescent 19F-PFC-labeled moDC for the 2x106 cell high dose 
injection condition (A) and for the 0.5x106 cell low dose injection condition (B). Digital 
morphometric quantification using an Olympus IX50 phase contrast inverted microscope is 
shown in (C), which appears to occur in a dose-dependent manner (C). Counterstaining with 
DAPI (blue) confirms that red fluorescent signal is the result of intact cells at 100X 
magnification (D). The green box is the same area as shown in the orange box inset at 400X 
magnification. White scale bars represent 200 µm at 100X magnification and yellow scale 
bar represents 100 µm at 400X magnification. A Leica DM IRE2 inverted brightfield 
microscope was used to capture DAPI overlay images. Image-Pro® Plus 5.1 software was 
used with both microscopes to capture, process and measure images. Data is shown as 
means ± SEM (t-test, p > 0.05). 
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Appendix II- Murine APC-based cancer immunotherapies  
7 Appendix II 
7.1 Materials and Methods 
7.1.1 Animals 
C57Bl/6 male mice (8-10 weeks old) were purchased from Charles River Laboratories 
(Wilmington, USA) and C3H/HeJ male mice (8-10 weeks old) were purchased from 
Jackson Laboratories (Bar Harbor, USA). C3H/HeJ mice served as an allogeneic source of 
hematopoietic cells compared to C57Bl/6 mice. All experiments were pre-approved by an 
Animal Use Subcommittee at the University of Western Ontario and conducted in 
accordance with an approved protocol from the University of Western Ontario’s Council 
on Animal Care (Protocol #2015-046). Where necessary, mice were anaesthetized with 2% 
isoflurane in oxygen unless stated otherwise.  
7.1.2 Reagents 
DMEM was purchased from ThermoFisher Scientific (Burlington, Canada) and completed 
with 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, minimal 
essential MEM NEAA, sodium pyruvate (10 mM), HEPES and 2-mercaptoethanol (55 
µM) (all from ThermoFisher Scientific). Murine GM-CSF was obtained from PeproTech 
(Montreal, Canada).  
To generate PBMC, HBSS, PBS and trypan blue were obtained from ThermoFisher 
Scientific, while BSA and NGS were purchased from Calbiotech (Spring Valley, USA) 
and Jackson Immunoresearch (West Grove, USA), respectively. Lympholyte®-M cell 
separation media was obtained from Cedarlane (Burlington, Canada). 
For flow cytometry, CD19-PE (6D5), CD11b-Alexa Fluor 700 (M1/70), CD3e-FITC (145-
2C11), CD3e-BV421 (145-2C11), CD4-Alexa Fluor 700 (GK.15), CD8a-APC (53-6.7) 
were obtained from Biolegend. CellTrace™ CFSE cell proliferation kit and CD3e 
monoclonal antibody (145-2C11) were obtained from ThermoFisher Scientific and 
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Vectashield® Hard Set mounting medium with DAPI was purchased from Vector 
Laboratories (Burlington, Canada).  
ACK lysis buffer, EasySep™ mouse CD90.1 positive selection and EasySep™ mouse T 
cell isolation kits were purchased from Stemcell Technologies, Vancouver, Canada). 
Lastly, Celsense, Inc. (Pittsburgh, USA) supplied both 19F-PFC cell labeling agents, CS-
1000 ATM and CS-1000 ATM DM Red, with the latter being the red fluorescent version 
of CS-1000 ATM. 
7.1.3 Murine PBMC isolation and 19F-PFC labeling 
C57Bl/6 and C3H/HeJ mice were euthanized with isoflurane, peripheral blood was 
collected and spleens were removed. The spleen was then pushed through a 70 µm filter 
(VWR) with HBSS to create a single cell suspension. ACK lysis buffer was used to remove 
red blood cells from cell pellet and the 5 minute reaction was stopped with ice cold HBSS. 
Splenocytes were then resuspended in HBSS and overlaid onto Lympholyte®-M cell 
separation media for gradient centrifugation (20 min, 800xg, 20°C, no brakes) to enrich for 
PBMC. PBMC were enriched from peripheral blood by diluting 1:1 in room temperature 
HBSS and overlaid onto Lympholyte®-M cell separation media as mentioned above. 
PBMC were pooled and then resuspended in complete DMEM at 5x106 cells/mL and 
supplemented with GM-CSF (20 ng/mL). Half of these cells were co-cultured with red 
fluorescent 19F-PFC (5 mg/mL) overnight at 37°C/5% CO2. The following day, PBMC 
were collected for each condition and blocked on ice for 30 minutes with 5% NGS (v/v) in 
HBSS+0.1% BSA. After washing, PBMC were stained for lineage markers CD11b-Alexa 
Fluor 700, CD19-PE and CD3e-FITC for 25 minutes on ice. PBMC were resuspended in 
HBSS+0.1% BSA and fixed with 4% PFA until acquisition on a LSRII analytical flow 
cytometer (BD Biosciences) to assess fluorescent 19F-PFC uptake of PBMC compared to 
control PBMC for each of the 3 main lineages of cells in PBMC.   
7.1.4 Murine MLR 
C3H/HeJ PBMC were enriched for from splenocyte cell suspensions as mentioned above 
and CD3+ T cells were removed from suspension using EasySep™ mouse CD90.1 positive 
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selection kit and manufacturer’s instructions. The remaining cells were cultured overnight 
at 5x106 cells/mL in complete DMEM media supplemented with GM-CSF (20 ng/mL) and 
half of these cells were also cultured with 19F-PFC at 5 mg/mL. Following overnight 
culture, cells were collected and washed in HBSS and then resuspended at 2.5x106 cells/mL 
in complete DMEM media and serially diluted starting from 2.5x105 cells per well in 
triplicate. Then, PBMC were isolated from C57Bl/6 splenocytes as previously described 
above and CD3+ T cells were enriched using EasySep™ mouse T cell isolation kit and 
manufacturer’s instructions. Isolated T cells were labeled with CFSE as mentioned above. 
CFSE+ T cells were resuspended at 3x106 cells/mL in complete DMEM and 100 µL was 
aliquoted to each well such that an MLR can be carried out for 4 days at 37°C/5% CO2 
(positive control wells were coated overnight with anti-CD3e antibody at 2 µg/well). After 
four days of incubation, wells were washed in buffer and following the same staining 
procedure as listed previously, cells were stained for CD3e-BV421, CD4-Alexa Fluor 700 
and CD8a-APC and CFSE dilution was used as a readout to assess allogeneic T cell 
proliferation. 
7.1.5 Adoptive cell transfer 
Murine PBMC that were 19F-PFC-labeled as well as unlabeled control PBMC were washed 
extensively with PBS and formulated into a 8x106 cell injection in 300 µL PBS. 
Intraperitoneal injections were performed into 3 mice for both conditions. In a separate 
experiment, murine PBMC were isolated, labeled with 19F-PFC and then immediately prior 
to injection, were labeled with CellTrace™ CFSE as described previously and 
intraperitoneal injection of 5x106 19F-PFC-labeled CFSE+ PBMC was administered into 3 
mice.  
7.1.6 MRI of murine PBMC migration 
For studies that required 19F cellular MRI imaging, C57Bl/6 mice were imaged 24 hours 
following footpad injection. Mouse imaging was performed with a 9.4 T Varian small-
animal MRI scanner (Santa Clara, CA, USA). A 3D-bSSFP sequence was used for both 
proton and 19F MR imaging. Animals were imaged alongside a reference tube containing 
a known 19F concentration (3.33x1016 19F/μL or 7.3x1016 19F/μL) suspended in agarose. 
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Mice were anesthetized with 2% isoflurane, with breathing rate and temperature monitored 
throughout the scan. MRI was performed using a dual-tuned birdcage volume coil 
(diameter 2.2 cm, length 5.1 cm), tuned to 400.2 MHz and 376.8 MHz for proton and 19F 
imaging, respectively.  For proton imaging the scan parameters were: TR = 5.0 ms, TE = 
2.5 ms, rBW = 78 kHz, FA = 30°, PC = 4, averages = 3, resolution = 200x200x200 μm3, 
and NEX = 3.  For 19F imaging the parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 
kHz, FA = 70°, PC = 4, averages = 200, resolution = 1x1x1 mm3, and NEX = 200. To 
avoid 19F present in isoflurane confounding the 19F-PFC signal, imaging was performed by 
centering on the 19F-PFC Cell Sense-specific frequency as previously described270. The 
total protocol time for both proton and 19F imaging was under 90 minutes.   
7.1.7 19F-PFC loading efficiency and signal quantification 
The mean intracellular 19F content of murine PBMC was determined by NMR spectroscopy 
using a 400 MHz Varian vertical spectrometer.  First, a known number of 19F-PFC-labeled 
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a 
solution containing 100 µL of 5% Triton X-100.  After lysing, the cells were transferred to 
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with 
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA 
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal 
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters 
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm. 
The number of PBMC detected within MR images was determined with Voxel TrackerTM 
software (Celsense Inc, Pittsburgh, PA)270, 308. Prior to analysis, a signal correction was 
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest 
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal 
contained within a hand-drawn ROI was compared to the average signal produced by the 
reference tube containing a known 19F concentration. This information was used alongside 
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at 
the ROI.   
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7.1.8 Post-MRI lymph node histology 
For the intraperitoneal injections that consisted of 5x106 19F-PFC-labeled CFSE+ murine 
PBMC, the mesenteric lymph nodes were removed after 19F MRI, fixed with 4% PFA and 
cryopreserved successively in 10, 20 and 30% sucrose solutions. Cryosections (16 µm) 
were placed on VWR Microslides Superfrost® Plus (VWR) and coverslipped with 
Vectashield® Hard Set mounting medium with DAPI (Vector Laboratories) to stain nuclei.  
Confocal imaging was then performed to image a 100X magnification of the whole lymph 
node followed by a 630X to identify originally-injected and intact CFSE+ cells using a 
Leica TCS SP8 confocal microscope (Concord, Canada).  
7.1.9 Statistical analysis 
All data was presented as the mean with the standard error of the mean. A two-way 
ANOVA (Graph Pad Prism, Version 7, La Jolla, USA) was used with multiple comparisons 
being assessed. Significance was considered if p ≤ 0.05. When written, the number of 
independent experiments is denoted by (N) while the number of replicates per independent 
experiment is defined by (n).  
7.2 Results 
7.2.1 The three main cell lineages of murine PBMC label with red 
fluorescent 19F-PFC 
Murine PBMC were enriched from splenocyte single cell suspensions and diluted 
peripheral blood of C3H mice after undergoing gradient centrifugation. These cells were 
left unlabeled or cultured overnight with the red fluorescent version of 19F-PFC (5 mg/mL). 
After labeling, PBMC were collected from culture and using flow cytometry, surface 
staining of both red fluorescent 19F-PFC-labeled PBMC and control PBMC was conducted 
to identify the three main cell lineages found in PBMC. Also, after lineage identification, 
red fluorescent 19F-PFC incorporation for each lineage was measured and compared to 
control cells of the same lineage using a shift in the mean fluorescence intensity as a result 
of fluorescent label uptake (Fig. 7-1). When comparing red fluorescent 19F-PFC-labeled 
PBMC (black histograms) to control, unlabeled PBMC (blue histograms), greater than 96% 
of CD19+ B cells incorporated fluorescent 19F-PFC (Fig. 7-1A), 99.46% of CD11b+ 
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myeloid cells labeled with fluorescent 19F-PFC label (Fig. 7-1B) and greater than 70% of 
CD3+ T cells were fluorescent as a result of 19F-PFC label incorporation (Fig. 7-1C).  19F-
PFC labeling and phenotyping of cell lineages has been conducted using C57Bl/6 PBMC 
enriched from peripheral blood and splenic cell suspensions, yielding similar results (data 
not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1. The three main cell lineages contained within murine PBMC 
label with red fluorescent 19F-PFC but to varying degrees.  
Figure 7-1. The three main cell lineages contained within murine PBMC label with red 
fluorescent 19F-PFC but to varying degrees. Murine PBMC isolated from the spleens of 
C3H mice using gradient centrifugation were labeled with red fluorescent 19F-PFC as 
assessed by flow cytometry. Greater than 96% of CD19+ B cells (A, black histogram), 
99.46% of CD11b+ myeloid cells (B, black histogram), and 72.33% of CD3+ T cells (C, 
black histogram) label with red fluorescent 19F-PFC when compared with unlabeled cells 
of the same lineage (A-C, blue histograms). 
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7.2.2 Murine APC labeling with 19F-PFC does not affect functional 
ability to induce allogeneic T cell proliferation 
After verifying red fluorescent 19F-PFC incorporation into all 3 main lineages of murine 
PBMC, it needed to be determined whether this labeling had a functional effect on the 
PBMC when compared to control, unlabeled PBMC. To determine if functional differences 
do exist between these two populations, a MLR was conducted. C3H PBMC were depleted 
of CD3+ T cells using positive magnetic bead selection. Half of the remaining cells were 
cultured with 19F-PFC while the other half served as control PBMC. Both conditions were 
supplemented with murine GM-CSF (20 ng/mL). After overnight culture, both cell 
conditions were then combined with allogeneic CFSE-labeled CD3+ T cells that were 
negatively selected for from C57Bl/6 mice. After 4 days of allogeneic cell culturing was 
complete, CFSE dilution was used to determine allogeneic T cell proliferation. Upon 
selecting for singlet CD3+ and CD4+ or CD8+ T cells (Fig. 7-2A-D), CFSE dilution was 
measured and it was determined that there was no significant difference in APC 
functionality as a result of 19F-PFC labeling. Both CD4+ (Fig. 7-2E, red) and CD8+ (Fig. 
7-2E, blue) allogeneic T cell proliferation was unaffected by C3H APC labeling with 19F-
PFC.  
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Figure 7-2. 19F-PFC does not affect the functionality of C3H APC as assessed 
using a MLR.  
Figure 7-2. 19F-PFC does not affect the functionality of C3H APC as assessed using a 
MLR. C3H APC were isolated as a result of positive selection removal of CD3+ T cells. 
A MLR was then conducted for 4 days with C57Bl/6 T cells that were negatively selected 
for and labeled with CFSE.  Allogeneic T cell proliferation was measured by flow 
cytometry using CFSE fluorescence dilution as a readout. Viable (A) singlet (B) cells 
were then gated on CD3 to identify T cells (C) and further gated to specifically examine 
CD4+ and CD8+ T cells separately (D). The percentage of allogeneic T cell proliferation 
was measured for each APC cell number and is summarized in (E) for CD4+ T cells (red 
dashed and solid lines) and CD8+ T cells (blue dashed and solid line). Data shown as 
means ± SEM (two-way ANOVA, p > 0.05). 
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7.2.3 19F-PFC-labeled murine PBMC can be detected in vivo using 
19F cellular MRI 
C57Bl/6 19F-PFC-labeled PBMC from diluted peripheral blood and splenic cell 
suspensions were labeled overnight with 19F-PFC (5 mg/mL). The next day, 8x106 19F-
PFC-labeled PBMC were formulated into an injection dose in 300 µL PBS and were 
injected intraperitoneally. Twenty-four hours after injection, C57Bl/6 mice were scanned 
using a dual-tuned 1H/19F volume coil on a 9.4 T MRI that detected 19F-PFC-labeled cells 
in the inguinal lymph node (green, 2x105 cells) and axillary (yellow, 0.7x105 cells) lymph 
node (Fig. 7-3A). In a second mouse, 19F-PFC-labeled murine PBMC were detected at the 
injection site (purple, 1x106 cells) and the sacral lymph node (orange, 1x105 cells). 
Miscellaneous signal was also detected in the intraperitoneal cavity as was calculated to be 
1.14x106 19F-PFC-labeled cells (Fig. 7-3B). Identical injections were performed for control 
unlabeled PBMC and no 19F signal was detected. The images are representative of two 
independent experiments with n=3 for each experiment.   
7.2.4 Verification of in vivo 19F signal 
To confirm that the signal detected in draining lymph nodes following an intraperitoneal 
injection was from originally-injected cells, 5x106 CFSE+ 19F-PFC-labeled murine PBMC 
were intraperitoneal injected (N=2, n=3). Twenty-four hours later, mesenteric lymph nodes 
were removed and cryopreserved. Mesenteric lymph node cryosections were 
counterstained with DAPI and using confocal microscopy, CFSE+ cells were detected and 
are the source of 19F signal detection in the lymph nodes (Fig. 7-3C).  
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Figure 7-3. 19F-PFC-labeled murine PBMC migration to draining lymph 
nodes is detected and quantified using 19F cellular MRI following 
intraperitoneal injection.  
Figure 7-3. 19F-PFC-labeled murine PBMC migration to draining lymph nodes is detected 
and quantified using 19F cellular MRI following intraperitoneal injection. Twenty-four 
hours after intraperitoneal injection of either 5x106 or 8x106 19F-PFC-labeled PBMC, 
C57Bl/6 mice underwent 19F cellular MRI at 9.4 T using a dual/tuned 1H/19F volume coil. 
In one representative mouse, 19F signal was detected and quantified in the inguinal lymph 
node (green) and axillary lymph node (yellow). Two reference tubes are visible and denoted 
as R (A). In a separate mouse, 19F-PFC-labeled PBMC were detected and quantified in the 
sacral lymph node (gold), the injection site (purple) and a signal in the intraperitoneal cavity 
(likely the mesenteric lymph nodes) was also detected (blue) (B). Data is representative of 
2 independent experiments, with 3 mice receiving an intraperitoneal injection per cell 
culture condition. In one of two replicate experiments, 5x106 19F-PFC-labeled murine 
PBMC were also labeled with CFSE and using confocal microscopy and counterstaining 
with DAPI to reveal nuclei, originally injected murine PBMC can be detected in the 
mesenteric lymph node. The mesenteric lymph node is shown at 100X magnification, with 
the red box representing the location of the 630X inset image. Scale bar represents 500 µm 
(white) and 50 µm (gold) for 630X inset (C). 
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